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Abstract 
Prostate cancer (PCa) is the most commonly diagnosed cancer amongst 
Western males. PCa progression is strongly linked to steroid receptor 
signalling, however the modulation of steroid receptor expression in PCa 
is incompletely understood. 
Lipocalin 2 (LCN2) is a secreted protein which binds to Fe3+-containing 
siderophores and was originally identified as part of the innate immune 
response. LCN2 has been proposed as a potential biomarker for a range 
of cancers. However, LCN2 effects appear to be tissue specific. LCN2 
expression is associated with poor prognosis in breast cancer, but with 
good prognosis in pancreatic cancer where it has been used 
therapeutically. The role of LCN2 in prostate cancer is poorly 
understood, in particular its effects on steroid receptor regulation.   
To elucidate the role of LCN2 in prostate cancer, the LCN2 gene was 
ectopically expressed in LNCaP cells to generate the LNCaP-LCN2 cell 
line. LNCaP-LCN2 cells had elevated androgen receptor expression 
which was linked to increased levels of KLK3 (PSA). LNCaP-LCN2 cells 
also had reduced levels of Estrogen receptor α (ERα), but increased 
expression of ERβ. This was combined with higher levels of E-cadherin, 
but not to changes in other EMT markers. 
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Reciprocally, LCN2 was suppressed using RNAi in the PC3 cell line to 
generate PC3-shLCN2 cells. PC3-shLCN2 displayed a distinct change in 
morphology, with increased cell size and a sub-population of multi-
nucleated and highly enlarged cells. PC3-shLCN2 cells had reduced 
proliferation, and lost the ability to form colonies in a 3D substrate. With 
regards to steroid receptors, PC3-shLCN2 cells had increased ERα 
expression, but reduced ERβ expression. This was also combined with a 
loss of E-cadherin and EGFR.  
Microarray analysis of PC3-shLCN2 cells identified changes to 
expression of a wide range of genes including VEGF-R, SPARC and 
KLK6. Functional grouping of differentially expressed genes suggests 
that LCN2 in involved in a range of cellular processes including hormone 
receptor response, Wnt signalling and cell cytoskeletal integrity.  Many, 
but not all genes identified by microarray were responsive to 
recombinant LCN2 protein indicating a paracrine function for the protein. 
Treatment of PC3 cells with the iron chelator Deferoxamine resulted in 
phenotypic changes similar to those found in PC3-shLCN2 cells which 
suggest that LCN2 functions in part due to intracellular iron regulation. In 
summary, the data presented in this thesis suggests that LCN2 has both 
pro- and anti- tumourigenic properties  in prostate cancer and that the 
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protein is involved in a much wider range of functions than previously 
described. 
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1.1 Anatomy and function of the prostate 
 
The prostate is a critical component of the male reproductive system and is common 
to all mammals. In humans, the prostate gland is approximately 4.5-5 cm in 
diameter, and is of a similar size and shape to a chestnut and is found directly 
beneath the bladder (Myers, 2000).  
The primary function of the prostate gland is to secrete an alkaline fluid which is a 
major constituent of semen. This alkaline microenvironment increases the lifespan of 
spermatozoa by neutralising the slightly acidic environment found in the female 
reproductive tract which is present as an anti-microbial fluid (Myers, 2000). Without 
the alkaline fluid, sperm would be unable to survive long enough for fertilization to 
occur. Neutralisation thereby provides an optimal pH for reproduction. The alkaline 
fluid contains acid phosphatases, a range of proteolytic enzymes and zinc (Owen 
and Katz, 2005). Also present is prostate specific antigen (PSA), which is critical to 
maintaining the liquidity of semen, and allows sperm cells to swim unhindered (Lilja, 
2003). 
As the prostate’s role is primarily reproductive, the size of the prostate is relatively 
small in pre-pubescent males, but enlarges rapidly upon the onset of puberty 
(McLaughlin et al., 2005, Myers, 2000). In post-pubescent males, the prostate is 
approximately 10-20g in weight and has an inverted conical shape, with the base at 
the bladder neck and the apex at the urogenital diaphragm (Leissner and Tisell, 
1979). The prostate gland is not uniform in physiology; rather it can be divided into 
zones. These zones are the peripheral zone (which comprises ~75% of tissue), 
transitional zone and central zone (Figure 1.1) (McNeal, 1981). Surrounding these 
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areas is the stroma. Each of these zones has specific functions and change in size 
and volume through puberty. In terms of pathology, prostatic tissue forms a 
honeycomb-like structure, consisting of ducts, comprised of epithelial tissue forming 
roughly spherical structures. These ducts are relatively simple structures, comprising 
of a few tissue layers, surrounded by stromal tissue which connects the ducts and 
creates structure (Myers, 2000). Luminal cells are responsible for producing PSA 
and alkaline fluid, which drain into the ducts, which are connected to the ejaculatory 
duct. The urethra runs through the centre of the prostate from top to bottom. The 
urethra and ejaculatory ducts are connected through small openings which allow 
passage of the seminal fluid (McNeal, 1981). 
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Figure 1.1 Histology and anatomy of the prostate: A- Haematoxylin and Eosin 
straining of healthy prostate tissue. Walls of glands/ducts are stained purple. Stromal 
regions are stained pink (commons free-of-use image). B Prostatic zones: 1= 
Peripheral Zone, 2= Central Zone, 3= Transitional Zone, 4= Anterior Fibro muscular 
Zone. B= Bladder, U= Urethra, SV= Seminal Vesicle (adapted from Algaba, 1991) 
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1.2 Histology and cell types of the prostate gland. 
The prostate is relatively simple in terms of cellular composition. The majority of 
prostate tissue is comprised of a layer of epithelial tissue which form the secretory 
ducts surrounded by connective and stromal tissue. The stroma surrounds and 
connects epithelial tissue and is consists of a fibroblasts, smooth muscle tissue and 
endothelial cells (Myers, 2000). As well as providing structural support, the stroma is 
also believed to interact with the epithelial layers and induce signalling(Lee, 1996).  
 The inner layer of the epithelial tissue is formed of cuboidal luminal cells (Figure 
1.2)(Lang et al., 2001).  These cells are relatively differentiated, and are responsible 
for producing PSA. The luminal cells are surrounded by a layer of flat, and less 
differentiated basal cells. These basal cells provide a structural attachment base for 
luminal cells, and also provide a source of new, undifferentiated cells. The basal 
layer is also believed to contain purported prostate stem cells (Signoretti et al., 2000, 
Collins et al., 2005). In addition, the basal layer also contains transit amplifying cells, 
which are partially differentiated into luminal cells. Interspersed within the basal layer 
are a small number of neuroendocrine cells. As their name suggests, 
neuroendocrine cells have a dendritic appearance (Abrahamsson, 1999, Bonkhoff, 
1998), and express a number of neuropeptides. The role of neuroendocrine cells is 
not fully resolved, but it is believed that they are involved in tissue maintenance and 
differentiation. Indeed, they are known to secrete growth factors such as VEGF and 
a wide range of signalling peptides (Sun et al., 2009).  
Luminal and basal cells differ markedly with regards to gene expression. The two cell 
types express different keratins: Basal cells are known to express both Keratin 5 and 
18, whereas luminal cells express Keratin 18. In keeping with their role of tissue 
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generation, basal cells express the proliferation marker Ki67, whereas the terminally 
differentiated luminal cells do not (Sherwood et al., 1991, Tran et al., 2002).  
Basal and luminal cells differ in their expression of cell adhesion and structural 
molecules. The adhesion molecule E-cadherin is expressed at high levels in luminal 
cells, but does not express the filament vimentin, whereas basal cells express 
vimentin but not E-cadherin (Tomita et al., 2000). This is also true of the cell surface 
basal marker CD44 which is not expressed in luminal cells but is in basal cells 
(Collins et al., 2005). 
One of the key differences between luminal and basal cells is in the expression of 
both androgen Receptor (AR) and PSA (Liu et al., 2002). Basal cells express neither 
AR nor PSA, and this ability is only conferred on cells which have differentiated fully 
to luminal cells (transit amplifying cells also express neither AR nor PSA) (Goldstein 
et al., 2010, Smith and Catalona, 1994).   
 
 
 
 
 
 
 
  
26 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 1.2 Overview of cell types in the prostate. A- Cross section of a prostate 
secretory duct. The prostate secretory duct is comprised of cuboidal luminal 
epithelial cells surrounded by a layer of basal cells interspersed with neuroendocrine 
cells. B- Changes in expression of key genes from basal to secretory cells. Basal 
cells express CD44, which is lost in secretory cells. Secretory cells gain expression 
of PSA and AR (Modified from Tran et al,. 2002). 
 
A 
B 
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1.3 Prostate cancer: Epidemiology, causes and classification. 
Prostate cancer (PCa) is the most commonly diagnosed form of cancer amongst 
Western males. According to recent statistics, approximately 40,000 men were 
diagnosed with PCa every year in the Britain alone, making up 25% of all cancer 
diagnoses for males (Cancer research UK statistics,-www. 
cancerresearchuk.org/cancer-info/cancerstats/types/prostate/incidence/).Worldwide, 
around 1 million people are diagnosed with PCa every year. Prostate cancer survival 
rates are improving, but nevertheless, PCa still has a high mortality rate. In Britain, 
approximately 10,000 men die each year as a direct result of the disease (Cancer 
research UK statistics). 
Whether a man will develop prostate cancer is dependent on a range of factors. By 
far the greatest risk is associated with advanced age. Only 1% of new prostate 
cancer diagnoses are in patients under 50 years. The incidence of PCa increases 
rapidly, with over 75% of cases being diagnosed in men over 65 (Bray et al., 2010).  
Over recent decades, diagnosis of PCa has increased dramatically due to a 
combination of ageing populations in developed countries and improved screening 
techniques. 
In addition to age, there are a number of factors which increase the risk of 
developing prostate cancer. Only around 5% of PCa is associated with hereditary 
genetic mutations. Of these, mutations in either BRCA1 or BRCA2 are commonly 
found a source of PCa development, and can increase the risk of PCa development 
by up to 5 times (Levy-Lahad et al., 2000). These mutations are usually associated 
with breast cancer, and indeed having a mother with breast cancer has been 
associated with an ~20% increased risk (Hemminki and Chen, 2005).Having a father 
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or brother with PCa also greatly increases the probability of developing the condition 
oneself by between 100-200% (Hemminki and Chen, 2005). 
PCa has widely variable rates in different countries, with Western developed 
countries showing the highest incidence and Eastern countries such as Japan 
having significantly fewer cases (Jadvar, 2011). This distinction is believed to derive 
mostly from differences to diet and activity rather than genetic factors as men with 
Asian ancestry living in the USA or Europe show similar levels of diagnosis to the 
Caucasian population (Jadvar, 2011). Diet has been shown to be a partial 
determinant for PCa in a number of studies. Soya based products- consumed 
frequently in Asia- have been shown to reduce PCa incidence by 26-30% in Asian 
males (Yan and Spitznagel, 2009). Carotenoids including vitamin A have also shown 
to reduce risk (Giovannucci et al., 1995). Other more tenuous preventatives have 
included green tea, coffee and omega-3 fish oils (Jian et al., 2004, Berquin et al., 
2007). As with all diet based studies however it is difficult to confirm whether these 
effects are purely due to food intake or overall lifestyle differences. Relative to other 
cancer types, smoking is not a major factor in PCa, although it may increase risk 
moderately (Huncharek et al., 2010). In a very large study, Roddam et al. (2008) 
showed no correlation between circulating androgens or estrogens and the risk of 
developing PCa (Roddam et al., 2008). 
 
The vast majority (>95%) of prostate cancers are adenocarcinomas, or neoplasia of 
glandular epithelial tissue. The remaining 5% of tumours are mostly neuroendocrine 
tumours (Jadvar, 2011). PCa sarcomas are relatively rare but not totally absent. 
Approximately 75% of PCa tumours originate in the peripheral zone of the prostate, 
with a further 20% originating in the central zone. Tumours arising from the central 
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zone are relatively rare (2-3% of cases), but have been shown to be more 
aggressive in behaviour (Cohen et al., 2008).  
A potential precursor to prostate cancer is known as Prostatic intraepithelial 
neoplasia (PIN). This is a more benign disease whereby there is increased cell 
proliferation, but where the basal layer of the prostate remains intact (Montironi et al., 
2007). In PCa, the basal layer is often disrupted or even absent. Whether PIN 
necessarily precedes carcinogenesis itself is however still under discussion (Herawi 
et al., 2006).  
Until fairly recently, the origin of PCa was believed to be in the luminal cells 
(Stoyanova et al., 2013). This was due to the similarity of histological sections of 
tumours with epithelial cells. However, a number of studies (Goldstein et al., 2010) 
have since demonstrated that basal cells are also implicated. Indeed, other studies 
have shown interaction between the basal and epithelial layers in stimulating PCa 
tumour growth (Tuxhorn et al., 2002a, Tuxhorn et al., 2002b). 
Prostate cancer grade is determined histologically by the Gleason grading system 
which ranges from 1 to 5, where 5 has the least differentiation and the poorest 
prognosis. Two samples are usually identified based on the most common and 
second most common patterns. The scores are then combined to give a total score 
from 2-10.  For example, a high scoring grade may hence be labelled as 5+2=7. A 
further, more clinical scoring system known as tumour-node-metastasis (TNM) 
system. TNM classification is based on the presence and size of primary tumours, 
evaluation of lymph nodes, and the presence and distance of metastases. TMN and 
Gleason scores may be combined to assess a disease stage, ranging from stage I to 
stage IV, with stage IV being the most severe (Thorson and Humphrey, 2000). 
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Diagnosis of PCa is most commonly performed through either physical examination 
or punch biopsies, or through the PSA blood test (Velonas et al., 2013). At early 
stages, PCa is often associated with increased sensitivity to androgens, and to an 
increase in the expression of AR (Feldman and Feldman, 2001). Under normal 
conditions, AR is sequestered in the cytoplasm by Hsp90 and Hsp70 (Reebye et al., 
2012). Upon binding of AR to testosterone or dihydrotestosterone (DHT), AR is 
released and relocates to the nucleus where it is dimerised and acts as a 
transcription factor, binding to androgen-response elements enabling the 
transcription of numerous genes, including PSA (Figure 1.3). The increase in PSA is 
therefore a good initial indicator for determining abnormal proliferation. While the 
PSA test has disadvantages, as it does not detect all prostate cancers, and in many 
cases produces many false positives, the PSA test has enabled the early detection 
and treatment of PCa for thousands of men. Indeed, the PSA test is now freely 
available for all men over 50 in the UK. Diagnosis can be followed up with a biopsy 
test to rule out false positives due to temporary infection and to test for tumour 
grade. 
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Figure 1.3 Mechanisms of androgen receptor function. The majority of 
testosterone (97%) circulates in the bloodstream where it binds to one of two 
proteins: or albumin sex hormone binding globulin (SHBG). Testosterone is reduced 
into dihydrotestosterone (DHT) by 5α-reductase. DHT is 2-3 times more potent than 
normal testosterone. DHT binds to AR facilitating the dissociation of AR from heat 
shock proteins (HSP), thus allowing it to dimerise and translocate into the nucleus. 
Here, the DHT/AR complex engages with specific chromatin regions, androgen 
response elements (AREs), to control target gene expression such as PSA and 
genes responsible for growth and Survival (Adopted from Feldman and Feldman, 
2001). 
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1.4 Treatment of prostate cancer: The problem of Androgen independence and 
metastasis  
Cancer of the prostate alone is not usually fatal as the prostate is not a vital organ 
such as the liver or lungs. As such, early stage PCa is focused on tumour 
management and hormone starvation. The majority of prostate cancers express both 
androgen receptor and hence PSA. Indeed, cancer cells require AR’s ability to bind 
to DHT to enable cell division and drive growth. Therefore, first line treatment for 
PCa involves hormone deprivation therapy (Attard et al., 2011). Patients may 
undergo a prostatectomy or radiotherapy, thereby cutting off the supply of 
androgens(Tammela, 2012). Alternatively, AR signalling is blocked by chemical 
inhibitors. Clinically, the most common inhibitor in use currently is bicalutamide 
(Casodex®) (Wirth et al., 2007). Bicalutamide is an anti-androgen which is able to 
preferentially bind to AR, thereby inhibiting the binding of DHT. Over time this leads 
to hormone starvation and eventually tumour reduction and can even act as a total 
cure. 
While hormone deprivation treatment is highly effective in treating low grade prostate 
cancer, this method often not able to totally clear the disease completely. As 
mentioned in section 1.3, many PCa tumours require the expression of androgen 
receptor for growth. In many cancers however, particularly in those patients which 
have already undergone hormone refractory treatment, cells become androgen 
independent (AI). In this case, cells remove the need for androgen signalling and are 
able to evade drugs such as bicalutamide (Garcia and Rini, 2012). There are a 
number of proposed theories as to how cells become androgen independent, and 
there is considerable variation between patients (Reviewed (Pienta and Bradley, 
2006). A well-defined mechanism for AI is termed the bypass pathway, whereby 
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through mutation, the anti-apoptotic protein BCL2 is over expressed, preventing cells 
from apoptosing after steroid withdrawal. Alternative mechanisms include AR being 
able to bind to non-steroids such as EGF and signal independently of testosterone 
(Pienta and Bradley, 2006). 
As mentioned in section 1.3, prostatic tumours by themselves are rarely fatal. 
Disease progression therefore is dependent on the tumour metastasising to other 
areas of the body. In prostate cancer, approximately 90% of advanced patients have 
metastases in bone tissue.  Other common metastases are to lung (46%) and liver 
(25%) (Bubendorf et al., 2000). The reasons why PCa cells specifically target the 
bone as opposed to other tissue is still not fully resolved. However, studies have 
suggested that PCa cells are attracted by cell surface integrins such as avβiii which 
are present on bone cells, and enable attachment of the cancer cell to the bone 
tissue (McCabe et al., 2007, Schneider et al., 2011). Bone cells also produce a 
number of chemoattractants such as SPARC (Derosa et al., 2012, Shin et al., 2013). 
Conversely, PCa cells are also able to modify the bone tissue environment. One way 
in which this is done is by secreting factors such as Wnts, which activate osteogenic 
pathways, allowing entry into the tissue (Dai et al., 2008). 
 
Metastatic PCa cells often show signs traditionally associated with epithelial-
mesenchymal-transition (EMT). As the name suggest, EMT is process whereby 
epithelial cells change gene expression and morphology, and instead express 
mesenchymal markers and have increased migration and plasticity. EMT is a 
necessary cellular function associated with processes such as wound repair and 
development which are hijacked by cancer cells (Micalizzi et al., 2010). Common 
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characteristics of EMT include the loss of E-cadherin expression, as well as 
increased expression of E-cadherin inhibitors such as SNAI1, TWIST1 and ZEB1. 
Conversely, cells in EMT increase expression of N-cadherin and other intracellular 
filaments such as vimentin (Thiery et al., 2009). 
There are a number of causes for EMT involving a range of cell signalling 
mechanisms which are often interlinked. One well established mechanism is via the 
receptor TBFβR. Upon binding to its ligand TGF, TGFβR is able to activate the 
transcription factors known as Smads (Heldin et al., 2012, Xu et al., 2009). These 
transcription factors are then able to relocate to the nucleus where they are able to 
both inhibit epithelial marker genes and drive mesenchymal marker expression. 
Smad proteins have also been shown to interact with other EMT genes such as 
ZEB1 (Xu et al., 2009). While the TGFβ-Smad pathway is known as the canonical 
pathway, TGFβ is also known to activate a range of other signalling mechanisms 
such as the MAP-Kinase pathway, which is also able to interact with SNAI1(Vincent 
et al., 2009) (Figure. 1.4). 
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1.5 Cell lines used in prostate cancer research 
Ideally, all studies of prostate cancer would be performed in vivo. However, in order 
to obtain much more rapid, higher output, and less ethically problematic data, cell 
lines have been derived from patients which are able to proliferate almost 
indefinitely. Cell lines also have a benefit of being generated from human tissue, 
thereby removing any issues of species differentiation, as there is still some debate 
as to whether a mouse model is phenotypically similar to what occurs in the human 
prostate (Reviewed by (Ittmann et al., 2013). Numerous PCa cell lines exist, 
nevertheless, the lines LNCaP, PC3 and DU145 are by far the most commonly used 
in research (Table 1.2) (Sobel and Sadar, 2005). 
The LNCaP cell line is derived from needle aspiration biopsy of a lymph node 
metastatic lesion from a 50-year-old white man (Horoszewicz et al., 1980). Cells 
grown relatively sparsely in tissue culture conditions and are often elongated and 
maintain a degree of polarity. LNCaP cells show less tumorigenicity than most other 
PCa cell lines. LNCaP cells attach poorly to plastic and can LNCaP cells are notable 
for their expression of androgen receptor and PSA. LNCaPs also express Estrogen 
receptor α. However, LNCaP cells do have a mutation at T877A which leads to more 
non-specific steroid binding (Sobel and Sadar, 2005). As a result of AR expression, 
LNCaP cells require androgens and other steroids in order to proliferate normally, 
and will have significantly reduced growth in steroid free media. With regards to 
karyotype, there is a large degree of aneuploidy, with cells containing ~33-90 
chromosomes. The cell line does however have a wild type p53. The LNCaP cell line 
is also the parent population for many other lines, some of which have been 
generated to be androgen independent such as LNCaP-AI and LNCaP-104s (Sobel 
and Sadar, 2005). 
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PC-3 cell line was derived from a lumbar vertebral metastasis in a 62-year-old white 
man (Kaighn et al., 1978). This cell line is highly tumourigenic, and is greatly 
metastatic in xenograft models. Cells form moderately tight colonies and cells are 
often somewhat irregular in shape. A key feature of PC3 cells is that they do not 
express androgen receptor or PSA, and are able to proliferate in only 1% serum 
(Sobel and Sadar, 2005). Aneuploidy is ubiquitous in the cell line, with an average 
chromosome number of 58 PC3 cells contain a mutation in the TP53 gene which 
causes a frame-shift mutation resulting in a premature stop codon (van Bokhoven et 
al., 2003). PC3 is also the parental line for other derivative cell lines such as ALVA-
31 and PC3-1A (Sobel and Sadar, 2005). 
The DU-145 cell line was derived from a tumour mass excised from the brain 
metastasis of a 69-year-old white man with both prostate cancer and lymphocytic 
leukaemia (Stone et al., 1978). DU145 cells are epithelial in origin and were the first 
PCa cell line to be fully described. DU145 cells do not express AR or PSA, but are 
not as tumorigenic as PC3 cells but do proliferate rapidly. Aneuploidy is also present. 
DU145 cells are heterozygous for p53, which is partially active. Due to the rare 
nature of the brain origin of DU145, there is some debate as to whether this cell line 
accurately models prostate cancer but it does serve as a model for cell signalling 
(Sobel and Sadar, 2005).  
Other prostate cell lines sometimes referred to literature include PNT2, which is 
derived from normal prostate epithelial tissue from a 33 year old male immortalised 
with an SV40 virus. These cells are non-tumourigenic, and express AR and PSA 
(Sobel and Sadar, 2005). VCaP cells are a cell line which is derived from a vertebral 
lesion of a 59 year old male, but express AR and PSA. 
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Cell Line AR expression P53 status Tumorigenicity 
LNCaP Yes Wild type Low 
PC3 No Null High 
DU145 No Mutated Moderate 
PNT2 Yes Wild type None 
Table 1.1 Overview of commonly used prostate cell lines  
 
1.6 Key signalling mechanisms in prostate cancer:  
1.6 NF-κB signalling 
Nuclear factor kappa-B (NF-κB) is a transcription factor complex which sits at the 
centre of a wide range of cellular processes (Sen and Baltimore, 1986). NF-κB is 
most commonly associated with rapid cellular responses such as innate immunity 
and inflammation. NF-κB itself is a complex comprised of p50 and RelA (Gilmore, 
2006). Under non-activating conditions, the NF-κB complex is sequestered in the 
cytoplasm by IκB (Perkins, 2007).  Stimulation via cell surface receptors, leads to the 
activation of IKK, which in turn phosphorylates IκB.  Phosphorylation enables IκB to 
be targeted for proteasomal degradation, allowing NF-κB into the nucleus where it 
associates with co-activators and binds to DNA and helps drive transcription   
(Senftleben et al., 2001) (Figure 1.4). The NF-κB pathway has been shown to have a 
large amount of both upstream and downstream cross-talk between other signalling 
pathways.  IKK has been shown to be activated by the p53 pathway (Kawauchi et 
al., 2008) and mTOR/AKT signalling (Lee et al., 2007). NFκB is also known to 
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regulate a range of other pathways including inducing transcription Hypoxia-inducible 
factor 1α (HIF-1α) (Rius et al., 2008). NF-κB also activates transcription of interleukin 
1β (IL1β) (Cowland et al., 2006). Indeed, IL1β itself is an activator of the NF-κB 
pathway, creating a positive feedback loop (Hartupee et al., 2008, Niu et al., 2004). 
With regards to prostate cancer NF-κB has been shown to be indicative of a poor 
prognosis in patients (Karin et al., 2002). It is also a key component of inflammation 
in cancer.  NF-κB has also been shown to lead to an androgen independent 
phenotype, and is up-regulated in hormone refractory patients (Suh and Rabson, 
2004, Zhang et al., 2009). A study by Nadiminty et al  (2012) demonstrated that NF-
κB itself interacts with the N-terminal of AR, enabling its translocation to the nucleus 
and also assists in recruiting co-activators to AR transcription sites, and can enable 
the transcription of androgen independence linked genes (Nadiminty et al., 2010). 
Also, NF- κB over expression has been assist in AR entering the nucleus, and is 
present at greater levels in androgen independent PCa cell lines (Jain et al., 2012). 
As with any pathway however, the precise role of NF-κB is likely to be dependent on 
the presence and absence of other factors. 
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Figure 1.4 The NF-κB pathway. Under non-stimulating conditions, the NF-κB 
complex, comprising of RelA and p50 is sequestered in the cytoplasm by IκB. When 
activated, IκB is phosphorylated by IKK, and is targeted for proteasomal degradation. 
The NF-κB complex is then free to enter the nucleus, where it binds to co-activators 
and drives mRNA expression (Commons free image). 
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1.8 Hedgehog Signalling: Mechanism of action 
The hedgehog (Hh) signalling pathway plays an essential role in the regulation of, 
differentiation, proliferation patterning and growth of the embryo, and is a key 
regulator of cell proliferation. The hedgehog pathway was first identified in 
Drosophila Melanogaster studies, where Hh mutant larvae had a hairy or hedgehog 
like appearance for which Nüsslein-Volhard and Wieschaus won the Nobel prize 
(Nusslein-Volhard and Wieschaus, 1980).  It was later found that Hh is actually a 
secreted protein (Bumcrot et al., 1995).  Hh is highly conserved across animals 
(Krauss et al., 1993, Ingham et al., 2011), however whereas D. Melanogaster has 
only a single Hh protein, in humans there are 3 sub-types namely Sonic Hedgehog 
(SHH), Desert Hedgehog (DHH) and Indian Hedgehog (IHH), of which SHH is by far 
the most studied (Krauss et al., 1993). 
After being secreted, SHH binds to the transmembrane protein PTCH1 (a 
homologue of Patched in D.Melanogaster). Under non-stimulating conditions, one of 
PTCH1’s main functions is to sequester SMO (Figure 1.6) (a homologue of 
Smoothened in D.Melanogaster, thereby inhibiting its activity. Upon binding to SHH, 
SMO is released, allowing to be targeted for phosphorylation by CK1α and GRK2 
protein kinases at the C-terminal end which induces conformational changes 
allowing SMO to translocate to the primary cilium (Figure 1.5) (Chen et al., 2004).  
Following migration to the cilium, SMO is then able to interact with Suppressor of 
Fused Homolog (SUFU). Under non stimulating conditions, SUFU is located in the 
cytoplasm where it is bound to group of proteins called GLI1, GLI2 or GLI3 (grouped 
as GLI). When these proteins are bound, GLI is phosphorylated and is targeted for 
proteasomal degradation by ubiquitination (Rahnama et al., 2006). However, under 
stimulating conditions, SMO preferentially binds to SUFU, freeing GLI and causing 
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conformational change GLI so that is not degraded and is also able to enter the 
nucleus (Alcedo et al., 2000) (Figure 1.5).  
 
The GLI (GLI1, 2 and 3) proteins are zinc-finger transcription factors which are the 
primary effectors of the Hedgehog signalling pathway. GLI1 was first isolated in 
human glioma cells (hence the name), where it was found to be highly up regulated 
(Rahnama et al., 2006, Kinzler et al., 1987). Both GLI1 and GLI2 are generally 
considered to be transcriptional promoters and share the same DNA consensus 
binding sequence of GACCACCCA (Kinzler and Vogelstein, 1990). GLI3 on the 
other hand is usually described as a transcriptional repressor.  In most unstimulated 
cells, GLI2 is the member which is most highly expressed, whereas in Hh stimulated 
cells, active GLI2 will drive the transcription of GLI1. GLI1 and GLI2 share many 
overlapping characteristics and active forms are both able to transcribe PTCH1, 
thereby generating a positive feedback look (Liu et al., 1998). However, to prevent 
hyper-stimulation, GLI1 also transcribes Hedgehog interacting protein (Hip) which 
also binds and sequesters SHH as an alternative to PTCH1 (Olsen et al., 2004). 
GLI1 has also been implicated in the transcription of cell cycle factors such as Cyclin 
D2 and FOXM1 (Teh et al., 2002). GLI expression is also linked to the suppression 
of apoptosis, and has been shown to increase expression of BCL2 However, while 
the overall Hh is relatively well understood, the actual global transcriptional effects of 
GLI1 and GLI2 are still poorly understood.  
 
42 
 
 
Figure 1.5 Overview of the Hedgehog pathway. Left panel- When inactive, PTCH1 
sequesters SMO in the cytoplasm. GLI1/2 is bound by SUFU, and by destruction 
complexes including GSK-3β which targets it to the proteasome leaving only GLI3 to 
act as a repressor. When active (right panel), the Hedgehog family bind and inhibit 
PTCH, allowing SMO to migrate to cilia where it prevents SUFU function and aids in 
GLI modification and activation. Active GLI1/2 enters the nucleus where it drives 
transcription of PTCH, Cyclin D1 and HIP (Modified from 
cellsignal.com/reference/pathway/Hedgehog.html) 
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1.9 Hedgehog signalling in development and disease 
The hedgehog pathway was initially identified with regards to embryonic 
development. The Hh pathway is critical in the formation of skeletal tissue, in colon 
and gastroenterinal tissue development and in the patterning of organs such as the 
lungs (Heussler and Suri, 2003, Laufer et al., 1994, Marigo et al., 1996). Expression 
of SHH in embryonic limb buds in particular is now widely accepted to help 
differentiate tissue and is the leading determinant in digit formation in the hands and 
feet (Marigo et al., 1996).  The Hh pathway is also active in adult cells albeit at lower 
levels, where it performs a wide range of functions. GLI1 is expressed in the hair 
follicle root sheath (Ghali et al., 1999), and is also necessary for the maintenance of 
tissues with high turnover such as neural and gut tissues (Ramalho-Santos et al., 
2000). Hh signalling also has roles in bone fracture repair (Wang et al., 2010). 
Due to the Hh pathway’s critical involvement in development, it therefore follows that 
it is associated with a number of congenital disorders such as polydactyly (having 
extra fingers), as well as neurological conditions involving malformation of the fore 
lobe of the brain (Ming et al., 2002, Traiffort et al., 2004).  
Aside from developmental diseases, by far the most investigated role of the Hh 
pathway is in cancer. One of the first links to cancer came from patients with Gorlin 
syndrome (Ming et al., 2002). Gorlin syndrome is an autosomal inherited disorder 
with symptoms which include skeletal deformations, particularly in the ribs and 
vertebrae. However, the man symptom of the syndrome is the propensity to develop 
numerous basal cell carcinomas (BCCs), and patients are highly susceptible to 
ultraviolet sunlight.  Genetic studies on Gorlin patients revealed that sufferers have 
mutations in the PTCH1 gene which inactivates one allele (Ming et al., 2002). 
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Subsequent loss of heterozygosity then leads to the constitutive activation of Hh 
pathway, giving rise to tumours. Gorlin syndrome is a relatively rare disease (~1 in 
20,000), however novel BCC tumours are the most common form of any cancer, with 
an incidence rate of ~75/100,000 people (Traiffort et al., 2004). While incidence is 
high, survival rates are very high, in part due to very low rates of metastasis (only 1-
2% of cases) and relatively easy surgical removal. Nevertheless, surgery can lead to 
bad scarring, especially on the head and face. The prevalence of BCCs increases 
with both exposure to sunlight and the fairness of skin (as a result, Australia has 
greatly increased incidence). Johnson et al demonstrated that ~85% of BCCs have 
mutations in the PTCH1 gene, and a further 10% have mutations in SMO (Johnson 
et al., 1996). Both mutations lead to the Hh pathway being over-stimulated and the 
proliferation of tumour tissue. Within the pathway, both GLI1 and GLI2 have been 
directly implicated in the formation of BCC tumours (Dahmane et al., 1997). Mouse 
studies whereby GLI1 was overexpressed generated skin tumours with a high level 
of similarity to BCCs (Nilsson et al, 2000). Heterozygous Ptch1+/- mice are also 
more prone to develop tumours following ultraviolet exposure . 
Although many BCCs are excised surgically, in order to prevent scarring and 
recurrence drugs have since been developed which target the Hh pathway. The 
majority of pharmacological inhibitors target SMO. Cyclopamine was originally 
identified after it was found that sheep which had eaten the plants had only one eye 
and numerous other defects (Taipale et al., 2000). It was later found that 
Cyclopamine is a naturally occurring small molecular inhibitor of SMO, and hence Hh 
signalling. Subsequently, KAAD-Cyclopamine has been developed as a more potent 
artificial derivative. Other SMO inhibitors such as SANT-1 and Sonidegib have also 
been tested with mixed success (Yang et al., 2010).  Drugs have also been 
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developed which target the GLI family specifically. GANT-61 has been shown to 
inhibit GLI 1,2 and 3 in pancreatic cancer xenograft model (Fu et al., 2013), however 
to date, there have been no in vivo studies published.  
1.10 The Hedgehog Pathway in Prostate Cancer 
As well as BCCs, the Hh pathway has been implicated in a number of other cancers 
including breast, medulloblastomas and lung (Yang et al., 2010). The Hh pathway 
has also been shown to be active in prostate cancer. The Hh pathway is active in the 
embryonic development of the prostate gland where it regulates gland polarity and 
ductal budding. The pathway continues to be active in the adult where it is necessary 
for epithelial upkeep and regeneration, although levels are lower than in the embryo. 
Unlike in BCCs, the Hh pathway in prostate cancer is not usually associated with 
PTCH1 or SMO mutations, indeed mutations of these genes are virtually absent in 
patients. Mutations to SUFU have however been observed at low frequency (Chen et 
al., 2011).  
Currently, there are a number of mechanisms proposed for the development of Hh 
based prostate cancer growth, often labelled type I, II, III and IIIb (Figure 1.6). Type I, 
or ‘ligand independent growth’ is similar to BCCs as mentioned above, whereby 
mutations, usually SUFU in PCa lead to constitutive activation of the Hh and GLI 
pathways.  Type II growth or ‘ligand dependent autocrine growth’ is where Shh 
activates the Hh pathway, leading to GLI1 and GLI2 expressing both more PTCH1 
and Shh, thereby creating a positive feedback loop and over-proliferation of cells. 
Type II growth has previously been detected in PCa (Kharkodar et al 2004), however 
the precise reasons which stimulate initial elevated Shh growth is still relatively 
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unclear.  Factors such as NF-κB have been proposed in PCa, and elevated Shh may 
be as a result of mutations in other signalling pathways. 
Type III or ‘ligand dependent paracrine’ growth states that rather than single cancer 
cell mutations, growth is dependent on stromal cell activation (Figure 1.6). Shh 
secreted from the cancer cell is able to activate the Hh/GLI1 pathway in surrounding 
stromal cells. GLI1 then initiates the production and secretion of other growth factors 
such as VEGF, Wnts and IGF from the stromal cells. These growth factors then 
promote the growth of the cancer cells. Conversely, the stromal cells themselves 
may secrete Shh (This hypothesis is sometimes known as Type IIIB). This theory of 
cancer growth is based on developmental studies which have shown that Shh 
secreted by the epithelium is received by the mesenchymal stroma and directly 
stimulates proliferation in the mesenchymal tissue.  This form of signalling has been 
detected in number of cancer  subtypes including pancreatic cancer, and have also 
recently been shown to be present in prostate cancer. A study Zunich et al (2012) 
demonstrated that osteoblasts derived from bone tissue used paracrine signalling to 
promote the Hh pathway in the LNCaP cell line and propose this mechanism as a 
partial driver or bone metastasis. 
Aside from autocrine/paracrine signalling, a further mechanism of Hh mediated 
growth is through cancer stem cells. The cancer stem cell (CSC) theory states that 
rather than all cells within a tumour being proliferative, the growth of the tumour is 
driven by a small subset of cells which possess stem-like qualities which enable 
them to produce progeny but retain self-renewing qualities. The hedgehog pathway 
is a key in the maintenance of stem cell in normal tissues, and helps drive growth, 
particularly in embryogenesis (Taipale and Beachy, 2001, Zhou and Kalderon, 
2011). (Taipale and Beachy, 2001, Zhang and Kalderon, 2001).  The Hh pathway 
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was also been implicated in the formation of CSCs in a number of different cancer 
types, particularly gliomas, breast and most notably chronic myelogenous 
leukemia(Merchant and Matsui, 2010). The Hh pathway has been shown to activate 
a number of key CSC related genes, including nestin, CD44 and BMI1 (Yang et al., 
2010).  The Hh pathway also works with the Wnt pathway to maintain the CSC 
phenotype and the two pathways are thought to activate each other (Taipale and 
Beachy, 2001). In prostate cancer, the Hh pathway has been implicated in the 
maintenance of a CSC phenotype, where GLI1 has been shown to co-localise with 
the stem cell marker CD44.  In 2011, Chang and colleagues demonstrated that Shh 
overexpression in mice prostate led to the development of tumours with strong 
indicators of  CSCs, such as a p63+ and CD44+ state  (Chang et al., 2011) . 
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Figure 1.6: Different methods of Hedgehog signalling in [a] Type I ligand 
independent cancer: Mutations in either PTCH1, SMO or SUFU lead to the 
constitutive activation of GLI1 [b] Type II ligand dependent autocrine -cancer cells 
produce Hh, which is able to activate the pathway in the same cells. [c] Type III 
ligand dependent paracrine- cancer cells secrete Hh which activates the GLI1 
pathway in stromal cells. Stromal cells then feed back to the cancer cell with signals 
such as Wnt, Vascular endothelial growth factor (VEGF) and Insulin growth factor 
(IGF) [d] Reciprocally, in type IIIb ligand dependent paracrine tumours stromal cells 
secrete Hh activating the pathway in the cancer cell. [e] Hh signalling in self-
renewing cancer stem cells that may come from the stroma or the cancer cell itself. 
The expression of GLI1 can lead to activation of stem-like phenotypes which provide 
the tumour with ability to grow indefinitely (modified from Scales & de Sauvage 
2009). 
PTCH1 
SMO 
Mutations 
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1.11 The cell of origin in prostate cancer- links to androgen independence and 
Hedgehog signalling. 
One of the unresolved questions surrounding prostate cancer in general is the cell of 
origin for tumours, and whether PCa starts in epithelial or basal cells. Initial prostate 
tumour growth often shows signs of being derived from epithelial cells, including 
expression of androgen receptor and high PSA production. On the other hand, basal 
cells have also been proposed as the cell of origin for some tumours due to their 
ability to proliferate and differentiate. Increasingly, there is evidence that rather than 
one or the other, prostate cancer has a large degree of heterogeneity and that both 
cell types can function as a cell of origin, but that the resultant tumours have differing 
characteristics (Goldstein et al., 2010). Tumours with a cell of origin derived from 
luminal cells lead to a generally poorer prognosis and more rapid early tumour 
growth (Wang et al., 2013b). Basal cell origin tumours on the other hand may be 
more prone to metastases and androgen independence. It has also been shown that 
the basal and luminal cells promote each other’s growth. A further idea is basal 
tumour cells are able to acquire a more luminal like morphology, or vice versa.  
Wang and colleagues (2009) demonstrated basal-luminal transition may be 
dependent on the expression of homeobox genes particularly Nkx3-1 (Wang et al., 
2009). Xin (2013) also demonstrated while basal cells may be the cell of origin, 
particularly in metastases, basal-luminal transition often occurs in distal tumours 
driving their more rapid growth (Xin, 2013). However, one caveat of this theory is that 
it tends to only explain androgen responsive tumours. Androgen independent 
tumours on the other hand appear to acquire more basal characteristics, especially 
loss of AR expression. 
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The mechanisms which stimulate cells to become androgen independent or to lose 
AR expression completely are still relatively unknown. The Wnt pathway (particularly 
Wnt11) has been shown to mutually inhibit the expression of AR (Zhu et al., 2004). 
Bernard et al (2003) also showed that c-Myc expression results in an androgen 
independent state in LNCaP cells (Bernard et al., 2003).  
In 2008, Shaw et al found that androgen independent PCa cells were sensitive to the 
(Shaw and Prowse, 2008) Hh antagonist Cyclopamine, suggesting an active Hh 
pathway, and that high levels of PTCH1 are present in circulating androgen 
independent PCa cells. The team also found that Hh and HER2 (ErbB2) signalling 
worked synergistically to promote an androgen independent phenotype. 
Subsequently, Chen et al (2010) found that Cyclopamine treatment resulted in dose-
dependent modulation of the expression of genes that are regulated by androgen 
and that targeted suppression of SMO by siRNA reduced expression of androgen-
inducible KLK2 and KLK3 in androgen deprived cells without affecting the expression 
of androgen receptor (AR) (Chen et al., 2010). It was also found that GLI2 itself co-
localised with AR as evidenced by immunoprecipitation. As well as regulating AR, Hh 
has also been strongly associated with a further change which is believed to occur in 
epithelial-basal transition, namely EMT. This link between Hh signalling and EMT 
has been shown in other cancer types (e.g. gastric cancer), but relatively little 
information exists with regards to prostate cancer (Gonnissen et al., 2013).  
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1.12 Aims of study 
Based on previous findings, members of the Neill lab, especially Dr. Sandeep 
Nadendla hypothesised that Hh signalling (specifically GLI1) was regulating both AR 
expression and EMT, and was responsible for cells controlling a basal phenotype. 
Levels of  GLI1 was were analysed in a range of PCa cell lines and it was found that 
GLI1 activity was higher in androgen receptor cell lines (PC3 and DU145) than in cell 
lines where AR was expressed (LNCaP, PNT2). GLI1 was ectopically expressed in 
the LNCaP cell line to generate an LNCaP-GLI1 cell line, leading to a notable 
change of phenotype whereby cell colonies formed a basal-like or cobblestone 
morphology, and formed tight and distinct colonies whereas standard LNCaP cells 
are less compact (Nadendla et al., 2011).LNCaP-GLI1 cells proliferated a much 
higher rate than controls . As well as morphological changes, LNCaP-GLI1 cells also 
lost the expression of AR and were resistant to bicalutamide. Also, LNCaP-GLI1 
cells displayed strong signs of an EMT phenotype including a loss of E-cadherin, and 
an increase in vimentin. LNCaP-GLI1 cells showed expression of basal cell markers, 
particularly CD44 and ΔNP63 (Nadendla et al., 2010). Microarray analysis on 
LNCaP-GLI1 cells further confirmed an androgen independent and EMT phenotype 
as well as a range of other gene expression changes. The initial aim of this study 
therefore was to investigate whether this change was potentially reversible and 
whether subsequent silencing of GLI1 would change morphological or gene 
expression and for LNCaP-GLI1 cells to return to a more luminal phenotype. 
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In addition to the considerable morphological and phenotypic changes and the 
switch to an AI state GLI1 appeared to mediate a range of biological processes 
including proliferation, apoptosis and EMT. To obtain a global view of gene 
expression in LNCaP-GLI1 cells, and to elucidate the pathways being 
activated/deactivate, a genome wide mRNA microarray was carried out by S. 
Nadendla (Thesis: Sandeep Nadendla, 2011) comparing gene expression profiles 
between LNCaP-pBP and LNCaP-GLI1, (also PC3 and DU145 cell lines). As 
mentioned above, when gene expression was analysed, a 10-fold cut off yielded 262 
differentially regulated transcripts (144 up and 120 down) in LNCaP-GLI1 cells 
compared to LNCaP-pBP cells.  Of the genes that were up regulated, the gene 
LCN2 was shown to have a 55 fold increase in LNCaP-GLI1 compared to LNCaP-
pBP cells (Nadendla et al., 2011).  When gene ontologies were grouped, LCN2 was 
the only gene that appeared in both the Androgen independence and the EMT 
signatures. Indeed, when the Androgen independence associated genes were 
delineated separately, LCN2 showed a response to GLI1 far greater than any other 
genes in the group (Figure 1.7). LCN2 therefore appeared to be a good candidate for 
further investigation with regards to both EMT and AI and it was hypothesised that 
LCN2 may be responsible, at least in part for the effects seen in LNCaP-GLI1 cells. 
As such, LCN2 was chosen as a candidate for further investigation (See chapters 4-
8). 
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Figure 1.7: Partial heat map of genes grouped according to gene ontology that 
are regulated by Gli1 in LNCaP cells. Analysis was carried out on LNCaP (LN-
GLI1), DU145 and PC3 cells. Red colours represent the higher fold expression 
values. Blue colours represent decreases in expression. Data is representative of 
average of triplicate values. All values relative to LNCaP-pBP. (Taken from Nadendla 
et al,. 2011). 
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1.13 The Lipocalin Family 
Lipocalin 2 is a member of the Lipocalin family of proteins. This family is comprised 
of approximately 30 structurally dissimilar proteins which are mostly secreted and 
associated with the transport binding and of small hydrophobic molecules (Flower et 
al., 2000). The term ‘Lipocalin’ is somewhat broad, encompassing a range of 
proteins which share as little as 20-30% homology to each other.  Despite their 
differences in amino acid composition, all members of the lipocalin family share a 
similar 3D structure. All members of the family contain a ‘Lipocalin fold’. This 
structure comprises of an 8 β-sheets, which form hydrogen bonds to form an anti-
parallel β-barrel structure which forms a cup like structure, inside of which is a 
binding site for specific ligands (Flower, 2000). The Lipocalin structure is found in all 
eukaryotes and in gram negative bacteria, although actual sequence similarity both 
at the genetic and protein level differ greatly between species  (Flower, 1996). Most 
lipocalins also have an L1 loop, which is a linking structure which also functions as a 
cap or lid which can either prevent entry into or out of the binding domain(Flower, 
2000).   As many proteins within the Lipocalin family were identified before the group 
was defined, the majority of proteins, somewhat confusingly do not contain the name 
Lipocalin. Members of the family include Apoplipoprotein (which binds to 
progesterone and other steroids) and CRABP2-a retinoic acid binding protein 
produced in eye tissue (Chakraborty et al., 2012).  Of genes with the name Lipocalin 
(LCN), LCN1, 2, 6 8,9 12 10 and 15 have been identified. However of these, only 
LCN1 (an endonuclease produced in tear ducts) and LCN2 have been described 
functionally (Glasgow et al., 2002). 
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Figure 1.8- 3D structure of LCN2 bound to iron-associated siderophores: LCN2 
forms a cup like structure formed of 8-β sheets (in blue). The L1 loop (purple) acts as  
lid-like structure regulating entry. Siderophores (green) are able to enter LCN2 where 
they are tightly bound. (Image license free from http://www.ebi.ac.uk/pdbe-
srv/view/images/entry/1l6m600.png) 
1.14 Structure of LCN2 
Lipocalin 2 is labelled under a range of different names which reflect its initial 
discovery and characterisation, specifically 24p3, NGAL and Uterocalin. The first 
name given to lipocalin 2 was 24p3. This name was proposed by Hraba-Renevey 
and colleagues in the first identification of a 24kDA protein which was found to be 
over-expressed in SV-40 virally induced mouse kidney cells (Hraba-Renevey et al., 
1989).   Later, Flower et al identified this protein as a member of the lipocalin family 
(Flower et al., 1991). In 1994, Borregard et al. described a human homologue of 
24p3. This protein formed part of the gelatinase (i.e. MMP9) complex found in 
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neutrophils. Thus, this protein was termed Neutrophil-gelatinase-associated-
Lipocalin or NGAL (Kjeldsen et al., 1994). NGAL is still commonly used, especially in 
the renal biology field. Uterocalin is a further name which found in older literature but 
has since dropped out of use. 
Regarding the 3D structure of lipocalin 2, the protein differs from other lipocalins due 
to the presence of a 20 a.a. N-terminal signal peptide, although the lipocalin domain 
itself still makes up ~75% of the protein (Coles et al., 1999). LCN2 forms a cup like 
structure as with other members of the family toward the base of the cup structure is 
a bulge consisting of a concentration of hydrophobic amino acids tryptophan, 
phenylalanine threonine and valine.  The  entrance of the cup structure on the other 
hand is has a number of polar residues such as Lysine 125 which project inwards 
which may help in providing affinity for substrates (Goetz et al., 2000). In this respect 
LCN2 differs from other members of the family. The LCN2 protein is a relatively 
small protein of only 198a.a. in length. It is important to note that much of the work 
performed on Lipocalin2 has been performed in mice. However in terms of residues, 
mouse Lcn2 shares only a 62% homology with the human form (Chakraborty et al., 
2012, Kjeldsen et al., 2000). This is particularly relevant to functional studies as it not 
yet known whether this impacts on binding activity. Lipocalin 2 is usually described 
as a monomer of 25 kDa. In their initial description of  LCN2, Kjeldsen et al. also 
described a 46 kDa homodimer and a homotrimer of 70 kDa which are linked by 
sulphur bonds, but these dimers have not been further investigated in terms of 
function (Kjeldsen et al., 1994).  
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1.15 Function of Lipocalin 2 
LCN2 does not contain any known phosphorylation sites, nor does it act as a 
transcription factor (Goetz et al., 2000). LCN2 has been shown to be glycosylated, 
although this has not been well characterised (Miyamoto et al., 2011). In terms of 
cellular localisation, relatively little is known. While LCN2 is known to be secreted, 
within the cell LCN2 is believed to be located primarily within the cytoplasm, but has 
also been shown to be present within the nucleus. LCN2 does not contain a nuclear 
localization sequence, but may be able to shuttle in and out of the nucleus due to its 
small size. 
Despite its small size and lack of phosphorylation activity, LCN2 has been 
associated with a range of cellular functions. LCN2 was first described as being 
associated with MMP9. MMP9 is a matrix metalloprotease which is involved in the 
remodelling and breakdown of the extra-cellular matrix, with particular affinity for 
collagen V (Yan et al., 2001). LCN2 is able to bind to MMP9 covalently (Figure 1.9), 
thereby stabilising it and preventing its MMP9’s inhibition by TIMP1 (Van den Steen 
et al., 2006).  Notably, this interaction does not occur in murine tissue, as the mouse 
Lcn2 does not contain the same cysteine residues necessary for binding. 
LCN2’s main function was derived in part from observations in LCN2-/- knockout 
mice. These mice looked phenotypically healthy. However they were found to be far 
more susceptible to bacterial infection than wild type mouse (Flo et al., 2004). 
Bacteria need a number of nutrients to survive, one of which is iron (specifically 
Fe3+). However in a host organism, iron is not readily available in its free state, or is 
bound up inside other host cells or proteins. To combat this deficiency, bacteria 
produce and secrete siderophores.  Siderophores are a broad range of organic 
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compounds that are able to incorporate Fe3+ into their structure.  By producing 
siderophores and re-incorporating them, bacteria are able to scavenge any freely 
available iron, and thereby enable growth or proliferation . While some bacteria are 
only able to scavenge free iron, other bacteria such as E.Coli, Listeria and 
Salmonella are able to produce siderophores which have an even stronger affinity for 
iron, and are extract it from the host’s own proteins and enzymes.  To help fight 
against these bacterial attacks, animal cells produce LCN2.  LCN2 is able to bind to 
siderophores, essentially trapping them and preventing their uptake by the bacteria 
(Flo et al., 2004, Richardson, 2005, Srinivasan et al., 2012) (Figure 1.9). Specifically, 
LCN2 has a higher affinity for catecholate siderophores which form larger molecules 
rather than hydroxamate siderophores such as deferoxamine which tend to form 
long chains (Flo et al., 2004). 
Once LCN2 has bound the siderophores, its function is not simply to sequester them, 
but instead LCN2 is able to transport them back into the cell. Exactly how LCN2 is 
transported in and out of the cell is not fully understood, but two potential receptors 
have been identified: SLC22A17 (also known as BOCT or NGAL-R) and Megalin 
(Devireddy et al., 2005, Bao et al., 2010), which is also able to transport a wide 
range of other ligands. Once inside the cell, LCN2 is able to release the iron, which 
can drive a large number of different processes (discussed below). However, LCN2 
is also able to capture non-iron bound siderophores and transport them inside the 
cell. When these are released they are free to bind to intracellular iron (Figure 1.9) If 
this happens too much, it has been proposed that this can lead to a critical loss of 
the mineral and potentially to apoptosis through up-regulation of the pro-apoptotic  
BIM (Devireddy et al 2005) although there is considerable debate as to whether 
LCN2 is pro- or anti-apoptotic overall is a matter of considerable debate. Briefly, the 
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apoptotic actions of LCN2 may be dependent on the exact type and concentration of 
siderophores –there is great variation in chemical structure and Fe3+ binding, or on 
tissue type (Tong et al., 2005, Tong et al., 2003).  Alternatively the anti or pro- 
apoptotic effects may be due to pre-existing conditions within each cell type. Indeed 
even in identical conditions Lcn2 over-expressing cells have been shown to have 
opposing effects (Gwira et al., 2005). It should also be noted that there are likely to 
be considerable differences in LCN2’s effects in culture conditions compared to 
whole tissue. 
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Figure 1.9 Basic overview of LCN2 function: LCN2 is secreted by cells where it is 
binds to iron containing siderophores. These are then shuttled back into cells via 
receptors such as Megalin or LCN2R. Siderophores are released from LCN2 which 
subsequently drive iron dependent growth and signalling. Alternatively, LCN2 is able 
to bind to and stabilise MMP9 leading to invasion or metastasis. 
 
4.4 Lipocalin 2 in human physiology. 
LCN2 is expressed in a range of tissues. GeneAtlas data, as well as other more 
specific studies show that in normal human physiology, the highest expression is in 
bone marrow, pancreatic islets and the trachea (Su et al., 2004). This represents 
LCN2’s close association with neutrophils, which are generated in the bone marrow, 
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as well as its links to T-cells which are matured in the thyroid (Orabona et al., 2001). 
LCN2 not usually expressed at very high levels in other types of tissue, but can be 
up regulated in disease (see below).  In mice, Lcn2 is expressed specifically in the 
basal layer of hair follicles, and not in other dermal layers. LCN2 is a secreted 
protein, and as such can be found in blood plasma. In one of the earliest descriptions 
of LCN2, Kjdelsen et al used LCN2 ELISA to determine an average blood plasma 
level of 72ng/ml, although there was high variation, and a range from 40 to 109ng/ml 
(Kjeldsen et al., 1994).  This is has been subsequently confirmed in wider scale 
studies and average plasma levels are generally between 70-120 ng/ml depending 
on the exact methods used (Shapiro et al., 2010). LCN2 is also found in urine, albeit 
at lower levels. Urine LCN2 levels in healthy adults typically range from 20-30ng/ml 
(Bennett et al., 2008). 
1.16 The Signalling mechanisms of Lipocalin 2 
Since its discovery, LCN2 expression has been shown to be regulated by a range of 
different signalling mechanisms. These signalling pathways are however often 
connected, and indeed the literature concerning exactly what inhibits or promotes 
LCN2 expression is often either cell specific (especially between mouse and human) 
or completely contradictory. Despite this, what is becoming increasingly clear is that 
LCN2 is linked to many of the key pathways in cells. 
Of all the potential regulators of LCN2, the transcription factor NF-κB is the most 
closely associated. Briefly, NF-κB. Under non-stimulating conditions, NF-κB is bound 
by its inhibitor IκB, which sequesters NFκB in the cytoplasm. Under activating 
conditions, due to a range of upstream receptor tyrosine kinases, IκB is 
phosphorylated by IKK in complex with NEMO. This enables IκB to be targeted for 
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proteasomal degradation by ubiquitinases. This frees NFκB which is able to enter the 
nucleus and activate transcription  (See above, section 1.6) (Karin et al., 2002).  
LCN2 was first linked to NFκB signalling by Cowland et al in 2003 who demonstrated 
that the LCN2 promoter contains an NFκB consensus binding site (Cowland et al., 
2003). Interestingly, this study also showed that even though NFκB binding to the 
LCN2 promoter occurred after both IL1βand TNFα activation, expression occurred 
only after Il1B activation. A follow up paper then demonstrated the requirement for 
IκBζ which is not induced by TNFα (Cowland et al., 2006). A number of other 
subsequent studies have also demonstrated a strong link between NFκB and LCN2 
(Iannetti et al., 2008, Karlsen et al., 2010, Glaros et al., 2012, Borkham-Kamphorst et 
al., 2011). In many cases, a link to Il1β activation is emphasised, although IL-6 and 
IL-8 have also been proposed as activating LCN2 in an immune setting. 
LCN2 has been shown to be regulated by Hypoxia Inducible factor 1α (HIF-1α)(Viau 
et al., 2010). HIF-1α is transcription factor which is stabilised in response to low 
oxygen concentrations. HIF-1α expression is tightly controlled by NF-κB. HIF-1α 
stability is regulated by procollagen-proline dioxygenase which hydroxylates HIF-1α 
targeting it for degradation (Maxwell and Salnikow, 2004), which is in turn regulated 
by intracellular iron levels . However, LCN2 itself has been shown to regulate HIF-1α 
expression and help drive angiogenesis related expression via VEGF (Yang et al., 
2013). As such, there may be feedback mechanisms involved with LCN2, HIF-1α 
and iron regulation 
Aside from NFκB, a range of other activators of LCN2 have proposed. A STAT1 
binding site was observed at the LCN2 promoter by (Zhao and Stephens, 2013), who 
also indicated a role for ERK signalling, albeit indirectly through NFκB. The LCN2 
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promoter region also contains a binding site from the transcription factor C/EBP, 
which is also associated with NFκB. There are however 6 members of the C/EBP 
family labelled α to ζ. It was shown by Karlsen et al that C/EBPβ and C/EBPδ had no 
effect on LCN2 expression (Karlsen et al., 2010). On the other hand, the opposite 
has been shown by both Du et al (2010) and Zhang et al (2012) in the case of 
C/EBPβ only (Du et al., 2011, Zhang et al., 2012). Also, C/EBPζ has been identified 
as an LCN2 repressor (Wang et al., 2014). 
Other regulation mechanisms for LCN2 include Wnt signalling. In mouse Lcn2, active 
Wnt signalling was found to reduce both mRNA and protein expression of Lcn2, and 
this appeared to have little effect on intracellular iron levels, although removal or iron 
itself did reduce Lcn2 expression, indicating that Wnt regulation is iron independent. 
This mechanism however has not  been further explored and has not been 
demonstrated in humans. 
Overall, it appears that the regulation of LCN2 is fairly complex, while NFκB is 
important, there are ever more links to other transcription factors being discovered at 
a growing rate. 
1.17 Lipocalin 2 in non-cancer based disease 
As LCN2 is a secreted protein, which is relatively easy and cheap to detect in either 
blood or urine, there has been significant focus on whether it may be used as a 
diagnostic markers for a wide array of different diseases and conditions which 
ranges from diabetes to HIV/AIDS (Where LCN2 plasma levels are lower in more 
severe patients(Landro et al., 2008)) . LCN2 has been implicated in heart disease 
and myocardial infarction, and also following organ transplantation. In both cases, 
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elevated LCN2 levels have been observed. LCN2 has most commonly been 
associated with severe organ dysfunction or injury.   
To date, the most common practical application of LCN2 as a diagnostic tool has 
been with Acute Kidney injury (AKI). AKI is a rapid and extremely dangerous form of 
renal failure.  However, being an internal organ, its symptoms are not easily 
observed. AKI is a somewhat broad term for the symptoms resulting in significant 
loss of renal function and nephron activity. AKI may result from drug side effects, 
trauma (especially in surgery) or sepsis. AKI is a major cause of hospital admission, 
and 10-20% of patients  show some form of AKI especially amongst those aged 65+. 
It also has a high (up to 50%) mortality rate  (Haase-Fielitz et al., 2009).  AKI is 
usually assessed through blood creatinine levels, which is the standard method of 
diagnosis. However, creatinine levels are notoriously imprecise. Creatinine is also 
unable to finely distinguish between sepsis-related and non-sepsis AKI. It can also 
not define whether AKI is due to direct trauma or not. As such, other markers have 
been explored to help complement existing testing methods. LCN2 has emerged as 
one of the primary candidates for this detection, indeed, a large to be significantly 
majority of LCN2 based literature concerns just this one area (Note: LCN2 is still 
often called NGAL in AKI papers). NGAL has been shown elevated in AKI patients in 
a range of studies (Shapiro et al., 2010, Gabbard et al., 2010, Makris et al., 2009). In 
a major study, it was showed that  urinary LCN2 levels at were significantly higher 
among patients who went on to develop AKI [155.5 (50.5-205.9) ng/mL vs. 8.0 (5.7-
17.7) ng/mL].  LCN2 was also more sensitive to the sepsis status of AKI patients, 
which may be reflective of its anti-bacterial function (Bagshaw et al., 2010). There is 
however still considerable debate about the specifics of which patients shows 
greatest response, and how accurate blood vs urine readings are etc. LCN2 has 
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been trialled in patients but required better characterisation before it can be used in 
wide scale clinical settings. Nevertheless, a meta-analysis by Haase et al. did show 
that LCN2 is indeed a reliable indicator for AKI, especially in children (Haase et al., 
2009). Despite the large volume of clinical studies on LCN2 and AKI, it is somewhat 
notable that there are relatively few studies on the actual biological effects of 
elevated LCN2 serum levels. Martines et al. (suggest that LCN2 is secreted to assist 
with iron imbalance, whereas Haase et al. propose that it is either anti-bacterial, or 
possibly even a non-functional marker (Haase et al., 2009, Martines et al., 2013). 
Also, there are very few cell-based studies in terms of LCN2’s intracellular or 
extracellular effects in AKI. 
LCN2 has also been associated with a host of other diseases or conditions including 
a range of skin conditions including in the basal layer of eczema and psoriasis 
patients, where LCN2 was up-regulated (Mallbris et al., 2002).  More recently, LCN2 
has even been linked to neurological disorders. LCN2 -/- mice exhibit signs of 
memory loss and anxiety (Ferreira et al., 2013). In humans, levels of LCN2 have 
been observed in patients with Alzheimer’s disease, and positive correlation to 
cognitive impairment has been observed (Choi et al., 2011, Naude et al., 2012).  
Overall therefore, literature to date appears to support the idea that LCN2 is 
produced as a response to stress, this is particularly noticeable in acute trauma ,but 
is also present in more chronic conditions. However, the actual effects of this LCN2 
production are still poorly understood. Whether the presence of LCN2 is purely anti-
bacterial, or whether it contributes to cell survival is not yet fully understood but our 
understanding of LCN2’s effects and regulation is steadily increasing. 
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1.18 Lipocalin 2 in cancer. 
In recent years, LCN2 has attracted ever more attention in relation to cancer; both as 
an diagnostic marker, but also a potential mechanistic driver of the disease. Indeed, 
LCN2 has been associated with an ever-widening array of different cancer types. 
There is however also a large amount of variation between cancer sub-types. Indeed 
the literature surrounding LCN2 and cancer is often highly contradictory. In general, 
the data published so far suggests that the role of LCN2 is highly tissue specific and 
cannot be simply considered as “pro-” or “anti-” tumorigenic, but that a number of key 
features are common to most cancer types.  
Non-solid tumours 
 
Currently, there has been increased interest in the role of LCN2 due its role in 
Chronic myeloid leukaemia (Arlinghaus and Leng, 2008). Here, LCN2 has been 
shown to be a critical determinant of the BCR-ABL+ fusion gene’s function. Higher 
levels of LCN2 were also recorded in patients with more advanced disease state 
(Leng et al., 2008). 
Pancreatic and Colorectal cancer 
 
Significant efforts have been devoted to the role of LCN2 in Pancreatic cancer. 
Pancreatic cancer has an extremely high mortality rate of around 95%. Hence the 
need for an early diagnostic marker is of the utmost importance. Early studies by 
Moniaux et al. identified NGAL as having a strong positive correlation to tumour 
differentiation and severity, albeit in a relatively small number of patient samples 
(Moniaux et al., 2008). By contrast, in the same year Tong et al used ectopic 
expression of LCN2 in pancreatic cell lines to show that LCN2 inhibits both 
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angiogenesis and migration, and this correlated it its expression in well differentiated 
tumours, but not in poorly differentiated tumours (Tong et al., 2005). In a key follow 
up study, Tong et al provided some key mechanistic studies in cell lines whereby the 
presence of EGF led to a decrease in LCN2 expression (Tong et al., 2011). It was 
also found that EGF, by activating EGFR inhibited E-cadherin expression (via ZEB1), 
which in turn led to the activation of NF-κB and hence LCN2 transcription. Other 
studies have since strengthened the view that high LCN2 is favourable in pancreatic 
cancers, is related to reduced EMT (Figure 1.10) (Xu et al., 2012a). A picture is 
emerging which supports LCN2 being up-regulated in low grade tumours, but lost in 
higher grade. As such, LCN2 has been identified as a potential diagnostic marker 
from plasma (Slater et al., 2013, Kaur et al., 2013). Indeed, in one of the first 
practical applications of LCN2, Xu et al used an oncolytic virus containing LCN2 to 
transfect pancreatic cancer cells which dramatically reduced tumour growth in vitro 
and in vivo by increasing apoptosis of tumour cells, and some xenograft tumours 
were completely eradicated (Xu et al., 2012a). There are hence early trials currently 
ongoing investigating whether similar effects are seen in human patients follow that 
of rodent models. 
 
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Potential regulation of LCN2 expression by EGFR and NF-κB.  
Stimulation of EGFR by EGF, this in turn inhibits E-cadherin expression via ZEB1 
repression.  E-cadherin may activate NF-κB  (via IKK) which drives LCN2 
transcription. In parallel, EGFR helps stabilise HIF-1α, possibly in response to iron 
levels which drives LCN2 expression. (Adapted from Chakroborty et al., 2012) 
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In contrast, in colorectal cancers LCN2 has been strongly associated with a poor 
prognosis  (Barresi et al., 2011). A recent study has shown LCN2 as a good 
prognostic marker of both tumour grade and tumour size  (Marti et al., 2013). 
Recently, Reilly et al. demonstrated that not only was LCN2 linked to advanced 
tumour grade, but that it was closely linked to the level of iron within the tumour 
tissue. The authors also indicate that a more wide scale testing of plasma LCN2 
levels in relation to colorectal cancer patients is ongoing with results due in the 
coming years (Reilly et al., 2013). 
LCN2 has also been associated in an increasing number of other cancers with mixed 
results. LCN2 expression was shown to have a negative correlation to differentiation 
in thyroid and endometrial cancers (Iannetti et al., 2008, Lin et al., 2011, Liao et al., 
2013). Conversely LCN2 had a positive correlation to tumour differentiation in 
ovarian cancer, rectal and gastric cancer (Playford et al., 2006, Du et al., 2011). 
Overall therefore, a picture is emerging that indicates that the role of LCN2 is likely to 
be tissue specific (Table 4.1). A distinction must also be drawn between having 
advanced or early stage tumours as the role of LCN2 may be different as the 
disease progresses. 
Breast Cancer and steroid signalling. 
 
Breast cancer is now the most commonly diagnosed cancer type among women 
(Siegel et al., 2013). While BCa is a highly complex disease, a strong component of 
its growth is its dependence on hormones and hormone receptors. The early stage 
of BCa is dependent on a range of steroid receptors, most notably Estrogen receptor 
(ER), Progesterone Receptor (PR) and receptor tyrosine kinases such as Her-2 
(Alderton, 2012). Elevated levels of these receptors are strongly associated with 
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tumour severity and growth and as such are often targets for therapy (e.g. 
Herceptin). However, in many cases, especially in refractory tumours, cells are able 
to evade the need for steroid based growth by acquiring an ER-, PR- or HER2- 
status. Indeed, some tumours show no expression of all three types and are termed 
triple-negative. While the severity of these triple-negative tumours is debated and 
very heterogeneous, they are dangerous as they cannot be targeted by drugs such 
as Herceptin (Dawood et al., 2010).  
The first study linking LCN2 to BCa by Stoesz et al showed that LCN2 expression 
was heterogeneous in human tissue, but appeared to be concentrated in the lumen. 
Moreover, while there was no correlation to HER2 status, there was a significant 
correlation between LCN2 and an ER- status (Stoesz et al., 1998). Following on from 
this study, a range of other groups have also shown a link between LCN2 and a 
steroid receptor negative status. Bauer et al, in a much larger study showed a very 
strong correlation between LCN2 expression in vivo and ER- status and poor 
histological grade, but also to higher HER2 levels (Bauer et al., 2008). Using a 
mouse model, Leng et al (2009) showed that Lcn2-/- mice had significantly less 
tumour growth and metastasis. The group also showed that HER2 itself is able to 
regulate LCN2 levels through NF-κB (Leng et al., 2009). 
 
In a key study, Yang et al provided evidence of an positive correlation between 
LCN2 expression and BCa tumour grade. Further to this, the group also analysed an 
LCN2 over-expressing clone in MCF7 cells, and reciprocally used siRNA for 
temporary LCN2 suppression (Yang et al., 2009). Results obtained showed an 
inverse correlation between LCN2 and ERα. In addition, the group also noted that 
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LCN2-high clones had EMT-like characteristics with reduced E-cadherin and 
elevated vimentin levels. It was also demonstrated that EMT was being affected via 
the ER/Slug axis, and when ERα was subsequently over-expressed in LCN2 high 
cells, the EMT phenotype was reversed. This study also showed limited data of E-
cadherin (but not ERα) being reduced by recombinant LCN2 protein. However in this 
instance, only a minor change was observed, and only after treatment with a very 
high concentration of 100μg/ml of protein. It should also be noted that there were 
significant.  Differences in expression between clones created (Yang et al., 2009). 
Overall however, there is steadily increasing evidence between a negative 
correlation between LCN2 and ERα (Guo et al., 2012). What is less clear however is 
whether it is LCN2 affecting ERα or vice versa, or there being a potential feedback 
loop between the two genes. Both breast and prostate cancer share a common in 
characteristic in that steroid receptor negative status generally confers a poorer 
prognosis. To identify some of the common genetic features between the two cancer 
types, Creighton et al preformed microarray analysis on a large number of ER- 
breast cancer tissues and cell lines, and AR- prostate cancer cell lines. Of the many 
hundred genes found for each category, only 51 were found to be common to all AR- 
and ER- cells/tissues forming a “common signature of hormone independence”. 
Within this set, one of the most prominent genes was LCN2 (Figure 1.11) (Creighton, 
2007). 
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Cancer Type LCN2 correlation 
Pancreatic Generally positive correlation to 
good prognosis 
Colorectal Positive correlation to high 
tumour grade 
Thyroid Negative correlation to tumour 
differentiation 
Ovarian Positive  correlation to tumour 
differentiation 
Breast Positive correlation to poor 
prognosis and ER- status 
Prostate Positive correlation to tumour 
grade 
 
Table 1.2 Overview of LCN2 in different cancer types 
 
 
 
 
 
 
Figure 1.11 List of genes which associated with ER- and AI status in BCa cell 
lines and tissue and PCa cell lines. Right- Table of genes which form a ‘common 
signature of hormone independence’. LCN2 highlighted in yellow (Adapted from 
Creighton et al, 2006) 
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1.19 Lipocalin 2 in Prostate cancer  
Compared to other cancer types, the role of LCN2 in PCa is very poorly understood. 
To date, only two studies have directly addressed the issue. Mahadevan et al. did 
not assess the role of LCN2 in PCa directly, but rather used it as a model for 
identifying LCN2 regulation. In this study, the authors found that LCN2 was elevated 
in PCa cells through endoplasmic reticulum induced stress via the unfolded protein 
response. Moreover, they identified NF-κB as a key mediator of LCN2 induction. 
While this study does not provide any information about LCN2 in PCa per se, it does 
provide further evidence that LCN2 is produced in response to acute stress 
(Mahadevan et al., 2011). 
Very recently, a study by Tung et al (2013) provided a more in depth analysis of 
LCN2 in PCa. Higher LCN2 levels were found to correlate to poorer tumour 
differentiation and higher Gleason score. Also, using shRNA, the group also 
suppressed LCN2 expression in DU145 and PC3 cells. Suppressed LCN2 
expression resulted in  an increase in cells in G0/G1 arrest. This was also associated 
with a reduction in cell migration. It was also found that cells without LCN2 had 
higher levels of p21 and phospho and total-p53, reciprocally, Cyclin D1 was reduced 
in these cells. Finally, a xenograft model in mice showed that when LCN2 knockout 
cells were injected, tumour weight volume was significantly reduced. This study 
however did not investigate the effects of LCN2 on hormone receptor regulation, or 
EMT, and also leaves open some key questions about the global effects of LCN2 
(Tung et al., 2013). As such, the role of LCN2 in PCa is a worthwhile area of 
investigation. Given that steroid receptor expression in PCa is of critical importance, 
any potential role of LCN2 warrants further study and may provide insight as to 
exactly what role LCN2 is playing in this disease.  
74 
 
 
 
Chapter 2 
Materials and Methods 
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2.1 Cell and Tissue Culture. 
The parental cell lines PC3, DU145, LNCaP were all obtained from the European 
Collection of Cell Cultures (through Sigma-Aldrich, St Louis, MO, USA) and normal 
prostate epithelial PNT2 cells were 
kindly provided by Norman Maitland (University of York).  The MCF7 breast cancer 
cell line was provided by Dr Sahira Khalifa (QMUL) derived from a stock from Cancer 
Research UK. 
 
Prostate and breast cancer cell lines, particularly those which express oestrogen 
receptors are known to react strongly to the presence of phenol red, which acts as 
ER agonist. To eliminate any interference from phenol red, all cells were cultured in 
phenol red- free RPMI 1640 medium supplemented with 10% (v/v) FBS, L-Glutamine 
(2 mM), penicillin (50 μg/mL) and streptomycin (50 mg/mL) (all Lonza. Basel 
Switzerland). All cell lines were cultured in either T-25 or T-75 flasks (Fisher 
Scientific, Loughborough, UK) and incubated at 37oC in a humidified incubator with 
5%CO2/95% air until they reached 70-80% confluence, with media being changed 
every 3-4 days depending on cell density. 
2.2 Splitting and Counting Cells 
To split cells, media was removed, and flasks rinsed lightly with PBS and aspirated. 
1X Trypsin-EDTA (PAA, Little Chalfont, UK) was added (3mL for a T-25 flask, 5mL 
for a T-75), and incubated at 37oC for ~5 minutes, or until all cells were free floating. 
Trypsin was neutralised through the addition of warm FBS containing media in a 1:1 
(v/v) ratio and transferred to 15 mL tubes. Cells were centrifuged for 5 minutes at 
1200 RPM, and the supernatant aspirated. The resultant pellet was suspended in     
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1 mL of FBS containing media and counted using a haemocytometer. Cell counts 
were assessed using an average of the outer 4 quadrants of the haemocytometer 
grid and multiplied by 10,000 to obtain a total number of cells per pellet. Under usual 
circumstances, cells were split 1:10 into new flasks and supplemented with fresh 
media   
2.3 Retroviral transduction 
 
Retroviral transduction provides a powerful method to study the effects of a specific 
gene in cells. The process utilises the virus’ abilities to integrate into chromosomal 
DNA. Before viral particles can be generated, the coding sequence for the gene of 
interest is inserted into a bacterially derived plasmid through ligation. The inserted 
gene is situated between two flanking LTR (long terminal repeat) sequences and a Ψ 
signalling motif. Plasmids are then transfected into Phoenix cells. Phoenix cells are 
modified 293T- human embryonic kidney cells which have been inserted with viral 
packaging proteins GAG, POL and ENV. When the gene-containing plasmid is 
inserted into the Phoenix line it will generate viral particles which are released into 
the media (Figure 2.1). Viral particles are then centrifuged into cells and the gene is 
inserted into the chromosomes and constitutively driven by a Cyclomegalovirus 
promoter. 
 
 
 
 
 
77 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Overview of viral transfection. Plasmids containing gene of interest 
are transfected into Phoenix (ΦNX) cells and combine with viral packaging proteins 
to produce a virus which can be added to other cell lines. 
2.4 Generation of an LCN2 containing plasmid. 
Plasmids containing the LCN2 gene were kindly supplied by Dr Zhimin Tong (M.D. 
Anderson, Texas, USA). However, overall yields were very low. As such, the entire 
LCN2 coding sequence was amplified directly from plasmids via RT-PCR 
PLATINUM® Pfx kit (Invitrogen, Carlsbad, CA, USA) using  primers with a modified 
phosphorylated 5’ end using the sequences: 
 
Forward- 5’[Phos]GAAATCATGCCCCTAGGTCTCC3’, and reverse   
5’[Phos] CACTCAGCCGTCGATACACTG 3’. PCR amplification was carried out 
using  reaction: PLATINUM® Pfx DNA polymerase-0.5 μl, 1 μl template DNA, 1.5μl 
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Primer mix (both Forward and reverse), 1.5 μl 10mM dNTP mix, 1 μl 50nM MgSO4, 
5μl Pfx amplification buffer, 39.5μl dH2O.   Reactions were performed using 35 
cycles of 95oC- 15 secs, 60oC-30 secs, 68oC-60 secs. Resultant DNA was ~2 μg/μl 
and was purified by running on a 0.8% (w/v) agarose gel and cut out under UV light 
and dissolved in QB buffer (supplied with Platinum pfx kit) in a 3:1 ratio at 50oC for 
10 minutes. Dissolving reactions were stopped using a 1:1 volume of 100% 
isopropanol (v/v) and centrifuged through a DNA collection column for 1 minute. 
DNA was spun dry and diluted with 50μl elution buffer. 
 
The pBABE-puro plasmid is a constructed circular DNA containing numerous 
restriction sites (Figure 2.2). Plasmids also contain both ampicillin and puromycin 
resistance genes. 0.5 μl of pBABE-puro plasmid was cut using the SALI restriction 
enzyme (New England Bioscience, MA, USA) for 1hr at 37oC in Buffer 3 and BSA 
(both from New England Bioscience, Boston, MA, USA) according to the 
manufacturer’s instructions. 1 μl of Antarctic phosphatase (New England Bioscience, 
Boston, MA, USA) was added to de-phosphorylate the hanging ends and incubated 
for 30 minutes at 37oC. Both enzymes were deactivated by heating to 65oC for 20 
minutes. A further restriction enzyme Klenow (New England Bioscience, Boston, MA, 
USA) was utilized to remove the hanging ends of DNA and create blunt ended DNA 
fragments. 0.5μ l Klenow, plus 1 μl of dNTPs were added to the reaction and 
incubated for 15 minutes at 12oC. All reactions were deactivated by incubated at 
75oC for 20 minutes.  Cut pBABE-puro was then isolated in an 0.8% (w/v) agarose 
gel then dissolved and purified as above. 
For the ligation reaction, a fragment to plasmid ratio of 3:1 was utilised according to 
manufacturer’s recommendations and the size of the DNA fragments taken into 
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consideration (LCN2 gene fragment= 600 base pairs, vector fragment =5100 base 
pairs). 10 reactions were created each with 5 μl of pBABE-puro (@8 ng/μl) and 2.25 
μl of LCN2 gene fragment (@10 ng/μl) were supplemented with T4 ligase, 1 μl of 
ATP buffer mix (both New England Bioscience, Boston, MA, USA and made up to 10 
μl with dH2O. The reactions were left overnight at room temperature.  
 
Ligated plasmids were transfected into TOP10 OneSHOT competent bacteria 
(Invitrogen, Carlsbad, CA, USA) using a heat shock method at 42oC as per 
manufacturer’s instructions and plated onto ampicillin containing agar plates and left 
overnight at 37oC as well as control bacteria containing plates. Colonies were then 
selected for amplification by MINIprep (Qiagen, Venlo, NL) as per manufacturer’s 
instructions. Pelleted bacteria were digested and DNA extracted, then eluted using 
elution buffer.  
As blunt-ended ligation was used for gene insertion, it was necessary to determine 
whether the DNA fragment was orientated in the correct position.  The LCN2 gene 
was found to contain a SCAI restriction site, as well as being present in pBABE-puro. 
Thus, a double digest was performed on the plasmids using SCAI and BAMHI, which 
has one restriction site on the pBABE-puro backbone. Correct orientation was 
determined based on gene fragment size, with correct orientation displaying bands 
of ~600bp in length whereas incorrect orientation displayed a 200bp fragment. 
 
2.5 Generation of the LNCaP-LCN2 and LNCaP-pBP cell line. 
Phoenix cells were seeded into 6-well plates with 50,000 cells per well, 
supplemented with 2ml of DMEM media and allowed to attach for 24hrs at 37oC in a 
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humidified incubator with 5%CO2/95% air. For transfection, plasmid was added to 
transfection reagent Fugene 6 (Roche, Basal, Switzerland) at a ratio of 1:3 in  97  μl 
of serum free media in a glass tube.  For the LCN2 containing plasmid (@335 ng/μl), 
3 μl of plasmid was added to 3 μl of Fugene whereas for native vector (@1000 ng/μl) 
1μl of plasmid was added to 3 μl of Fugene.  Transfections were left to rest for 10 
minutes at room temperature with very gentle mixing. 103 μl of the mix was then 
added drop wise to each well and incubated for 24hrs followed by a media change to 
remove Fugene toxicity. Cells were incubated for a further 24 hours. In parallel, 
LNCaP cells were seeded at high density and allowed to seed for 24 hrs. 
Media was removed from Phoenix cells and filtered through a 40μm carbonated filter 
(Fisher, Loughborough, UK) and a 5ml syringe. Resultant media was supplemented 
with polybrene (5 µg/ml). Filtered media was then added to LNCaP cells in a 6 well 
plate and centrifuged at 3000 rpm for 60 minutes at 32oC. Virus containing media 
was then removed and LNCaP cells supplemented with fresh RPMI1640 media and 
incubated for 24 hrs after which LNCaP cells were supplemented with 1 μg/ml of 
puromycin. A control plate of LNCaPs was also supplemented with puromycin and 
selection of clones was carried out until 100% of un-transfected cells had died. The 
remaining population of cells was henceforth known as LNCaP-LCN2 and LNCaP-
pBP (empty vector) cells. (Note, LNCaP-LCN2 was sometimes labelled as LNCaP-
NGAL for labelling purposes to aid identification) 
Validation of the LNCaP-LCN2 cell line was performed using qPCR for the LCN2 
gene as well as ELISA and western blotting.. well as ELISA and Western blotting.
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Figure 2.2 Vector map of pBABE-puro. Vector contains numerous restriction sites, 
an SV40 promoter region, puromycin and ampicillin resistance genes. Inserted 
genes are flanked by two LTR regions and a Ψ site. For LNCaP-LCN2, the LCN2 
gene fragment was inserted at the SAL1 site (1397). 
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2.6 Synthesis of the LNCaP-GLI1 cell line. 
The LNCaP-GLI1 cell line was previously created in our lab by Dr. Sandeep 
Nadendla. The methods used  for the generation of this cell line were identical to 
LNCaP-LCN2 (section 2.3). Briefly, amphotropic retroviral particles containing either 
the  pBABE-puro (empty vector) or the pBABE-PURO-GLI1 were generated using 
the Phoenix packaging cell line (Nolan Laboratory, Stanford, USA). Parental LNCaP 
cells were exposed to the viral particles through centrifugation at 300xg for 1 hour at 
32oC and supplemented with polybrene (5µg/ml). After 72 hours, cells were 
subsequently selected with puromycin to generate the LNCaP-pBP and LNCaP-GLI1 
cell lines.  
In parallel, Dr Sandeep Nadendla also generated the PC3-GLI1, DU-145 and NEB-1-
GLI1 (keratinocyte) cell lines using identical methods, but substituting for LNCaP 
cells. 
2.7 Synthesis of the PC3-shLCN2 cell line. 
Short hairpin RNA (shRNA ) is a robust and long term method for the silencing of a 
specific gene. shRNAs are short sequences of RNA (19-21bp) in length. These RNA 
sequences are bound to an antisense strand and connected with a short hairpin 
loop. The sequences for these hairpin loops may be contained within a lentiviral 
vector which is able to integrate into chromosomal DNA. The lentiviral vectors also 
contain constitutive promoters to drive RNA synthesis in the cell. 
Upon transcription, the RNA strands form natural hairpin structures, and are targeted 
by the protein Drosha which cleaves the pre-microRNA structure so that can be 
exported from the nucleus by Exportin.  Once in the cytoplasm, the hairpin structure 
is cleaved by Dicer leaving two RNA strands. The antisense strand of RNA is then 
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targeted by the RISC complex and together these bind the sense strand of mRNA of 
the target gene which is then targeted for destruction (Figure 2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 shRNA-Mechanisms of action. Plasmids containing shRNA sequence 
are transfected into cells and inserted into chromosomal DNA. Transcribed shRNA 
forms a hairpin loop which is cleaved by dicer into siRNA strands. Single strand 
siRNA is bound by the RISC complex and is able to target corresponding mRNA 
sequences for degradation. (www.sbct.com) 
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For the generation of a PC3-shLCN2 cell line, pLenti-L6H vectors containing a short 
hairpin (sh)RNA sequence were kindly supplied by Dr Zhimin Tong (Tong et al., 
2005) (M.D. Anderson, Texas, USA) who in turn received from the Jang-Seong Kim 
laboratory  (Mogam Biotechnology Research Institute, Yongin-city, South Korea) 
(Lee et al., 2006) targeting LCN2 with the sequence 5’ 
CACCATGCCCCTAGGTCTCCTGTGG-3’, with expression under the U6 constitutive 
promoter. Vectors also contain a blasticidin resistance gene This vector has been 
used in published papers by both groups. In addition, a control vector containing 
shRNA with a non-targeting empty vector sequence was provided. These were 
combined with the viral packaging vectors pCMV (Addgene, MA, USA) containing 
genes encoding for GAG and POL, and the pMDG-VSVG containing VSVG 
(Addgene) These vectors were amplified as above using the QIAPrep Spin Maxiprep 
kit as per the manufacturer’s instructions. Plasmid vectors were transfected into 
OneShot® TOP10 chemically competent bacteria (Invitrogen, Carlsbad, CA, USA) 
and spread on 1% agar plates containing ampicillin (100μg/ml) and incubated 
overnight at 37oC. Single colonies were selected and added to 1ml of LB broth to 
form starter cultures. Starter cultures were added to 200ml of LB broth (15g/l in 
distilled water and autoclaved) and shaken overnight at 37oC.  Bacterial solutions 
were placed into 50ml plastic tubes and centrifuged at 4000rpm for 15 minutes and 
supernatants discarded. Pellets were suspended in 10ml of buffer P2 and rested for 
5 minutes. 10ml of buffer P3 was added and chilled on ice for 20 minutes.  Solutions 
were centrifuged for1 minute at 10,000 rmp at 4 oC. Supernatants were decanted into 
Qiagen-tip 500 columns and allowed to drain through followed by 2x washed by 
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buffer QC DNA was eluted using 5ml of buffer QF. DNA was precipitated by adding 
7ml of isopropanol, then centrifuged for 1 minute at 10,000 rpm. Tubes were rinsed 
using 5ml of 70%  (v/v) ethanol, followed by  centrifugation for 1 minute at 10,000 
rpm. Remaining ethanol was removed by centrifugation and air-drying. DNA was re-
suspended in 1ml of dH2O 
 293-FT cells (provided by Dr. Cleo Bishop, QMUL, UK) were grown in high glucose 
DMEM (Lonza) at a density of 50,000 cells/cm2 in a six well plate and allowed to 
attach for 24 hrs. 293-FT were then transfected using FuGene (Roche) in serum free 
media, with a total plasmid to Fugene ratio of 3:2. Lentiviral vectors were 
supplemented with the vectors pCMV, pMDG which contain the GAG, POL and ENV 
viral proteins and either pLenti-L6H-shLCN2 or pLenti-L6H-shControl. In parallel, 
PC3 cells were seeded at 30,000 cells/well in a 6 well plate and allowed to settle for 
24hrs. 
Viral particles were filtered using a 40nm carbonated filter and supplemented with 
polybrene (5µg/ml).Virus containing media was then added to parental PC3 cells and 
underwent centrifugation at 300xg for 1 hour at 32oC. Fresh media was then added. 
After 72 hours, cells were subsequently selected with blasticidin (1µg/ml) (PAA 
laboratories, Little Chalfont, UK) until all un-transfected control cells had died after 
approximately 2 weeks, thereby creating both the PC3-shLCN2 and PC3-shControl 
cell lines.  Using an identical protocol, but using MCF7 cells, the cells lines MCF7-
shLCN2 and MCF7-shControl were created. 
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2.8 Short interfering-RNA targeted gene suppression. 
Short interfering RNAs (siRNAs) provide a powerful tool for temporary suppression 
of a target gene. The method of siRNA suppression is similar to that of shRNA, 
except that they do not contain a hairpin structure. As such siRNAs can be 
transfected directly into cells without the need for a viral vector. However, this means 
that any suppression is temporary and will only last until the siRNAs are used up by 
the cell or degrade. 
siRNA suppression of GLI1: 
 
7000 cells/cm2 were reverse-transfected with control siGLO (Dharmacon, Lafayette, 
CO, USA), Silencer® Select Negative Control No.1, or siRNA targeting GLI1 
(Ambion Silencer® Select s5815 or s5816) and/or GLI2 (Ambion Silencer® Select 
s5817) using the Hiperfect (Qiagen) transfection reagent to produce a final 
concentration of 30 nM; Briefly, siRNA was pipetted onto fresh plates and rested for 
2 minutes before being diluted in 100µl of serum free  RPMI 1640 media and rested 
for a further 15 minutes followed by addition of cells and FBS (10% v/v) containing 
media. Fresh FBS (10% v/v) containing medium was added 24 hr post-seeding. RNA 
and protein was extracted from samples 96 hours post-seeding. For time course 
analysis, extracts were taken at 2, 3, 4 and 7 days (including one additional media 
change) 
siRNA suppression of LCN2. 
 
Targeted suppression of LCN2 was carried out using OnTarget® Plus siLCN2 
(Thermo Scientific, Waltham, MA, USA) using the protocol listed above at an 
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optimised concentration of 50nM for 72 hours was determined. For time course 
analysis, extracts were taken after 2, 4 and 6 days post seeding. 
2.9 RNA extraction 
Prior to harvesting cells were washed twice with PBS, mRNA extraction was 
performed using RNEasy Mini Kit (Qiagen, West Sussex, UK) according to the 
manufacturer’s instructions. RLT plus buffer was supplemented with β- 
mercaptoethanol (1:1000). Genomic DNA was extracted using the gDNA extraction 
columns provided. RNA was eluted using 50µl of nuclease free H2O. Samples were 
quantified using a nanodrop  (Thermo Scientific, Waltham, MA, USA) at 260nm, with 
mRNA quality assessed using 260/240 (260nm detects total nucleic acids, 240nm 
detects background noise). All mRNA samples were stored at -80oC. 
2.10  cDNA synthesis 
Complimentary DNA (cDNA) was synthesised using a SuperScript® VILO™ cDNA 
Synthesis kit (Invitrogen™, Paisley, UK) using 2-2.5 ug of mRNA The reaction was 
carried out in a PCR machine with the following program: Samples are brought to 
room temperature of 25oC for 10min, followed by cDNA synthesis at 420C for 2hrs 
and a final reverse transcriptase inactivation or reaction termination step at 80oC for 
5min. The resultant cDNA was quantified using NanoDrop and stored at -20oC. 
2.11 RT-PCR 
RT-PCR was performed using REDMIX Mastermix (Thermo Scientific, Waltham, MA, 
USA) in nuclease free 200 μl tubes containing:  10 μl REDMIX ( in kit, containing Taq 
polymerase) , 6µl dH2O, 1µl each of forward and reverse primers (1 µM) 1µl MgCl2 
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(25nM), 2µl cDNA (100ng/µl). All reactions were carried out using the following 
profile: 
5 minutes at 95oC. 15 Seconds at 95oC, 18 seconds at 60oC (or similar annealing 
temperature). 20 seconds at 72oC.  Primer details are listed in Table 2.1. 
2.12 QPCR 
Quantitative polymerase chain reaction (qPCR) enables a real-time reading of cDNA, 
and hence mRNA levels of specific genes. qPCR works by attaching dNTPs which 
have fluorescent tags which are incorporated into double stranded DNA as it is 
amplified. Fluorescence is detected by lasers within the machine, and readings are 
taken at each cycle at the extension stage (Fig 2.4). The increasing intensity is 
recorded as a curve displayed on screen. Thresholds are arbitrary, but placed where 
curves reach X=Y (in most cases 0.2 fluoro-units.  The earlier the curve appears, the 
more mRNA is present for that gene (Figure 2.4). All values are then normalised to a 
housekeeping control gene. After the qPCR is run, a melt curve is generated. This 
can be used to identify the length of the cDNA fragment. In general, most fragments 
of 15-300bp produce peaks at ~85oC, whereas primer-dimers and other junk material 
produces peaks at ~75 oC and hence discarded. Multiple peaks indicate bands of 
more than one length being present. 
 
 
89 
 
 
Figure 2.4 qPCR analysis curves Sample figure of a qPCR curve using QIAGEN 
rotor gene software. Fluorescence is detected on the Y-Axis, with an exponential S-
curve generated for each reaction. The further left a curve, the greater the amount of 
starting cDNA. In this case, the blue and red curves reach the threshold ~1 cycle 
before yellow and green. 1 cycle= 2x more starting mRNA. I.e. blue and red samples 
have roughly double the amount this gene expressed. 
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QPCR analysis was carried out using a Rotor-Gene-Q machine  (Qiagen, West 
Sussex, UK) and associated software. Primers used are listed in table 2.1 
qPCR reactions were carried out using Rotor-Gene SYBR Green PCR Kit (Qiagen) 
containing fluorescent probes and dNTPs. All samples were performed in triplicate. 
Each sample contained the following components: 10μl SYBR Green, 5 µl dH2O, 1µl 
each of forward and reverse primers (1 µM) 1 µl MgCl2 (25 nM), 2 µl cDNA (100 
ng/µl). Primers are listed in table 2.1. Samples analysed on the Rotor-Gene-Q with 
the accompanying software using the following programme: 
5 minutes at 95oC 5 seconds at 95oC.  
5 seconds at 60oC (or similar annealing temp.) 10 seconds at 60oC x 45 cycles. 
15 minutes melt from 50oC to 99oC 
Analysis of the melting curve graph of the PCR product indicated that the data 
generated was from a single product and confirmed by running on a 1% (w/v) 
agarose gel. Relative induction values (x) were calculated using the formula x = 2-
ΔΔCT whereby Ct represents the mean threshold cycle of replicate analyses, ΔCt 
represents the difference between the Ct values of the target gene and the reference 
gene GAPDH, and ΔΔCt is the difference between the ΔCt values of the target gene 
for each sample compared to the ΔCt mean of the reference sample. 
To confirm whether cDNA fragment sizes were correct, following the qPCR run, 
samples for each gene were supplemented with loading buffer  (BlueJuice™ Gel 
Loading Buffer 10X, Invitrogen, Carlsbad, CA, USA) and run on a 1% (w/v) agarose 
gel. This was then cross-referenced to the melt curve generated by the Rotor-gene 
software. 
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Gene  Forward (5’ to 3’) (Reverse 5’ to 3’) 
AGR2 AGCCGCCGACTCACACAAGG AGGGTCTGGGGCAGTTTGGGT 
AR TACCAGCTCACCAAGCTCCT GCTTCACTGGGTGTGGAAAT 
BOCT CCAACTTCATTGCCCATGCC CTCTGTTGGGGTTCCCTTGT 
CD44 GTGATCAACAGTGGCAATGG CCACATTCTGCAGGTTCCTT  
E-cadherin TGCCCCCAATACCCCAGCGT ACGGTGGCTGTGGAGGTGGT  
EGFR CAGCGCTACCTTGTCATTCA TGCACTCAGAGAGCTCAGGA 
ERBB2 (HER2) TCCAGCCCTAGTGTCAGGTC CCAGCAGGGCTTCTTCTGT 
ESR1 (ERα) CCAGCACCCTGAAGTCTCTG ACTCATGTGCCTGATGTGGG 
ESR2 (ERβ) CGACCACTAAGGACTCTACC TCGCACTGGTACATGGCTAA 
GAPDH GCCTTCCGTGTCCCCACTGC GCTCTTGCTGGGGCTGGTGG 
GLI1 GAAGACCTCTCCAGCTTGGA GGCTGACAGTATAGGCAGAG  
GLI2 TGCCACTGGGAAGACTGCACC AAGGGCTTCTGCTCCCGCTG 
IL1B GGGCCTCAAGGAAAAGAATC TTCTGCTTGAGAGGTGCTGA 
KDR ACGGCGCTTGGACAGCATCA ATTTCGTGCCGCCAGGTCCC 
KLK3 (PSA) CACAGCCTGTTTCATCCTGA  AGGTCCATGACCTTCACAGC  
KLK5 TTTTCAGAGTCCGTCTCGGC ACACCAAGCACTTTGTCCCA 
KLK6 GTGTGCTGGGGATGAGAAGT CACATGTCAGGGTCACTTGG 
LCN2 CCCGTGTTGGGGGCTCTGCATG GTTGGTGTCACCACTCGGACG 
ΔP63  GTCCCAGAGCACACAGACA GAGGAGCCGTTCTGAATCTG  
P-Cadherin AACCTCCACAGCCACCATAG GTCTCTCAGGATGCGGTAGC 
SPARC CGCATGCGGGACTGGCTCAA TGAGGGGAGCACGCAGTGGA 
SLUG CTTTTTCTTGCCCTCACTGC GCTTCGGAGTGAAGAAATGC 
SNAIL ACCCCACATCCTTCTACTG TACAAAAACCCACGCAGACA 
SPRY1 AGGTCTGAAAGGGCAATCCG TTCCACCATGCTCTCAGCAG 
ST14 CCCAGACCTTCAGGTGTTCC TCAAGCAGAGCCCATTGAGG 
TWIST1 GTCCGCAGTCTTACGAGGAG CCAGCTTGAGGGTCTGAATC 
Vimentin TGGCCGACGCCATCAACACC  CACCTCGACGCGGGCTTTGT  
   
 
Table 2.1 List of primers used 
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2.13 Protein Extraction and quantification from Cell Lines. 
Prior to extraction, cells were washed in PBS. Protein extraction was carried out 
using a 50mM Sodium Hydroxide solution heated to 100o C. 220µl of hot protein lysis 
buffer (50 mM Tris–HCl, pH 8.0, 2% sodium dodecyl sulphate (SDS)) was added to 
cells, and removed with a cell scraper. Samples were boiled for 5 minutes before 
quantification. Protein levels were quantified using the Bio-RadDC Protein Assay 
detection kit (Bio-Rad, Boston, MA, USA) according to the manufacturer’s 
instructions. 20 μl of protein were added to 1 ml clear plastic cuvettes and 
supplemented with 98 μl of solution A and 2 μl of solution S, then rested for 3 
minutes. 800 μl of solution B was added and mixed gently. Proteins are bound by a 
copper tartrate solution, which is able to reduce folin, thereby turning the solution 
blue. The greater the intensity of blue colour, the greater the protein concentration. 
Values were measured at wavelength of 655 nm in a spectrometer and protein 
concentration calculated  against a standard curve derived from bovine serum 
albumen (provided in kit).Samples were all stored at -80oC for future use. 
 2.14 Western Blotting / Gel electrophoresis. 
Western blotting was performed using 8-12%  (w/v) polyacrylamide-tris gels.  Gels 
were comprised of. distilled water,30% (v/v) acrylamide gel, 1.5 M Tris (pH 8.8), 10% 
(w/v) SDS, 10% (w/v) ammonium persulphate (APS) and 
tetramethylethylenediamine (TEMED) (0.2% v/v).  TEMED and APS combine with 
the acrylamide to form long cross-linked chains. SDS interacts with the proteins, 
giving them a negative charge which enables them to be attracted by an electric 
current. The varying percentage gel was dependent on the molecular weight of the 
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relevant protein, with 8% gels used for detection of proteins >150 kDa, 10% gels for 
proteins 20-150 kDa and 12% gels for proteins <50 kDa.   
Prior to protein loading, protein samples were heated to 95oC for 3 minutes before 
loading dye was added (loading dye is at a 5x concentration, [100mM Tris-HCl (pH 
6.8), 200mM dithiothreitol, 4% SDS, 0.2% (w/v) bromophenol blue, 20% (v/v) 
glycerol]). ColorPlusTM (New England Bioscience, Boston, MA, USA) ladder was 
used For protein size verification. Biotinylated protein ladder (Cell Signalling) was 
also used in some experiments as an additional marker. After loading, the gel was 
subject to a current of ~100v for 1-2 hours until the loading dye had run off the gel.  
For mixed molecular weight gels, pre-cast 18-well gradient gels (4-15%) were 
obtained from BioRad (Berkeley, CA, USA). 
Protein was transferred to Hybond (Amersham Bioscience, Amersham, UK) 
nitrocellulose using a Trans-Blot Turbo Semi-dry transfer machine and transferred 
using the ‘mini-gel’ setting for 25 minutes. Following transfer, membranes were 
washed in PBS-T (0.2% v/v) and stained with Ponceau stain (Invitrogen, Carlsbad, 
CA, USA) to detect correct transfer. Membranes were then blocked in either  5% 
(w/v) milk or BSA mixed with PBS-T or TBS-T for 1 hour. Antibody (See Table 2.2) 
was added to fresh blocking solution, and membranes incubated overnight at 4oC. 
Following incubation, membranes were washed 3 times for 5 minutes in either PBS-
T or TBS-T, and incubated with HRP linked secondary antibody in milk for 1 hour at 
room temperature. Membranes were washed a minimum of 3 times in either PBS-T 
or TBS-T. Membranes were probed using an ECL Prime TM western blotting 
detection kit (GE Healthcare, Little Chalfont, UK). 
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Antibody  Specificity Company 
Androgen Receptor Rabbit Cell signalling (MA, USA) 
α-tubulin Mouse Santa-Cruz, CA, USA 
p-AKT Rabbit Cell signalling 
Total AKT Rabbit Cell signalling 
E-cadherin Rabbit Cell signalling 
EGFR (total) Rabbit Cell signalling 
p-EGFR Rabbit Cell signalling 
ERK (Total) Rabbit Cell signalling 
Estrogen Receptor α Mouse R&D systems, MN, USA 
Estrogen Receptor β Mouse R&D systems 
LCN2 Rat R&D systems 
Total mTOR Rabbit Cell signalling 
p-mTOR, total mTOR Rabbit Cell signalling 
pS6K Rabbit Cell signalling 
Vimentin Mouse Santa-Cruz 
p-4EBP1 Rabbit Cell signalling 
 
Table 2.2 List of Antibodies used. 
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2.15 ELISA 
Enzyme-Linked Immunosorbent Assay (ELISA) uses enzyme linked antibodies to 
detect levels of protein. This method is particularly useful for detecting secreted 
proteins, as in this case the protein can be extracted from media.  In sandwich 
ELISA, antibodies targeting a protein are attached to a plate and bind to the protein 
of interest. Further antibodies are then added which are bound to an enzyme which 
is degrades substrates into a colourful solution. The absorbance of this solution can 
then be measured using a colourimiter. 
For the detection of LCN2 protein an R&D systems (Minneapolis, USA) Quantikine 
ELISA kit DLCN20 was employed. Cells were seeded in T25 flasks (250,000 
cells/well) and incubated for 48 hrs (At which point cells are ~70% confluent). 3ml of 
media extracted directly from the T25 flasks and centrifuged at 2000 RPM for 5 
minutes to remove floating cells. Supernatant was transferred to Ultra-spin 
concentrating columns containing a protein filter (Fisher UK, Loughborough, UK) and 
centrifuged at 4000 RMP for 15 minutes, thus removing any material less than 10 
kDa in size. 
75μl of concentrated media was added to 100μl of assay diluent on the ELISA plates 
and incubated for 2hrs at 4oC. Washing and incubation of LCN2 conjugates were 
carried out according to the manufacturers’ instructions. Enzyme substrate was 
added at a 1:1 ratio and incubated for 30 minutes at room temperature in the dark. 
All samples were performed in triplicate. 
Plates were read using an Optima plate reader using wavelengths 450nm and 
570nm using a ‘flat-bottomed plate’ setting. Standard curves were generated using 
recombinant LCN2 protein concentrations as provided in the kit. 
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2.16 Cell Proliferation assays 
Alamar Blue 
Resazurin is a blue dye which is reduced by mitochondria to become pink in colour 
and is an effective assay of cell proliferation. Cells were plated into 12 well dishes at 
a density of 1x105 cells/cm2 in triplicate, and supplemented with 1ml of RPMI 1640 
media (with 10% v/v FBS). 24h post seeding, 100μl 10x Resazurin (AlamarBlueTM 
(Invitrogen, Carlsbad, CA, USA)) was added and incubated for 4 hours.   3x 100µl of 
the resulting media was added to an opaque 96 well plate from each well. Plates 
were then scanned in a plate reader at 570 nm. Cells were then washed with PBS 
and replenished with new RPMI 1640 media (with 10% v/v FBS). Readings were 
taken at either every 24 h or 48 h intervals 
2D colony formation Assay 
 
Cells were seeded in 6cm plastic dishes at a low density of 40 cells/cm2 and cultured 
for 14 days. Cells were washed with PBS and stained with 1x crystal violet (1% w/v 
in a 75% water/ 25% Methanol v/v solution) for 5 minutes before rinsing. Colony 
counting was performed manually using a 1 cm transparent grid (Fisher UK, 
Loughborough, UK). 
3D colony formation in soft agar 
 
To provide a 3D context for cell proliferation, cells may be cultured in an agar matrix 
so that cells are held in suspension. Six well plates were coated in a 1% (w/v) low 
melting point agarose gel (Sigma) and allowed to set and solidify.  Cells of interest 
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were split and suspended at 20,000 cell/ml in RPMI 1640 media (with 10% v/v FBS). 
Media and agarose gel were combined in a 1:1 ratio to generate a 0.5% agarose 
solution with 10,000 cells/ml. 1 ml of this solution was plated and allowed to set. 
Agarose layers were supplemented with 1ml of fresh RPMI 1640 media (with 10% 
v/v FBS) which was changed ever 2-3 days for a total of 14 days. Colonies were 
counted manually using a 1cm2 grid (Fisher UK, Loughborough, UK). Wells were 
stained with 1x crystal violet (1% w/v in a 75% water/ 25% Methanol v/v solution) for 
preservation. 
 
Senescence Assays 
β-Galactosidase senescence kit # 9869s were purchased from Cell Signalling  
(Boston, MA, USA) and used according to the manufacturer’s instructions. Cells 
were seeded at at 30,000 cells/well and cultured in 6 well plates for 3 days. Cells 
were fixed using the fixative solution provided in the kit and rinsed with PBS. 1ml of 
the β-Galactosidase staining solution containing X-Gal was added to wells and 
incubated overnight at 37oC in a CO2 free chamber. Senescent cells appear break 
down the X-Gal, creating a blue colour which is visible under a microscope. 
DAPI Analysis 
 
4',6-diamidino-2-phenylindole (DAPI) is a fluorescent dye which bind to A-T rich 
areas of  DNA in chromatin. DAPI bound to DNA fluoresces at 460nm which can be 
detected under the microscope.  Cultured cells were washed 3 times for 5 minutes 
each in PBS and fixed in a 4% (v/v) paraformaldehyde solution for 20 minutes at 
room temperature. Cells were washed again twice in PBS  then were incubated in a 
1:5000 DAPI solution (Purchased from Cell signalling) in PBS in the dark for 5 
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minutes. Cells were rinsed in PBS and imaged using a microscope with a 360nm 
ultraviolet laser. 
2.17 Migration assays 
Scratch wound assays 
 
Cells were plated in a 6cm plastic dish at a density of 30x105 cells/cm2 and incubated 
for 48h or until cells reached 100% confluence. Prior to the assay, 10 µg/ml 
mitomycin C was added to cells and mixed thoroughly incubated for a further 4 
hours. Using a 200 µl pipette tip, a line was scored through the middle of the dish. 
The resulting scratch is approximately 2mm wide. Width readings were taken using a 
Nikon Eclipse microscope, with 6 readings taken per scratch. The edge drawing 
function of Nikon microscope software (bundled with microscope) was also utilised to 
determine scratch widths. Scratch width was recorded after 24 hours. 
Live cell imaging 
 
To obtain a real-time assessment of cell movement and migration, time lapse 
imaging was employed. 
Cells were seeded into 6-well plates at a range of densities (10000, 20000 and 
50000 cells/well) and incubated at 37oC in a humidified chamber with 5% CO2 95% 
air for 24hrs. Plates were then placed in a humidity controlled and 5% CO2 
containing chamber. Bright field images of specific co-ordinates within each well 
were captured by a Nikon time-lapse microscope (BioStation IM-Q, Nikon Surrey, 
UK). Images were captured every 15 minutes for 18 hours. Images were collated into 
.avi format. 
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2.18 Microarray analysis 
Microarrays provide a whole-genome view of mRNA transcription. Microarrays are 
small chips containing oligonucleotides corresponding to each gene transcript in the 
human genome. RNA from cells of interest are converted to cDNA, then fragmented 
and labelled with fluorescent tags. If these fragments bind to oligonucleotide with a 
corresponding sense strand, they will fluoresce, and this is detected by scanners. 
Higher fluorescence equals greater amount of mRNA expression. 
For this study, GeneChip® Human Gene ST Arrays (Designed by Affymetrix, Santa 
Clara, CA, USA) were employed for microarray analysis. The GeneChip array 
contains probes for 36,079 human genes, including a number of microRNA 
sequences. Each gene is has multiple probes, preventing cases of false-positives. 
Microarray profiling was carried out for LNCaP-pBP vs LNCaP-LCN2 cells, and for 
PC3-shControl vs PC3-shLCN2 cells. With each cell line being performed in triplicate 
using 3 separate chips. Prior to testing, RNA (extracted using methods detailed in 
section 2.9) was subjected to quality control. Both quality control and the running of 
the GeneChip assay were kindly carried out by the Genome Centre at QMUL.  Raw 
data was normalised and noise reduction was applied before being assigned to 
individual genes using Affymetrix bundled software. To account for background noise 
and false positives, data was subjected to the multi array average (RMA) method. 
RMA utilises quantile normalisation that will fit all the chips used from the experiment 
into the same distribution and also gives them the same mean. This then provides an 
expression value for each gene. From this, differentially expressed genes (DEGs) 
can be separated based on P-values and fold change using -log values. 
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PANTHER pathway analysis 
 
PANTHER gene classification software (http://www.pantherdb.org)  is an online 
network analysis tool which works by sorting gene lists into their roles in biological 
processes. The software is also able to place genes into known signalling pathways 
based on previous literature.  Using raw Log fold expression values, an arbitrary cut 
off point of either +1.5 fold or -1.5 fold (relative to controls) was taken to select genes 
which were either up- or down- regulated. The gene symbols for the selected groups 
were imputed into the PANTHER software and analysed for pathway regulation 
using the histogram tool. Using the same tool, genes were also divided according to 
biological function. 
 
MetaCore analysis 
 
MetaCoreTM  pathway analysis provides a more in-depth analysis of gene ontologies 
and pathways. Metacore software is able to identify whether genes are transcription 
factors, kinases or cell membrane proteins etc. The software is also able to integrate 
genes into more statistically significant DEG pathways based on mathematical 
algorithms. Noise reduction also filters out many insignificant genes to provide a 
robust analysis of DEGs.  
The raw data was normalised using the MetaCore pathway analysis software 
(GeneGo, CA, USA) which was kindly done by Dr Joanne Selway and Avijit Guha 
Roy from The University of Buckingham.   
To generate the probabilities of gene expression between the control cell group and 
the  experimental cells, the Wilcoxon’s signed rank test was used whereby P-values 
were used to compare between different groups of genes. Tukey’s Biweight which 
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are then anti-logged to generate fold change values comparing the genes between 
samples (Gentleman et al., 2005). Genes with a P-value at or below 5% and a fold 
change greater than +/- 2 fold are considered as DEGs. DEGs were analysed in 
MetaCore using integrated GeneGo database of process networks  and cellular 
pathways. P-values represent the probability for a set of genes to appear on a 
network or process map to arise by chance. The smaller the P-value is, the less 
likely that the result has occurred by chance. The P-value also considers the number 
of genes from the experimental data versus the number of genes in the network 
map. The formula for calculating the P-value was: 
 
Gene-E analysis 
 
Gene-E software, (developed by the Broad Institute, Harvard, MA, USA) is an 
analysis tool which is able to generate heat maps of gene expression based on raw 
data and fluorescence intensities generated from microarray analysis. The Gene-E 
software is thus able to plot fluorescence values between samples on an X-Y plot. 
Raw fluorescence values were paired up with Affymetrix gene probe symbols. All 
unconfirned genes, pseudogenes genes without official gene symbols, as well as 
corrupted or blank data were removed from gene lists. Probe intensity comparison 
was carried out using the ‘2 way variables plot graph’ function. 
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2.19 Statistical Analyses 
Unless otherwise stated, or where it was logistically impossible, all experiments were 
performed in triplicate, and performed n=3 times at different time periods.  For 
experiments such as qPCR and Alamar blue, standard deviations were calculated 
using the formula. 
 
From this, the standard error of the mean may be calculated using the formula: 
   
 
Where     σχ = Standard deviation 
               N = Number of observations 
 
To determine statistical significance between two data sets, Student’s t-test was 
employed using the standard formula of: 
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Final values are shown as a p (probability) value, with p<0.05 being considered 
significant. P<0.01 and P<0.001 were also used for providing greater levels of 
significance. 
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Chapter 3 
Results: Suppression of GLI1 in 
Prostate Cancer Cell Lines 
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Introduction 
3.0 Background of previous work on Gli1 in PCa cell lines. 
The work presented in this chapter was follows on from the work carried out by 
Sandeep Nadendla and other members of the Neill lab (Thesis: Sandeep Nadendla 
08/2011). Below is a brief summary of the data obtained prior to the start of the 
project and which is necessary for the understanding of the following chapters and 
results. 
It has been described in previous studies that GLI1 and GLI2 expression in PCa is 
predominantly associated with basal cells, which are further associated with an 
androgen independent phenotype. However, the link between GLI and androgen 
independence was poorly understood (Chen et al., 2009, Shaw and Prowse, 2008).  
To assess the role of GLI in androgen independence in PCa, levels of GLI (both 
GLI1 and GLI2) were analysed across a wide range of PCa cell lines: LNCaP, PC3, 
DU145 and PNT2.  Luciferase reporter analysis revealed that GLI activity was 
significantly higher in the androgen independent cell lines PC3 and DU145 than in 
the androgen dependent LNCaP and PNT2 cell lines. It was thus hypothesised that 
GLI expression was contributing to the androgen independent phenotype. To further 
elucidate any role of GLI1 in the regulation of androgen receptor, GLI1 was 
ectopically expressed via a lentiviral vector in the LNCaP cell line - which had the 
lowest GLI1 expression- to generate the LNCaP-GLI1cell line.  Immediately following 
drug selection, LNCaP-GLI1 cells exhibited a distinct tightened or cobblestone cell 
morphology, whereas LNCaP-pBP (empty vector) cells exhibited a more diffuse 
morphology. This was evidenced by colony formation assays, whereby LNCaP-GLI1 
cells formed large and visible colonies, whereas controls did not. This tight 
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morphology was similar to that found in androgen independent DU145 cells. LNCaP-
GLI1 Cells were also rounder and less spindly in appearance. LNCaP-GLI1 cells 
also proliferated a significantly faster rate than LNCaP-pBP cells as shown by 
Alamar blueTM cell proliferation assays.  
Western blot analysis of LNCaP-GLI1 cells revealed a wide range of changes to 
protein expression.  Overall, LNCaP-GLI1 cells exhibited basal-like characteristics 
and a trend towards a stem-like phenotype. These characteristics included a change 
forming tight colonies, a higher rate of proliferation and changes to gene and protein 
expression. LNCaP-GLI1 cells expressed CD44, a key stem cell marker. Indeed, 
LNCaP-GLI1 cells exhibited many hallmarks of EMT including a total loss of E-
cadherin expression, coupled with an increase in vimentin expression and ΔNp63. 
Most notably, LNCaP-GLI1 cells did not express androgen Receptor which was 
coupled to Bicalutamide resistance, and overall maintained a basal-like phenotype. 
Microarray analysis of both LNCaP-pBP and LNCaP-GLI1 mRNA further confirmed 
that LNCaP-GLI1 cells had indeed entered into both an EMT and an androgen 
independent phenotype, as well as effects to a wide range of other genes (Thesis: 
Sandeep Nadendla 08/2011) (Nadendla et al., 2011). 
Given the previous data, there was a clear correlation between GLI1 and an AI and 
EMT phenotype. It was not known however whether the effects of GLI1 were direct 
or indirect. Furthermore, it was also unknown whether any phenotypic or gene 
expression was reversible, and whether cells could be returned to a luminal-like state 
through the subsequent suppression of GLI1.  
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As such, the follow on from the work carried out by Dr Sandeep Nadendla the aims 
of the experiments in this chapter were as follows: 
Determine if androgen receptor expression is restored in LNCaP-GLI1 cells through 
subsequent suppression of GLI1 through targeted siRNA. 
Determine if the expression of EMT, basal and stem markers such as E-cadherin, 
vimentin and CD44 are reversed following GLI1 suppression in LNCaP-GLI1 cells 
and observe any changes to morphology. 
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Results 
3.1Targeted suppression of Gli1 via siRNA does not reverse phenotype or 
gene expression in LNCaP-Gli1 cells. 
 
To determine whether phenotypic (particularly EMT and AI) changes observed in 
LNCaP-GLI1 cells could be reversed through siRNA targeted suppression. Two 
separate siRNA sequences were used to target GLI1; namely Ambion Silencer® 
Select #5815 and Silencer® Select #5816, with each sequence targeting a different 
section of mRNA transcript. According to the manufacturer’s optimal conditions, 
LNCaP-GLI1 cells were transfected with 30nM siRNA. The intracellular red 
fluorescent dye siGLO was used as positive transfection control.  (Cells were also 
transfected with 10nM siRNA, however this concentration proved to have no GLI1 
expression).  mRNA and protein were extracted from samples after 24, 48, 72, 96 
and 120 hours post transfection.  Visual observation of LNCaP-GLI1 cells following 
siRNA targeted silencing did not reveal any obvious phenotypic changes, with cells 
remaining in tight colonies (Figure 3.1 A).  
qPCR analysis of GLI1 gene expression revealed that both the 5815 and 5816 
siRNAs were effective in silencing GLI1.  Silencing increased linearly, peaking at 96h 
for both siRNAs before showing a slight loss of effect after 120h. Indeed, after 96h, 
mRNA expression of GLI1 was undetectable (no expression after 45 cycles) (Figure 
3.1B).  
Following confirmation of GLI1 silencing, RT-PCR was utilised to analyse expression 
of key GLI1 target genes, specifically the basal marker ΔP63 and androgen receptor.  
Results showed that despite the total silencing of GLI1 transcription, no changes to 
expression were observed in any of genes tested (Figure 3.1C). 
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GLI2 
 
LNCaP-GLI1 cells also express high levels of GLI2 mRNA (Thesis: Sandeep 
Nadendla 08/2011). GLI2 may therefore be responsible for maintaining the 
phenotype observed in LNCaP-GLI1.  Targeted siRNA silencing was performed on 
GLI2 using   Ambion Silencer® Select #5817. siRNA was transfected into LNCaP-
GLI1 cells for 24, 48, 96 and 120h. qPCR analysis revealed that siRNA targeted 
silencing was successful, with silencing peaking at 96 hours post transfection (230 
fold reduction in expression). No phenotypic changes were observed in LNCaP-GLI1 
cells (Figure 3.1A).  No change in GLI1 expression was observed. qPCR analysis 
was then employed to observe expression levels of the AR and ΔP63. Despite 
strong silencing of GLI2 (Figure 3.1B), no significant changes in expression were 
observed in any gene (Figure 3.1C). 
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Figure 3.1 Effects of suppression of GLI1 or GLI2 on morphology and gene 
expression: A Bright field images of LNCaP, LNCaP-GLI1 with siGLO control, and 
LNCaP-GLI1 cells +siGLI1 or +siGLI2 96hrs post transfection. x20 magnification B 
siRNA knockdown of both GLI1 and GLI2 as analysed by qPCR analysis. Values are 
fold induction relative to LNCaP-pBP controls after 96 hours post transfection +/- 
SEM.  C RT-PCR analysis of AR and ΔNp63 following siGLI1 or siGLI2 transfection 
(Representative of n=3). 
GLI1 
GLI2 
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3.2 Double GLI1 & GLI2 silencing 
GLI1 and GLI2 operate using positive feedback loops whereby they are able to 
initiate their own transcription (Regl et al., 2002). GLI1 is able to activate GLI2 
transcription and vice-versa. Moreover, GLI1 and GLI2 have been shown to 
transcribe an overlapping set of genes, and in many cases exhibit redundancy. It 
was therefore proposed that the targeted silencing of GLI1 may be compensated for 
by GLI2. Therefore, silencing of a single gene may be ineffective. 
To address this issue, a double targeted silencing of both GLI1 and GLI2 was 
performed by transfecting both Ambion Silencer® Select #5816 and #5817 in 
LNCaP-GLI1(both siRNAs were transfected at 30nM/ml . As both individual siRNAs 
were optimised to be most effective after 96h, mRNA and lysates were extracted at 
that time point only. 
 
96 hours post transfection no obvious changes were observed to cell morphology. 
LNCaP-GLI1 cells remained compact and highly proliferative (Figure 3.2A).  Total 
GLI activity, as detected by the GLI1 luciferase reporter was reduced by 105 fold. 
qPCR analysis revealed  26 fold and 30 fold reductions in GLI1 and GLI2 
respectively. Despite silencing of both GLI1 and GLI2, target genes were analysed 
via by both qPCR and RT-PCR showed no statistically significant change to mRNA 
expression in E-cadherin, vimentin, CD44, ΔP63 or AR (Fig 3.2B) 
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LNCaP-GLI1 (siGLO control) LNCaP-GLI1 +siGLI1 +siGLI2 
*** *** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Double siRNA knockdown of both GLI1 and GLI2. A-Cells were 
transfected with siRNA targeting both GLI1 and GLI2 for 96hrs- bright field images 
x20 magnification. B qPCR analysis of AR, EMT and stem markers in siGLI1/iGLI2 
LNCaP-GLI1 cells after 96hrs. Values are fold expression relative to LNCaP-pBP. +/- 
SEM. Statistical analysis was carried out using Student’s t-test ***p<0.001.   
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3.3 Prolonged Exposure to GLI1 and GLI2 siRNA 
siRNA targeting both GLI1 and GLI2 were shown to have optimal efficacy after 96 
hours. However, although mRNA is suppressed and while GLI1 protein has a short 
half-life, this may not be a sufficient time period for observable phenotypic change. 
To address this issue, LNCaP-GLI1, PC3 and DU145 cells were transfected with 
siRNA targeting both GLI1 and GLI2 (conditions as above) until cells reached ~70-
80% confluence whereby cells were split and re-transfected every 72-96 hours for a 
total of 14 days (i.e. 3 transfections in total). Following 14 days of siRNA exposure, 
no morphological changes were observed and cells did not revert to a luminal like 
shape (Figure 3.3A). Moreover, there was no visually obvious change to cell 
proliferation or cell toxicity. qPCR analysis also indicated GLI silencing similar to that 
recorded after 96h (Figure 3.3B).  The GLI target genes E-cadherin (CDH1), vimenin 
AR and ΔP63 were analysed via qPCR, however no significant changes to 
expression were observed in any cell, or in any cell line.  
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Figure 3.3 Long term siRNA suppression of GLI1. LNCaP-GLI1 cells were 
transfected for 14 days with siRNA targeting GLI1. A- Bright field images of LNCap-
GLI1 transfected with siGLO or siGLI1 for 14 days. B- qPCR analysis of GLI1 target 
genes in control and siRNA treated LNCaP-GLI1 cells. All values are relative to 
LNCaP-pBP  +/- SEM, n=3. Statistical analysis was carried out using Student’s t-test. 
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3.4 siRNA targeting of GLI1 and GLI2 in DU145 and PC3 cells 
As Ectopic GLI1 expression may have an exaggerated phenotype due to abnormally 
high levels of protein, the effect of GLI1 suppression was also performed in PC3 and 
DU145 cells. Both cell types expressed high levels of GLI1 and are both androgen 
independent and basal-like. Thus, it was investigated whether suppression of GLI 
would lead to a more luminal phenotype. Double knockdown of both GLI1 and GLI2 
was carried out as previously described to eliminate any redundancy effects. As 
above, suppression of GLI1 and GLI2 was successful in both cell types. However, 
following 96hrs of transfection, no change in phenotype was observed. Also, no 
changes were observed to either AR, or to EMT markers in either cell type (Figure 
3.4) 
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Figure 3.4  siRNA targeting of GLI1 and GLI2 in DU145 and PC3 cells. A-qPCR 
analysis of GLI1 and GLI2 in DU145 and PC3 cells following siRNA transfection of 
both siGLI1 and siGLI2, or by siGLO control for 96hrs in DU145 and PC3 cells. 
Values are fold change relative to LNCaP +/- SEM.  B- RT-PCR analysis of ΔNP63 
and AR following siRNA transfection of both siGLI1 and siGLI2, or by siGLO control 
for 96hrs 
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3.5 Pharmacological inhibition of Hedgehog pathway 
In addition to siRNA based targeting of GLI1 expression. I also employed the 
Hedgehog pathway pharmacological inhibitors KAAD-Cyclopamine and SANT1. 
These drugs target SMO and lead to a loss of GLI1 and GLI2 expression (Rubin and 
de Sauvage, 2006).  Both drugs were added to LNCaP-GLI1 cells to determine if 
they affected GLI expression and whether there was any effect on downstream 
targets. Drugs were added for 48hrs before harvesting, however neither KAAD-
Cyclopamine or SANT1 was able to able to significantly reduce GLI1 or GLI2 
expression. There was also no effect on downstream targets E-cadherin, AR and 
CD44 (Figure 3.5A). PC3 cells which also express high levels of GLI were used as a 
positive control for drug efficacy (Figure 3.5B)  
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Figure 3.5 Treatment of LNCaP-GLI1 cells pharmacological hedgehog 
inhibitors A LNCaP-GLI1 cells were treated with KAAD-Cyclopamine or SANT1 for 
48hrs. qPCR analysis of GLI1/2 and downstream GLI targets. B qPCR analysis of 
PC3 cells treated with KAAD-Cyclopamine or SANT1. Values are mean of n=3 
experiments ± SEM. Statistical analysis performed using t-tests. ***P<0.001 
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3.6  Discussion and conclusions. 
 
The change from an androgen-dependent to an androgen dependent phenotype is a 
critical transformation in the advancing of prostate cancer. As such it is necessary to 
determine the molecular mechanisms behind this shift.  It was previously 
demonstrated by our lab that ectopic GLI1 expression led to an androgen 
independent phenotype, and this was associated with an EMT. In the data provided 
here, I have shown that the phenotypes shown were unaffected by subsequent 
suppression of GLI. 
In this study, I employed siRNA to suppress GLI1 expression. While this was 
successful, I observed no subsequent changes to either morphology or gene 
expression, even after 14 days of suppression. It should be noted however that only 
a small range of genes were investigated for differential gene expression, and it is 
likely that suppression of GLI1 had effects other downstream targets which were not 
investigated. A   method of GLI1 suppression is through pharmacological inhibitors, 
specifically the SMO inhibitors KAAD-Cyclopamine and SANT1. These drugs were 
added to LNCaP-GLI1 cells, however, no significant changes were observed to GLI1 
levels. This was likely due to the naturally low levels of SMO in LNCaP cells, and 
ectopic expression of GLI1 may act independently of SMO altogether, or may be 
being produced at such a high level as to overwhelm the inhibitory effects of SMO.  
Cyclopamine, and to a lesser extent SANT1 are both used for the treatment of 
prostate cancer (Rubin and de Sauvage, 2006), and in particular other SMO 
antagonist drugs have been used to target cancer stem cell formation (Merchant and 
Matsui, 2010). However, in the results presented in this chapter, SMO inhibitors had 
little effect on downstream GLI expression in LNCaP-GLI1 cells and to GLI1 target 
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genes.  This therefore suggests that these drugs may be less effective in patients 
where prostate cancer cells have already acquired a cancer stem cell phenotype, or 
to PCa cells with already active GLI expression but low SMO levels. 
A further pharmacological inhibitor GANT61 has previously been shown to target 
both GLI1 and GLI2, however in our hands this drug had no effects on GLI 
expression on any cell lines tested, and at high concentrations was highly toxic, and 
as such was not investigated further.   
The GLI1 gene is expressed at low levels in the normal prostate, but is higher in the 
basal layer relative to epithelial cells. However it is greatly increased in prostatic 
hypoplasia.  The data generated from LNCaP-GLI1 cells provides an intriguing 
insight into how GLI1 is functioning and its downstream effects. As such, it was 
therefore important to fully investigate whether GLI1, a transcription factor was a 
critical mediator of the AI and EMT like phenotype. The data provided from 
temporary suppression of GLI1 however suggests that GLI1 is turning genes on and 
off, but that these changes are mono-directional, and once a gene is turned on, it 
cannot be turned off and vice versa. However, this hypothesis is somewhat unlikely 
given the data from 2 week suppression and the general characteristics of 
transcription factors. It is more likely that GLI1 activates a cascade of other genes or 
transcription factors which then in turn alter the expression of the downstream 
genes. While this is the more likely of the two hypotheses, exactly what mechanisms 
or pathways are being activated is not easily identifiable, as there are likely to be 
numerous interconnecting pathways. Some potential mechanisms which are 
activated by GLI1 are the Ras/MEK pathway which has been shown to interact with 
hedgehog signalling (Stecca et al., 2007). The TGF-β pathway has also been 
implicated in GLI1 signalling (Javelaud et al., 2012), as has the Wnt/β-Catenin 
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pathways (Yanai et al., 2008, Mullor et al., 2001). In a study by Nadiminty et al 
(2011) the group used microarray analysis to identify NF-κB regulated genes in the 
LNCaP cell line. A comparison of microarrays from our lab and the Nadiminty et al 
study revealed a degree of overlap. Out of 50 top up-regulated genes, 15 were also 
highly up-regulated in LNCaP-GLI1 cells including ANAX2, PLAU, TIMP1 and LCN2 
It is likely GLI1 is activating more than one pathway, and indeed there may be 
significant degrees of interconnectivity and feedback. Nevertheless, the data 
generated by Sandeep Nadendla (Nadendla et al., 2011) and the data in this chapter 
does indicate that GLI1, or its downstream targets are in part responsible for a shift 
to an androgen independent and EMT like phenotype, and potentially to the 
advancement of aggressive PCa. 
In conclusion, the data in this chapter suggests that GLI1 over-expression leads to 
an androgen independent and EMT phenotype which is non-reversible by siRNA 
based means. 
While significant research has been done on the exact mechanisms of the hedgehog 
pathway, comparatively little has been shown regarding the actual effects of GLI1 
activation on a global scale. However, the mechanism by which GLI1 was inducing 
androgen independence and EMT was still unknown. As such, I sought out genes 
which were up-regulated by GLI1 which might be driving the effects seen. Using the 
data already available from both LNCaP-GLI1 microarray data, as well as an 
extensive literature search, a number of potential candidates emerged as possible 
effectors of GLI1 and the cause of the phenotypic changes seen. Of these 
candidates, one gene in particular stood out as being worthwhile for further 
investigation. This gene was lipocalin 2. 
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Chapter 4 
Ectopic Expression of LCN2 in the  
LNCaP cell line 
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As previously mentioned in section 1. Lipocalin 2 was identified from microarray data 
which showed this gene to be highly upregulated in LNCaP-GLI1 cells, and that 
LCN2 featured in ontological groupings for both hormone resistance and 
subsequently chosen for further investigation. However, to date there is no published 
data on any links between LCN2 and hormone resistance in prostate cancer. As 
such it was decided to observe the effects of ectopic expression of the LCN2 gene in 
a prostate cancer cell line. Therefore aims of the work carried out in this chapter 
were as follows: 
Identify the expression levels of LCN2 in a range of prostate cancer cell lines and 
determine any links to GLI1 signalling 
Ectopically express the LCN2 gene in a cell line where there is little native 
expression; then determine the effects of LCN2 on steroid receptor expression, EMT 
and proliferation 
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4.1 Characterisation of LCN2 in LNCaP-GLI1 cells 
Lipocalin 2 was previously identified from microarray data in LNCaP-GLI1 cells, 
where ontological grouping of highly upregulated genes placed it in both EMT and 
hormone signalling ontology groups. As such, LCN2 was selected for further 
investigation to determine whether it was at least partially responsible for the 
phenotypic and signalling changes seen in LNCaP-GLI1 cells, particularly with 
regards to AR signalling and EMT. Microarray analysis showed a 55 fold increase of 
LCN2 mRNA between LNCaP-pBP and LNCaP-GLI1 cells. To validate this, more 
sensitive qPCR analysis was performed (Figure 4.1A) qPCR validation revealed that 
LCN2 showed a 3400 fold lower expression in LNCaP-pBP compared to LNCaP-
GLi1 expression (Figure 4.1B). 
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Figure 4.1: LCN2 in PCa cell lines A Table showing the 12 most up-regulated 
genes in LNCaP-GLI1 cells. Data shows comparison between LNCaP-PBP , DU145, 
and PC-3 PCa cell lines. B qPCR analysis of LCN2 expression in PCa cell lines. 
Data is presented as the mean +/- SEM for n=3 experiments. Statistical analysis was 
carried out using Student’s t-test to compare changes in LCN2 expression in relation 
to LnCaP-GLI1 cells. Statistical analysis was carried out using Student’s t-test  *** 
P<0.001.  
A 
B 
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4.2 LCN2 as an intracellular homodimer. 
Based on the data shown in section 4.1 which confirmed the up-regulation of LCN2 
mRNA expression in LNCaP-GLI1 cells, levels of LCN2 protein were also assessed. 
Western blot analysis was used to detect intracellular LCN2 protein expression in 
LNCaP-GLI1 cell lysates. For comparison, Western blot analysis was also carried 
out on lysates from DU145 and PC3 cell lines. Surprisingly, LCN2 protein expression 
was relatively low in some cell lines and did not appear to correlate with LCN2 
mRNA. Indeed, as shown in Figure 4.1A LNCaP-GLI1 had the highest mRNA 
expression of all PCa cell lines; however, LCN2 protein expression was the lowest of 
all cell lines with the exception of LNCaP-pBP (Figure 4.2A). In contrast PC3 cells, 
which did have relatively high levels of LCN2 mRNA (over 500 fold compared to 
LNCaP cells) also showed relatively high levels of LCN2 protein expression. 
However, it was also observed that the molecular weight of the LCN2 band detected 
was 45-48 kDa compared to the published molecular weight of 23-25 kDa. The 
antibody used in these Western blots was the one most commonly cited in the 
literature, LCN2 antibody MAB1757 (R&D) (Yang et al., 2009, Aberle et al., 1997, Flo 
et al., 2004, Tong et al., 2005). In all experiments carried out using this antibody 
rather than the traditionally described molecular weight of 23-25kDA, bands obtained 
via Western blot were consistently found at 45-48 kDa. This band was observed in 
every cell line tested including the MCF-7 Breast Cancer (BCa) cell line. Moreover, 
this band was reduced very significantly when LCN2 was silenced (See Chapter 5 
and Chapter 8) 
Since the 46 kDa band was approximately double the predicted molecular weight, I 
hypothesised that the band detected may be an LCN2 homodimer. A literature 
search revealed that LCN2 had indeed been previously described as a sulphur 
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linked 46 kDa homodimer by Kdjelsen et. al., (1993) in one of the first ever 
descriptions of the LCN2 protein. However, this homodimer has not been 
characterised and in all subsequent publications it is only mentioned in text. It was 
also noted from the literature search that the vast majority of previous publications 
measured only secreted LCN2 either by ELISA or Western blot, and not intracellular 
levels (Yang et al,. 2009). 
To further address this issue, alternative antibodies were tested targeting LCN2. The 
monoclonal NGAL-5G5 antibody (purchased from Santa Cruz) was used to probe 
whole cell lysates (Figure 4.2B). This antibody did produce bands at 24 kDa. 
However, expression was relatively weak, and was completely absent in LNCaP-
GLI1 cells. Tantalisingly, this antibody also appeared to show a doublet band for 
PC3 cells (possibly due to glycosylation) (Miyamoto et al., 2011). Unfortunately, the 
antibody worked only once and in subsequent experiments did not detect any LCN2 
bands. A replacement antibody also showed no LCN2 expression under any 
conditions tested and thus was not used for further research in this thesis. 
Over the course of this project, a number of other LCN2 antibodies became available 
for purchase. A further antibody R&D AF1757 was purchased in 2013. This antibody 
also detected a band at 23Kda, albeit weakly (Figure 4.2C). Notably however there 
were also faint bands present at ~45kDA. Again, this antibody appeared to be 
unstable, and produced only very dirty blots after a couple of uses. Unfortunately this 
antibody ceased to work before it was possible to test for LCN2 expression in 
LNCaP-GLI1 cells.  Despite the presence of dimers, as it provided the clearest and 
most stable results, and as it was the most cited, it was decided that all future work 
would be used using primarily the MAB1757 antibody. 
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4.2- Western blot analysis of cell lysates for LCN2. Western blot analysis of 
various antibodies targeting LCN2 showing presence of a 45 kDa band. A R&D 
MAB1757 rat monoclonal, 3 minute exposure. B Santa Cruz 5G5, mouse 
monoclonal 10 minute exposure. C- R&D AF1757 goat polyclonal, 10 minute 
exposure, PC3 and MCF-7 positive controls only. Western blots are representative of 
n=3 experiments for A, n=1 for B and C as antibodies ceased to work. 
 
A 
B 
A C 
B 
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As can be seen in figure 4.2A, not only was LCN2 protein being detected at a high 
molecular weight, but also evident was that LNCaP-GLI1 cells produced relatively 
little intracellular protein than was expected given that these cells produce much 
higher levels of LCN2 mRNA than PC3 cells (see Figure 4.6B). One possible reason 
for this discrepancy could be that LCN2 is more rapidly secreted from LNCaP-GLI1 
cells, and is thus not detected. To resolve these issues, cells were cultured for 48 
hours, and supernatants harvested under reducing and non-reducing conditions to 
investigate any sulphide-linked protein (Figure 4.3). PC3 cell lysates were also 
analysed to provide a positive control for the high molecular weight band.  
Also, it was previously found that expression of LCN2 in LNCaP-Gli1 cell lysates was 
lower than expected based on mRNA expression. However in cell supernatants 
expression of LCN2 in LNCaP-GLI1 cells was comparable to those found in PC3 
cells. Hence it may be seen that the discrepancy between mRNA expression and cell 
lysate protein expression is likely due to rapid secretion of monomeric protein. 
 Additionally, it was found that the 20-25 kDa band only was found under both 
reducing and non-reducing conditions in LNCaP-GLI1 c and DU145 cell 
supernatants. There was however a faint band at 45 kDa in reduced PC3 cells, this 
therefore demonstrates that the 45 kDa band is not due to protein extraction 
methods, but rather that intracellular LCN2 being detected by the MAB1757 antibody 
is in a homodimeric state, whereas secreted LCN2 is largely  monomeric. 
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4.3 Western Blot analysis of LCN2 in culture supernatants.  Cells were cultured 
for 48hrs and analysed using reducing and non-reducing conditions. Lysates were 
analysed using the R&D MAB1757 rat monoclonal antibody. Data shows that LCN2 
detected in cell culture supernatants displayed a band at ~20 kDa, whereas cell 
lysates displayed a band at ~45 kDa. Data is representative of n=3 experiments.  
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To further investigate the levels of secreted LCN2 protein by PCa cells, a LCN2 
specific ELISA was carried out (Figure 4.4A). The ELISA kit purchased from R&D 
systems contains the same MAB1757 antibody as used previously in Western blots 
shown above.  Results showed high levels of secreted LCN2 protein in LNCaP-GLI1 
cells (3.5ng/ml).  By comparison, PC3 cells showed the highest secreted LCN2 
levels amongst other PCa cell lines (1.75ng/ml).  
Combining ELISA and Western blot data, there appears to be wide variability 
between cells as to whether LCN2 is secreted immediately (as in LNCaP-GLI1 cells) 
or retained intracellular. I therefore hypothesised that rapid secretion may be due 
differential levels of lipocalin 2 Receptor (LCN2-R, also known as BOCT). While 
LCN2-R is very poorly  characterised, Devireddy et al., (2005) did show it to be a 
capable of both secreting and internalising LCN2 protein. qPCR analysis was carried 
out on LNCaP-pBP, LNCaP-GLI1 and PC3 cells. It was found that LCN2-R 
expression was 4.4 and 5.2 fold higher respectively relative to LCN2-R expression in 
PC3 cells (Figure 4.4B). While protein expression analysis was not performed, this 
result may help explain why secreted and intracellular levels vary between cell lines. 
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Figure 4.4 Analysis of LCN2 secretion by PCa Cell lines.  A Cells were cultured 
for 48hrs prior to harvesting of supernatants. ELISA was carried out on supernatants 
as described in Chapter 2: Materials and Methods. Results show the mean secreted 
LCN2 +/- SEM for n=3 experiments. Student’s t-test to compare LCN2 secretion 
against LNCaP-pBP cells. *** P<0.001. B qPCR analysis of LNC2-R in prostate 
cancer cell lines. Values are relative to PC3 +/- SEM, n=3 .Statistical analysis was 
carried out using Student’s t-test. 
*** 
A 
B 
*** 
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Overall, results indicated that high a level of LCN2 mRNA does result in increased 
LCN2 protein levels. However there is a wide difference in the localisation of the 
protein between cell lines. In LN-CaP-GLI1 cells, it appears that the majority of the 
protein is secreted rapidly by the cells. Conversely, in PC3 cells, LCN2 protein is 
retained inside the cell, as well as being secreted. When combined, the data 
indicates that LCN2 does appear to exist as a homodimer within the cell, but that 
only the monomer is secreted. Exactly how the LCN2 homodimer is cleaved however 
is unknown, but is likely to have significant effects on its function within the cell. 
 
4.3 Effects of GLI1 on LCN2 expression in PCa cell lines and NEB=1 
keratinocytes 
Since GLI1 was seen to lead to elevated levels of LCN2 in LNCaP cells, this was 
also investigated in a range of other PCa cell lines. Therefore, in parallel to ectopic 
expression of GLI1 in LNCaP cells, Sandeep Nadendla and other members of the 
Neill lab ectopically expressed GLI1 the in cell lines DU145, PNT2 and in the 
immortalised keratinocyte cell line NEB1 to generate DU145-GLI1, PNT2-GLI1 and 
NEB1-GLI1 stable cell lines respectively which were used for other projects. 
Subsequently, I probed protein lysates from these cells lines for LCN2 by Western 
blot. Results showed that ectopic GLI1 expression led to increased LCN2 expression 
in PNT2 cells. NEB1 cells also showed an elevated level of LCN2 expression relative 
to controls. However, no change was evident in DU145-GLI1 cells. Additionally, the 
MCF-7 cell line was utilised as a positive control (Yang et al,. 2009) (Fig 4.5). 
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Figure 4.5 Ectopic expression of Gli-1 in a range PCa cell types and in the 
immortalised keratinocyte cell line NEB-1. Gli-1 was ectopically expressed in DU-
145 and PNT-2 PCa cell lines, as well as in the NEB-1 keratinocyte cell line (See 
Section 2.6).Western blot analysis of LCN2  in cell lysates using the MAB1757 
antibody showed up regulation of LCN2 in PNT-Gli-1, NEB1-Gli1 and LNCaP-Gli1 
(Representative of n=3 experiments). 
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4.4 Effects  of GLI silencing on LCN2 expression. 
Using the same conditions as in section 3.2, targeted siRNA silencing of both GLI1 
and GLI2 was carried out using gene specific siRNA’s #5816 and #5817 
respectively. Silencing was carried out on both LNCaP-GLI1 cells and PC3 cells. 
PC3 cells were used as they have a high endogenous level of LCN2 and also high 
levels of GLI1 (Nadendla et al 2011). As previously mentioned, (See section 3.2), a 
double siRNA silencing (both GLI1 and GLI2) was also carried out to eliminate any 
redundancy effects. Results showed that despite strong silencing of both GLI1 and 
GLI2 expression, there was no significant change in LCN2 mRNA expression in 
either LNCaP-GLI1 or PC3 cells (Fig 4.6A). Also, no change was observed in LCN2 
intracellular protein expression by Western blotting in either LNCaP-GLI1 or PC3 
cells (Fig 4.11B). Additionally, no change was observed in secreted LCN2, as 
analysed by ELISA (Figure 4.6C). 
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Figure 4.6 Effects of siRNA knockdown of GLI on LCN2 expression: A qPCR 
analysis of LCN2 expression in PC3 and LNCaP-GLI1 following simultaneous double 
knockdown (dkd) of GLI1 and GLI2. GLI suppression is identical to Figure 3.4. Data 
in shows mean +/- SEM for n= 3 experiments. B Western blot analysis of PC3 and 
LNCaP-GLI1 following knockdown. mRNA and protein extraction were carried out at 
the same time. Data is representative of n=3 experiments. C ELISA analysis of 
secreted LCN2 protein in LNCaP cells 96hrs post transfection +/-SEM.***p<0.001 
Statistical analysis was carried out using Student’s t-test. 
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4.5 Generation of an LNCaP-LCN2 cell line: Cloning the LCN2 gene 
To further investigate the role of LCN2 in PCa cell lines, it was decided to analyse 
the effects of ectopically expressing LCN2 in LNCaP cells independently of GLI1 
overexpression. Since LNCaP-GLI1 cells showed such a marked change in LCN2 
expression and because these cells show marked changes in both AI and EMT, it 
was decided to address whether LCN2 played an important role in the phenotypic 
changes (e.g. AI and EMT). Because LNCaP cells have the lowest level of LCN2 
mRNA expression of all commonly used PCa cell lines, indeed, LCN2 expression is 
essentially undetectable via qPCR. Ectopic expression of LCN2 would not interfere 
with any endogenous protein. 
Previously published pLenti-L6H-LCN2 vectors containing the LCN2 gene were 
obtained from Dr. Zhimin Tong (MD Anderson, Texas), which had previously been 
used for ectopic expression in pancreatic cells (Tong et al, 2008). However, DNA 
extraction from the samples sent to us from his laboratory was very low (15ng/ µl). 
Multiple attempts to increase DNA yield through miniprep and maxiprep cloning 
techniques were also unsuccessful in obtaining a high enough yield suitable for 
transfection in part due to a very low uptake of plasmids by TOP10 competent 
E.Coli, with few colonies forming on agar plates (See materials and methods section 
2.5). 
To combat this issue, it was decided to sub-clone the LCN2 coding fragment from 
the pLenti-L6H-LCN2 plasmid. The entire fragment (724bp) was amplified by RT-
PCR, purified, and sub-cloned  into the pBABE-puro vector under the control of the 
constitutively-on cyclomegalovirus promoter (see materials and methods section 2.5)  
This new plasmid pBabe-PURO-LCN2 was successfully transfected into LNCaP 
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cells. As a control, empty pBabe-PURO plasmid was also transfected into LNCaP 
cells to generate an LNCaP-pBP cell line. (To differentiate between the LNCaP-pBP 
cell line generated as a control for LNCaP-GLI1, this cell line was also labeled 
LNCaP-pBP(2)). 
4.6 Characterization of the  LNCaP-LCN2 cell line. 
Following 2 weeks of selection by puromycin, cells were harvested and analyzed for 
LCN2 expression via qPCR, which confirmed a very large (>250 fold) induction of the 
LCN2 gene relative to LNCaP-pBP. No change to LCN2 expression was observed in 
LNCaP-pBP relative to parental LNCaP cells. When LNCaP-LCN2 cells were 
compared to other cell lines for LCN2 expression, mRNA levels were approximately 
similar to those found in PC3 and MCF-7 cells (additional positive control shown by 
Yang et al., 2009 to have high LCN2 levels) (Figure 4.7A) 
While mRNA expression was found to be very high in the LNCaP-LCN2 cells; when 
LCN2 intracellular protein expression via Western blot was examined, it was found to 
be relatively low in comparison (Figure 4.7B). In this regard, LNCaP-LCN2 cells 
displayed a similar characteristic to that found in LNCaP-GLI1 cells which also 
showed low expression of LCN2 intracellular protein. As such, it was theorized that 
LCN2 was being rapidly secreted from the LNCaP-LCN2 cells. To confirm this, 
ELISA analysis was performed on secreted LCN2 derived from cell supernatants. 
Results revealed a strong increase in secretion of LCN2 protein in LNCaP-LCN2 
cells (1.8ng/ml) relative to, PC3 cells (2.3ng/ml)  (Figure 4.7C) and comparable to 
levels of LCN2 secreted by LNCaP-GLI1 cells (See Fig 4.4A). 
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As with LNCaP-GLI1 cells, I hypothesized that rapid secretion may be due to higher 
LCN2-R expression. qPCR analysis of LCN2-R revealed that  LNC2-R expression 
was 4.6 fold higher than in PC3 cells, although there was no significant difference 
between LNCaP-pBP and LNCaP-LCN2 cell lines (Figure 4.7D). 
Overall, the data indicates that ectopic expression of LCN2 in LNCaP cells was 
successful, and that in a similar manner to that seen in LNCaP-GLI1 cells the LCN2 
protein is rapidly secreted by the cells 
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Figure 4.7 Ectopic expression of LCN2 in LNCaP cells. A qPCR analysis of LCN2 
expression relative to LNCaP-parental cells showing a significant increase in LCN2 
mRNA in LNCaP-LCN2 cells with comparison to PC3 cells (mean values +/- SEM for 
n=3 experiments.) B Western blot analysis of LCN2 protein in LNCaP-LCN2 shows 
only weak bands relative to PC3 and MCF-7 BCa cell lines (representative of n≥3 
experiments.) C ELISA showing secreted LCN2 in supernatant from LNCaP-LCN2 
and PC3 cells. D- qPCR analysis of LCN2-R expression in PC3, LNCaP-pBP and 
LNCaP-LCN2 cells +/- SEM. Statistical analysis was carried out using Student’s t-
test. 
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4.7 Effects of LCN2 on morphology of LNCaP cells: Morphology and 
proliferation 
(Note: Both LNCaP-pBP and parental LNCaP cells were used for all experiments 
unless otherwise stated) LNCaP-LCN2 cells were found to be stable over multiple 
passages. However, no obvious morphological changes were observed. No changes 
were observed to colony shape or formation, and cells also retained their spindle-like 
shape (Figure 4.8A) 
LNCaP-pBP and LNCaP-LCN2 cells were analysed for changes to cell proliferation 
by Propidium Iodide (PI) FACS cell cycle analysis. However, no significant changes 
in cell cycle were observed in LNCaP cells expressing LCN2 (Figure 4.8B-E). This 
analysis was carried out n=3 times using cells at different passages, but no 
significant differences were observed in any instance. 
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Figure 4.8 Effects of LCN2 expression on cell morphology and cell cycle in 
LNCaP cells. A- Brightfield image analysis of LNCaP-pBP and LNCaP-LCN2 cells 
(x20 magnification). B, D- FACS cell cycle analysis of LNCaP-pBP and LNCaP-
LCN2 respectively using propidium iodide.C, E- Breakdown of cell cycle populations: 
P3- G0 phase, P4- G1 phase P5-S Phase, P6-G2/M phase. Figures are 
representative of n=3, all experiments performed in triplicate. 
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4.8 Effect of ectopic expression of LCN2 on hormone receptor protein 
expression in LNCaP cells. 
 4.8.1 Androgen Receptor 
 
Because LNCaP-GLI1 cells were androgen independent and expressed high levels 
of LCN2, it was decided to investigate whether the high levels of LCN2 may be 
contributing to a loss of AR expression and may be involved in the AI state of these 
cells. AR expression in LNCaP-LCN2 cells was analysed by qPCR but no significant 
difference was observed in the levels of mRNA expression (1.11 fold increase 
relative to LNCaP-pBP) (Figure 4.9A). 
When AR protein expression was analysed by Western blot however, contrary to the 
expected decrease in AR I observed an increase in AR expression in LNCaP-LCN2 
cells relative to both LNCaP-pBP and LNCaP(Parental) cells  (Figure 4.9B).   
To confirm the activity of increased AR expression, qPCR analysis of the AR target 
gene KLK3 (encoding for PSA) was performed. LNCaP-LCN2 cells showed a 5.4 
fold increase in KLK3 expression relative to LNCaP-pBP cells, hence indicating that 
AR is indeed active and is able to elicit downstream effects (Figure 4.9A).  
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Figure 4.9 Effects of LCN2 on AR and KLK3 (PSA) expression. A- qPCR of AR 
and KLK3 (PSA) expression in LNCaP-LCN2 cells relative to expression in LNCaP-
pBP cells B- Western blot of AR expression in LNCaP derived cell lines. Data in 
panel A represent mean +/- SEM for n=5 experiments. Statistical analysis was 
carried out using Student’s t-test *p<0.05 **p<0.01 ***p<0.001 Western blot analysis 
is representative  of n=4 experiments. 
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KLK3 expression is known to be affected by cell density and cell confluence (Lilja, 
2003). The previous results were obtained from samples at 80% confluence. To 
eliminate any effects that changes to confluence may be having on AR and PSA 
expression, both LNCaP-pBP and LNCaP-LCN2 cells were harvested at 50%, 80% 
and 100% confluence. Cells were also seeded at high density but harvested after 24 
hours before they could divide and form colonies and were mostly single cells at 
80% confluence. qPCR analysis results showed that, as expected, AR mRNA levels 
remained constant. There were no significant changes in levels of expression of AR 
mRNA expression between LNCaP-LCN2 and LNCaP-pBP, and neither were there 
any significant differences between confluence levels (Figure 4.10A). In contrast, 
KLK3 levels showed moderate but significant increases to expression based on 
confluence. In LNCaP-pBP there was a 1.8 fold increase in KLK3 expression in 
100% confluent cells relative to 50% confluence. In single cell colonies however 
KLK3 expression was half that of 50% confluent cells, thus confirming that increased 
confluence does lead to elevated KLK3 (Figure 4.10B).   
At 50% confluence, KLK3 expression was 5.1 fold higher in LNCaP-LCN2 cells 
relative to LNCaP-pBP (Figure 4.10B). This ~1:5 expression ratio of KLK3 
expression  (LNCaP-pBP vs LNCaP-LCN2) was also maintained at 80% and 100% 
confluence. However, in single cells, this ratio was reduced to 1:2 (0.49:1.2 fold 
relative to 50% confluent LNCaP-pBP cells). 
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Figure 4.10 Effects of cell confluence on KLK3 and AR expression in LNCaP-
LCN2. qPCR analysis. Cells were harvested at a range of confluence levels. A 
shows androgen Receptor mRNA and B shows KLK3 mRNA expression in LNCaP-
pBP and LNCaP-LCN2 cells at 50, 80 and 100% density as well as cells in single cell 
colonies at 80% confluence. Values are relative to LNCaP-pBP at 50% confluence. 
Data represents mean +/- SEM, n=3. *P<0.05, **P<0.01, ***P<0.001. Statistical 
analysis carried out using Student’s t-test . 
A 
B 
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4.8.2 Estrogen Receptor 
 
Estrogen receptor (ER) is the primary receptor for the steroid estrogen. ER has two 
commonly expressed isoforms, namely ERα and ERβ. The two proteins share a 90% 
sequence homology, but are two separate genes on different chromosomes (6 and 
14 respectively) and are able to form both homodimers and heterodimers with each 
other ( Reviewed by (Zhao et al., 2008a)). Both proteins are able to activate similar, 
but non-identical signalling pathways (Zhao et al 2008.). While not true in some 
cases, increased ERα has been shown to lead to a reduction of ERβ and vice versa. 
LNCaP cells express both ERα and ERβ protein, with the ratio favouring ERα (King 
et al., 2006). 
LCN2 has previously been shown to regulate ER levels in breast cancer (BCa) by 
Yang et al (2009). In their study, a negative correlation was found between LCN2 
and ERα (ERβ was not mentioned). Because LCN2 expression has been associated 
with ER levels in BCa I decide to investigate whether a similar correlation occurred in 
LNCaP cells.  
qPCR analysis of LNCaP-LCN2 cells showed no changes in the expression of either 
ESR1 or ESR2 mRNA ( ERα and  ERβ respectively) (Figure 4.11A). However, when 
protein lysates were analysed via Western blot, distinct changes in expression were 
observed were observed although these did not correlate with mRNA expression, 
suggesting a post-transcriptional mechanism of regulation. ERα protein was 
markedly down-regulated in LNCaP-LCN2 whereas protein expression for ERβ was 
up-regulated, although the level of expression was still relatively much weaker than 
ERα (Figure 4.11B) 
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From these data it was apparent that in LNCaP-LCN2 cells there was marked down-
regulation of ERα and an increase in expression of ERβ. However, despite the 
changes in ER ratios, no significant changes were observed to the classical ER 
target gene ERBB2 (encoding for HER2 protein). However, a further ERβ target-
EGFR (Egloff et al., 2009, Zhao et al., 2008a)- did show a 4-fold increase to mRNA 
expression (Figure 4.11A). 
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Figure 4.11 Effects of ectopic LCN2 on expression of  ERα and  ERβ  and the 
ER target genes HER2 and EGFR.  A- qPCR analysis of ERα and ERβ and two 
target genes HER2 and EGFR B: Western blot analysis of  ERα and ERβ showed a 
loss of ERα, and a slight increase in ERβ. Data in panel A shows mean +/- SEM, 
n=3 experiments. Western Blot in panel B is representative of n= 3. mRNA and 
protein were extracted simultaneously. Statistical analysis carried out using 
Student’s t-test .***P<0.001 
α-tub 
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B 
(45 kDa) 
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4.9 Functional assessment of AR and ER expression in LNCaP-LCN2 cells 
Based on the data shown above in which I showed that LCN2 expression had 
stimulated an increase in AR expression and a marked down-regulation of ERα and 
up-regulation of ERβ experiments were performed to determine the functional 
relevance of these changes in AR and ER expression with regards to cell 
proliferation and response to receptor agonists and antagonists. 
With regards to Androgen receptor functionality; I investigated whether increased AR 
expression translated to greater sensitivity to the AR antagonist bicalutamide by 
employing Alamar Blue proliferation assays. LNCaP-LCN2 and, LNCaP-pBP were 
treated with the AR antagonist bicalutamide for 7 days. Results showed that LNCaP-
LCN2 cells were significantly more sensitive to bicalutamide treatment (i.e. had lower 
proliferation) than LNCaP-pBP controls after 7 days (n=3) (Figure 4.12A).  It should 
be noted however that androgen receptor in LNCaP cells contains a single point 
mutation in the ligand binding domain  and that progestagens, estrogens and several 
antiandrogens bind the mutated androgen receptor protein which may be mediating 
any response to either androgen or anti-androgen treatment (Veldshcotte et al, 
1992). 
Reciprocally, cells were cultured in charcoal-stripped serum (which removes steroid 
hormones necessary for LNCaP cell viability) and stimulated with the AR agonist 
dihydro-testosterone (DHT), a more potent form of testosterone. A concentration of 
10ng/L in accordance with previous studies (Xu et al., 2006) but this did not enhance 
proliferation (or enhance cell viability) compared to the control populations (Fig. 
4.12B). These results, therefore suggest that while AR may be more highly 
expressed in LNCaP-LCN2 cells, the protein may not be fully active in the cell. 
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Figure 4.12 LNCaP-LCN2 cells in response to AR agonists and antagonists. 
Alamar Blue analysis. A- LNCaP-pBP and LNCaP-LCN2 cells were treated with AR 
antagonist bicalutamide (10ng/L), with fluorescence readings taken until untreated 
cells reached 100% confluence. LNCaP-LCN2 cells had reduced proliferation in the 
presence of the drug. B- Cells were cultured in charcoal stripped media 
supplemented with DHT (100nmol/ml). All data is the mean of n=3 experiments, with 
each experiment preformed in triplicate. Error bars for each time point are very small 
and have been removed for figure clarity. ***P<0.001. Statistical analysis carried out 
using Student’s t-test. 
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B 
p<0.001 
152 
 
 
To assess whether loss of ERα  expression was functional and whether expression 
altered response to ER antagonists, I performed Alamar blue proliferation assays 
(carried out as above). LNCaP-pBP and LNCaP-LCN2 cells were treated with the ER 
antagonist ICI-182,780 (10μmol/ml). Response to the drug was after observed 4 
days of treatment, however there was no significant difference in proliferation rates 
between LNCaP-pBP and LNCaP-LCN2 cells (Figure 4.13A). 
 
Reciprocally, the effects on proliferation by ER agonists was also investigated. 
LNCaP-pBP and LNCaP-LCN2 cells were cultured in charcoal-stripped media 
stimulated with the ER agonist 17β-Estradiol- also known as E2 (100nMol/ml). In 
both cell types E2 slowed the rate of cell death, however, no significant changes to 
proliferation were observed. Indeed in all conditions, most cells had died after 6 days 
(Figure 4.13B).  
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Figure 4.13 LNCaP-LCN2 cells in response to ER agonists and antagonists. 
Alamar Blue analysis. A- LNCaP-pBP and LNCaP-LCN2 cells were treated with ER 
antagonist ICI-82,780 (10μg/ml), with fluorescence readings taken until untreated 
cells reached 100% confluence. No significant difference was seen between the cell 
types in response to the drug. B- Cells were cultured in charcoal stripped media 
supplemented with E2 (100 nmol/ml). All data is the mean of n=3 experiments, with 
each experiment performed in triplicate. Error bars for each time point are very small 
and have been removed for figure clarity. Statistical analysis carried out using 
Student’s t-test. 
A 
B 
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While there was little difference proliferation in response to DHT or E2, I also 
investigated the effects of this steroid on mRNA expression of downstream targets. 
LNCaP-pBP and LNCaP-LCN2 cells were cultured in charcoal stripped media and 
supplemented with 100nMol/ml of DHT or E2 for 48 hours.  
To assess the effect of these steroids on AR, mRNA expression analysis was then 
performed on the AR downstream target PSA (KLK3). In both LNCaP-pBP and 
LCN2 PSA expression was strongly decreased under charcoal stripped conditions. 
In both cell types, expression of PSA was rescued following treatment with E2. By 
contrast, PSA expression was only partially rescued after DHT treatment in LNCaP-
LCN2 cells, whereas in DHT treated LNCaP-LCN2 cells expression was rescued to a 
greater extent (Figure 4.14A). 
To assess the effects of ER, in addition to assessing KLK3 expression, I also 
investigated the expression of the ER target gene EGFR (Filardo, 2002) in cells 
grown in charcoal stripped media or after stimulation with E2 in LNCaP-LCN2 or 
LNCaP-pBP cells. In LNCaP-pBP cells, culture in charcoal stripped serum had no 
significant effects on EGFR expression; addition of either E2 or DHT to this CSS also 
had no effects (Figure 4.14B).  In LNCaP-LCN2 cells however, EGFR expression 
was significantly reduced in charcoal stripped media grown cells (Figure 4.14B).  
This expression was however rescued by supplementation of both E2 and DHT. This 
suggests therefore that LNCaP-LCN2 cells have become more responsive to 
steroids than LNCaP-pBP cells. It should be noted however that expression of EGFR 
is regulated by a number of mechanisms, and has a complex association with ER 
signalling (Egloff et al., 2009). AR has also been shown to up-regulate EGFR, and as 
such, this may explain an increased response to DHT (Brass et al., 1995). 
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Figure 4.14 Effects of AR and ER agonists on gene expression. LNCaP-pBP and 
LNCaP-LCN2 cells were cultured for 48hrs in either standard FBS, charcoal stripped 
(CS) media, or with CS supplemented with the ER agonist E2, or the AR agonist 
DHT. qPCR analysis of  A- PSA (KLK3) and B-EGFR. All values are relative to 
LNCaP-pBP cells cultured in standard FBS +/- SEM,n=3 experiments. Statistical 
analysis was carried out using Student’s t-test   
 
*** 
*** 
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A 
B 
156 
 
4.10 Effects of LCN2 expression on E-cadherin Expression in LNCaP-LCN2 
cells. 
Aside from androgen independence, one of the key features identified previously in  
LNCaP-GLI1 cells was that these cells showed many hallmarks of EMT including a 
loss of E-cadherin, increase in vimentin and increase in ΔP63(See section 3.1).  
LCN2 was also subsequently identified by microarray analysis in LNCaP-Gli1 as 
forming part of an EMT signature. Moreover, LCN2 has been identified as inducing 
EMT in breast cancer cells (Yang et al., 2009). As such, I investigated the effects to 
EMT markers in LNCaP-LCN2 cells and study the role of LCN2 in regulation of EMT. 
         
qPCR analysis of a range of EMT markers, including E-cadherin, vimentin, CD44, 
ΔP63 found no significant changes in expression of any of the genes tested. 
Furthermore, known EMT activators including TWIST1, SLUG and SNAIL also did 
not show any significant changes in expression (Figure 4.15A). However, the E-
cadherin repressor gene ZEB1 (Sanchez-Tillo et al., 2010) showed a 2.3 reduction in 
expression protein level.  
At a protein level LNCaP-LCN2 cells expressed notably higher levels of E-cadherin. 
Interestingly, there was no reciprocal change in vimentin expression (Figure 4.15B). 
Here, an increase in E-cadherin was observed in LNCaP-LCN2 cells. No change in 
expression was seen however for vimentin. It appears therefore, than rather than 
eliciting complete EMT, the effects of LCN2 seem to be specific to E-cadherin. 
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Figure 4.15: Expression of EMT genes in LNCaP-LCN2 cells. A- qPCR analysis 
of EMT related genes. Values are relative to LNCaP-pBP. Data is mean of n=3 
experiments ± SEM. Statistical analysis performed using Student’s t-test ***P<0.001  
B- Western blot analysis of E-cadherin and vimentin in LNCaP-Parental, LNCaP-
pBP and LNCaP-LCN2 cells. Note: Membrane is the same as figure 4.16. Results 
are representative of n=3 experiments.   
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4.11 Effects of LCN2 on LNCaP cell migration. 
To assess the functional relevance of ectopic LCN2 expression and the protein 
expression changes to E-cadherin in particular, but also AR and ER, LNCaP-LCN2 
cells were tested for changes in cell migration and invasion. The role of LCN2 in 
migration and invasion remains unclear. Previous studies including that by Mir et. al. 
(2011), have linked increased LCN2 expression to higher rates of both cell migration 
and invasion (Mir et al., 2012). Conversely, ectopic expression of LCN2 has been 
linked to reduced migration in liver cells (Lee et al., 2011).                   .     
LNCaP (Parental), LNCaP-pBP and LNCaP-LCN2 cells were cultured in 6cm dishes 
until 100% confluent and treated with Mitomycin C to remove proliferative effects. 
Scratches approximately 2000 nm wide were created and assessed after 24h. 
Results showed that LNCaP-LCN2 cells partially lost the ability to migrate into the 
scratch. After 24h, LNCaP-pBP cells reduced the width of scratches by an average 
of 751 nm, whereas LNCaP-LCN2 cells reduced the width of scratches by an 
average of 336 nm  (n=9, p<0.05) (Figure 4.16A-B). This result was also very evident 
at a visual level. This data also correlates with the higher levels of E-cadherin and 
ERβ, increased in both of which are associated with reduced migration (Kalluri and 
Weinberg, 2009, Zhao et al., 2008a) and suggest that in LNCaP cells, LCN2 is an 
anti-migratory factor. 
For invasion analysis, LNCaP-pBP and LNCaP-LCN2 cells were cultured on Matrigel 
coated inserts and placed under a chemo-attractive FBS gradient. However, results 
showed that neither LNCaP-pBP nor LNCaP-LCN2 cells were able to invade the 
Matrigel in sufficient numbers to produce any meaningful results, with only a handful 
of cells invading for each sample and as a result this area of investigation was 
abandoned. 
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Figure 4.16 Analysis of migration in LNCaP-LCN2 cells.  A Scratch wound 
migration assay. 100% confluent cells were treated with Mitomycin C before a 
scratch was made with a pipette tip. A minimum of 9 width readings taken per 
sample. A: Bright field image analysis of cells after 0h and 24hrs. B- Average width 
values after 0hrs and 24hrs. All experiments performed in triplicate. Values are mean 
of n=3 experiments ± SEM. Statistical analysis performed using t-tests. **P<0.01 
A 
B 
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4.12 mRNA Microarray Analysis of LNCaP-LCN2 cells  
As noted above, significant changes were to both mRNA and protein expression 
were observed in LNCaP-LCN2 cells. However, the genes tested provide only a 
small fraction of the possible genes being affected by ectopic LCN2. To gain a wide 
scale overview of the effects of LCN2, mRNA microarray analysis (AFFYMETRIX) 
was carried out comparing LNCaP-pBP cells to LNCaP-LCN2 cells. The 
AFFYMETRIX array chip is capable of analysis of ~28500 genes, with each gene 
having 6-10 probes. 
Data from the microarray analysis revealed only minor changes to expression across 
the genome. As per a wide range of studies, an arbitrary cut of 1.5 fold change was 
used to differentiate between differential expression or no change. Of the 28500 
genes analysed, only 175 genes showed a >1.5 fold change. Of these, 98 showed 
an decrease to expression in LNCaP-LCN2 and 77 genes showed an increase.  A 
partial list of genes may be seen in Tables 4.2 and 4.3. Of the genes with increased 
expression, was LCN2 itself. However, raw data showed only an 11-fold increase in 
LNCaP-LCN2 cells (compared to >250 fold increase as analysed by qPCR). Aside 
from LCN2, only three genes showed a >2 fold increase, namely CHRNA2 
(cholinergic receptor, nicotinic, alpha 2, SERPINB4 (Serpin peptidase inhibitor, clade 
B (ovalbumin) 4) and OR5B4 (olfactory receptor, family 5B2). A number of key 
cancer related genes however did show increases of between 1.5 and 2 fold tin 
expression including SNAI2, MMP7, and IL8. Intriguingly, LCN1, another member of 
the lipocalin family also showed a 1.7 fold increase in LNCaP-LCN2 cells. 
With regards to down-regulated genes, only 5 genes showed a >2 fold decrease in 
LNCaP-LCN2 relative to LNCaP-pBP cells.  GLT8D2, OVOS (Ovostatin) and 
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FLJ44896 fell into this category, but none of these proteins has been fully described 
in any literature. A further gene, AXNA1 however, has been extensively studied. 
AXNA1 (Annexin A1) is a Ca2+ dependent phospho-lipid binding protein which has 
been associated with a range of cancers. Annexin A1 is associated with NF-κB 
signalling repression, and has been shown to be up-regulated following ERα 
activation .   
Genes which showed either a >1.5 or <-1.5 fold change were analysed using 
PANTHER pathway analysis.  Biological function analysis revealed 55 genes 
associated with ‘Metabolic processes’ and 53 for ‘Cellular processes’, both 
categories however are fairly vague and broad. However, categories such as cell 
communication and immune response scored highly (35 and 27 genes respectively). 
Genes were also analysed for pathways, however only 31/146 were able to be 
categorized. Tantalizingly, inflammation and EGF signalling had the highest hits, 
although the sample is too small to provide any statistical results. 
Quite why the microarray data was so minimal is unknown. Indeed, qPCR analysis  
on the same sample of mRNA showed significant changes to genes such as KLK3. 
However, these did not appear in the microarray data. Also, an 11 fold increase of 
LCN2 itself is suspiciously low considering a >250 fold increase seen in qPCR.  
Nevertheless, results do indicate that LCN2 is able to elicit a genetic effect on 
LNCaP cells. 
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Gene Symbol Gene Description 
mRNA 
Accession 
Fold Change 
LNCaP 
(Control/LCN2) 
LCN2 lipocalin 2 NM_005564 11.0995 
CHRNA2 
cholinergic receptor, nicotinic, 
alpha 2 (neuronal) 
NM_000742 2.14394 
OR5B2 
olfactory receptor, family 5, 
subfamily B, member 2 
NM_001005566 2.02382 
LOC642947 
hypothetical protein 
LOC642947 
AK129705 1.92066 
UGT2B28 
UDP glucuronosyltransferase 2 
family, polypeptide B28 
NM_053039 1.9125 
CCDC141 
coiled-coil domain containing 
141 
NM_173648 1.87223 
GSTM1 glutathione S-transferase mu 1 NM_000561 1.8405 
LOC284861 hypothetical LOC284861 AK128837 1.80533 
RARRES3 
retinoic acid receptor 
responder (tazarotene induced) 
3 
NM_004585 1.76682 
SNAI2 snail homolog 2 (Drosophila) NM_003068 1.76363 
MMP7 
matrix metallopeptidase 7 
(matrilysin, uterine) 
NM_002423 1.74786 
HIST1H2BJ histone cluster 1, H2bj NM_021058 1.7427 
LCN1 lipocalin 1 (tear prealbumin) NM_002297 1.73229 
CCBE1 
collagen and calcium binding 
EGF domains 1 
NM_133459 1.70906 
ADH1C 
alcohol dehydrogenase 1C 
(class I), gamma polypeptide 
NM_000669 1.68051 
SNORD116-28 
small nucleolar RNA, C/D box 
116-28 
NR_003361 1.65406 
SOX7 
SRY (sex determining region Y)-
box 7 
NM_031439 1.63084 
LOC100128840 hypothetical LOC100128840 AK058065 1.62272 
BTC Betacellulin NM_001729 1.62111 
SPDYE3 
speedy homolog E3 (Xenopus 
laevis) 
NM_001004351 1.60832 
 
Table 4.1- List of top 20 genes found to be up-regulated in LNCaP-LCN2 cells 
relative to LNCaP-pBP. Anti-log fold change in expression generated from 
Affymetrix GeneChip array data. All values had p-values <0.001 
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Gene Symbol Gene Description Accession No. 
Fold Change 
LNCaP 
(Control/LCN2 
GLT8D2  
glycosyltransferase 8 
domain containing 2  
NM_031302  -2.195173545 
OVOS  ovostatin  BX647938  -2.169921723 
C8orf73  
chromosome 8 open 
reading frame 73  
NM_001100878  -2.094883478 
FLJ44896  FLJ44896 protein  AK126844  -2.025739974 
ANXA1  annexin A1  NM_000700  -2.011685811 
ZNF443  zinc finger protein 443  NM_005815  -1.989329149 
FAM99A  
family with sequence 
similarity 99, member A  
NR_026643  -1.919784002 
CNN3  calponin 3, acidic  NM_001839  -1.870763259 
RNU5A  RNA, U5A small nuclear  NR_002756  -1.867190337 
FAM129A  
family with sequence 
similarity 129, member 
A  
NM_052966  -1.862801566 
XAGE-4  XAGE-4 protein  AJ318895  -1.848473037 
NCRNA00116  
non-protein coding 
RNA 116  
BC064430  -1.845685829 
BICC1  
bicaudal C homolog 1 
(Drosophila)  
NM_001080512  -1.782203402 
S100A4  
S100 calcium binding 
protein A4  
NM_019554  -1.765239579 
LOC255411  
hypothetical 
LOC255411  
NR_029449  -1.753571189 
PRSS1  
protease, serine, 1 
(trypsin 1)  
NM_002769  -1.744886263 
OVOS  ovostatin  BX647938  -1.740736699 
OR8H1  
olfactory receptor, 
family 8, subfamily H, 
member 1  
NM_001005199  -1.737468714 
LOC644714  
hypothetical 
LOC644714  
BC047037  -1.732978793 
ND2  MTND2  ENST00000361453  -1.726101139 
 
Table 4.2- List of bottom 20 genes found to be down-regulated in LNCaP-LCN2 
cells relative to LNCaP-pBP. 
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4.13 Chapter Discussion 
The aim of ectopically expressing LCN2 in LNCaP cells was to identify whether it 
was regulating some of the phenotypic and gene expression changes previously 
seen in LNCaP-Gli1 cells, especially with regards to androgen independence and 
EMT. However, results showed that rather than promoting AI and EMT, LCN2 
instead had the effect of increasing AR and E-cadherin expression. 
Lipocalin 2 is a secreted protein with a molecular weight of ~25kDA. However, when 
I employed the MAB1757 (R&D) antibody on whole cell lysates, Western blot bands 
were consistently 48 kDa were seen. This band was not the LCN2/MMP9 complex 
(molecular weight 119kDA). The band was also present using different methods of 
cell lysis including RIPA buffer. The MAB1757 antibody is the most cited for LCN2 
(e.g. Mahadevan et al 2012; Yang et al 2009, Bi et al 2012), and until very recently 
the only monoclonal antibody for LCN2 commercially available. This antibody has 
been used previously on both cell supernatants and whole cell lysates, and is also 
used for ELISA testing. Notably, while molecular weights of 25kDA have been 
described for secreted LCN2 in previous literature, this data is absent when 
presented for whole cell lysates (E.g. Tong et al, 2008). LCN2 existing as a sulphur 
homodimer was first described by Kjeldsen et al in 1994. However in all subsequent 
literature, this point is mentioned in text only.  
In addition, as seen in figure 4.7 and 4.12, when intracellular levels of LCN2 were 
analysed in both LNCaP-Gli1 and LNCaP-LCN2 cells respectively, protein 
expression was lower than expected relative to mRNA expression. Analysis of 
secreted LCN2 however showed that the protein is produced, but is rapidly expelled 
from these cells, and that the secreted LCN2 is monomeric. It was also found that 
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expression of LCN2-R was higher in all LNCaP derived cell lines. While only qPCR 
analysis was carried out, this may provide a partial reason as to why LCN2 is 
secreted more rapidly than in PC3 cells. However, the precise functions of LCN2-R 
are very poorly understood, and may not necessarily have a role in LCN2 cleavage. 
The existence of different states of LCN2 within and outside the cell has also not 
been reported before, and exactly how or why this state occurs is unknown but may 
require cleavage of sulphur bonds. It would therefore be interesting to investigate the 
3D structure via either mass-spectrometry or crystallography and whether 
homodimeric LCN2 binds differently to substrates. Given that this antibody is also 
the most commonly used form for tissue immunohistochemistry, this has a potential 
impact on these types of results.  
Aside from the MAB1757 antibody, the 5G5 (Santa Cruz) and AF1757(R&D) 
antibodies mentioned in section 4.10 other antibodies were assessed including a 
polyclonal rabbit antibody from Abcam and an anti-rabbit polyclonal from Millipore 
(AB2267) However, in both cases antibodies were did not work or produced blots 
which were too dirty to use.  Other antibodies are now very recently available for 
LCN2, although there was insufficient time to analyse these sufficiently. 
In this study, contrary to predictions, I observed a novel positive correlation between 
LCN2 expression and Androgen receptor protein expression. mRNA expression of 
AR did not change however, and regulation appears to be post-transcriptional.  Post-
transcriptional or post-translational regulation has been reported at a number of 
levels including by targeting to E3 ligases (Yeap et al., 1999). Alternatively, AR 
mRNA is targeted by EBP1 for degradation (Lonergan and Tindall, 2011) . AR has 
also been shown to be regulated by a number of miRNAs including miR-221 and 
miR-31 (Sun et al., 2013, Lin et al., 2013). Both AR and LCN2 are also known to be 
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regulated to some level by NF-κB and this acts as a potential mediator of LCN2 
signalling. 
LNCaP-LCN2 cells were more sensitive to bicalutamide, however they did not show 
increased response to DHT. A higher concentration of DHT (1μM) was also 
attempted (n=1) but also showed no difference between the two cell types and was 
subsequently abandoned. It is therefore likely that even with increased AR 
expression, the addition of DHT alone is insufficient to rescue the LNCaP cells in 
charcoal stripped media.   
In addition to AR expression, a decrease in ERα, but increase in ERβ was observed. 
This data therefore correlates with previous data, particularly Yang et al 2009 which 
also showed a negative correlation between ERα and LNC2. However, other studies  
such as Yang et al., 2009 do not mention ERβ expression.  ERα : ERβ ratios are not 
always opposing,  but ERβ expression is known to  repress ERα expression and vice 
versa (Matthews and Gustafsson, 2003).  Despite a change in ERα: ERβ ratio, no 
significant changes were observed in LNCaP-LCN2 cells in response to either the 
ER agonist E2 or the antagonist ICI-082,780.  As with DHT, it is likely that 
supplementation with E2 alone is insufficient to promote growth in charcoal stripped 
media over many days. With regards to ICI-082,780, no resistance was observed in 
LNCaP-LCN2 cells. This may be due to ICI-082,780 binding to both ERα and ERβ, 
inhibiting the protein binding to estrogen (Matthews and Gustafsson, 2003). It is 
possible that the increased ERβ in LNCaP-LCN2 cells is counteracting loss of ERα. 
Alternatively, ERα expression did not totally disappear, and the low levels of ERα 
may be sufficient to confer sensitivity to the drug. 
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One of the aims of this chapter was to determine whether LCN2 affected EMT. 
Previously LCN2 was identified as being a member of the EMT ontological grouping 
in LNCaP-GLI1 cells (See Chapter 3 and Nadendla et al. 2011). Moreover, Yang et 
al., 2009 showed an inverse correlation between LCN2 and E-cadherin Results 
shown here (Figure 4.20) showed that LNCaP-LCN2 cells increased E-cadherin and 
induced an EMT phenotype. As such it was originally hypothesised that E-cadherin 
expression would be suppressed in LNCaP-LCN2 cells and cells would enter into an 
EMT phenotype. However, the results in this chapter suggest that LCN2 positively 
correlates to E-cadherin expression. Results also showed that rather than affecting 
all EMT related genes, specifically only E-cadherin expression was altered, and this 
was associated with a loss of the E-cadherin repressor ZEB1 (Graham et al., 2008).   
It is also possible that the changes to ERα and E-cadherin are linked. It is currently 
generally regarded that ERα acts as an inhibitor of E-cadherin expression (Park et 
al., 2008, Oesterreich et al., 2003). Additionally, ERβ has been shown to act as an E-
cadherin promoter, particularly in prostate cells (Park et al., 2008). ERβ activation of 
E-cadherin was also independent of vimentin. Interestingly however, regulation of 
ERα, ERβ and E-cadherin by LCN2 was post-transcriptional. Both ER isoforms are 
known to be regulated at multiple levels. ER is targeted to proteasomes by E2 
ligases (Le Romancer et al., 2011). As with AR, ER mRNA is also targeted by mIR-
221 for translational control (Zhao et al., 2008b). It is hence possible that LCN2 may 
be associated with this mRNA.  
In this study, microarray analysis was employed to obtain a more global analysis of 
LCN2’s effects. Although experiments were performed in triplicate, analysis was 
carried out at the same time. As noted in section 4.16, the gene expression profile 
was much lower than was expected given the changes to protein expression, and 
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genes such as KLK3 and ZEB1 did not show any significant difference in analysis. 
This may be attributable to a faulty or less sensitive chip. Alternatively it may that as 
microarray analysis often less sensitive that qPCR is and may be that changes to 
expression were not great enough to be detected the array.  In this case data may 
show that the effect of LCN2 ectopic expression has relatively little effect on LNCaP 
cells, possibly due to its high rate of secretion from cells. 
 
In conclusion, a number of points may be seen from the data in this chapter: 
1. LCN2 exists as a dimer inside the cell, but is secreted as a monomer and that 
secretion rates differ between cell lines. 
2. Ectopic LNC2 expression leads to a positive correlation to androgen Receptor 
and PSA expression 
3. Conversely, that LCN2 shows a negative correlation to ERα expression and 
changes the ERα:ERβ ratio 
4. Ectopic LCN2  expression shows a positive correlation to E-cadherin and to a 
loss of migratory potential. 
 
As ectopic expression of LCN2 in LNCaP cells introduced a gene where it was not 
previously present, to further investigate the role of LCN2 in PCa cells, it was 
decided to investigate the effects of suppressing expression in a cell line where 
LCN2 was naturally present, namely PC3 cells. 
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Chapter 5: The effect of 
 Suppressing LCN2 in the PC3 cell  
Line 
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Introduction 
The cell line PC3 is a commonly used PCa cell line (Sobel and Sadar, 2005). This 
line is derived from a PCa bone marrow metastasis. PC3 cells have high metastatic 
potential and are p53 null. PC3 cells are androgen insensitive, and do not express 
AR (van Bokhoven et al., 2003). As mentioned in section 4.10, PC3 cells  were 
identified as having the highest levels of LCN2 at the intracellular protein level 
amongst a range of PCa cell lines. This was further confirmed by qPCR data. 
Furthermore, PC3 cells were identified as having the highest levels of secreted 
LCN2 as determined by ELISA (2ng/ml). In addition, using the Gene Expression 
Atlas (http://www.ebi.ac.uk), PC3 was identified as having highest level of LCN2 
mRNA among all frequently cited PCa cell lines and was indeed had the highest 
level of LCN2 expression of all non-pancreatic cancer cell lines (Leung et al., 2012). 
Given that both PC3 and LNCaP-GLI1 cell lines expressed high levels of LCN2, and 
are both androgen independent. It was originally hypothesised that LCN2 may be 
driving AI in PCa, and that suppression of LCN2 may re-instate the androgen 
dependent phenotype. However, given that ectopic LCN2 in LNCaP cells led to 
increased AR, this is unlikely to be the case. However, as LCN2 is expressed at 
such high levels in PC3 cells, it was decided to investigate changes upon its 
suppression, particularly towards hormone receptor regulation. As ectopic LCN2 led 
to reduced ERα expression in LNCaP cells, any mirroring of this in PC3 cells would 
also provide a more concrete data on the precise role of LCN2 in PCa cell lines. 
 
 
171 
 
Results 
5.1 LCN2 expression in PC3 cells is not affected by SMO inhibitors 
LCN2 was the gene with one of the highest fold changes in LNCaP-GLI1 cells (See 
section 4.9), and PC3 cells also display high levels of Hedgehog signalling 
(Nadendla et al., 2011). As such, I aimed to determine whether inactivation of the 
hedgehog pathway and GLI1/2 in PC3 cells had any effect on LCN2 expression. 
Suppression of the hedgehog pathway was first attempted using the 
pharmacological hedgehog pathway antagonists KAAD-Cyclopamine and SANT1, 
which have been shown to inhibit GLI1/2 expression (Karhadkar et al., 2004). PC3 
cells were treated with the SMO KAAD-Cyclopamine and SANT1 (both at  50 and 
100 nmol/ml) for 72h.  The direct GLI inhibitor GANT61 (50 nmol/ml) was also used 
(Pan et al., 2012), however this was found to be toxic to cells and hence abandoned. 
Both KAAD-Cyclopamine and SANT1 suppressed the expression of GLI1 (Figure 
5.1A) However, no significant changes were seen to LCN2 expression (Figure 5.1B), 
suggesting that LCN2 is either not a direct GLI1 target, or that any activation by GLI1 
is irreversible. Despite this, it was noted that although GLI1 was suppressed by 
inhibitors, GLI2 expression was not as affected.  It is therefore possible that LCN2 is 
activated by GLI2 as well. 
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Figure 5.1 Effect of Hedgehog suppression on LCN2 by pharmacological 
inhibitors.  A PC3 cells were treated either KAAD-Cyclopamine or SANT1 for 72hrs. 
qPCR analysis of GLI1 and GLI2 expression relative to DMSO treated cells +/- SEM  
***p<0.001(n=3). (Figure is using the same data as figure 3.5) B Western blot 
analysis of LCN2 protein in PC3 cells treated with drugs at either 50 or 100 nMol/ml 
for 72 hours. Representative of n=3 experiments. 
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5.2 Suppression of both GLI1 and GLI2 does not affect LCN2 expression 
To further investigate the role of GLI1 in LCN2 regulation, and to also uncover any 
role of GLI2 as well, siRNA was employed to suppress both of these genes. Double 
knock-down of GL1 and GLI2 was performed simultaneously using the siRNAs 5816 
and 5817, both at concentrations of 20 nmol/ml. Suppression of GLI1 and GLI2 was 
confirmed by qPCR (See figure 3.4).   Expression of LCN2 however was unaffected 
at either the mRNA level (Fig 5.2A) or by Western Blot (Figure 5.2B).  
 Combined with the data from SMO inhibitors therefore, it appears that LCN2 is 
unaffected by subsequent inhibition of GLI or the HH pathway. As seen with LNCaP 
cells, expression of GLI1 does lead to significantly higher levels of LCN2, however, 
in both the case of LNCaP-GLI1 and in PC3 cells, subsequent inhibition of GLI had 
no effect on LCN2. As such, it was subsequently decided to investigate the effect of 
suppressing other signal transduction pathways associated with LCN2 regulation. 
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 Figure 5.2- Effect of GLI1/2 suppression by siRNA on LCN2 expression. PC3 
cells were transfected with siRNA targeting both GLI1 and GLI2. GLI suppression 
was previously confirmed  in PC3 cells (see Figure 3.4). A qPCR analysis of LCN2 
expression in PC3 cells transfected for 72hrs with both siGLI1 and siGLI2, or with 
siGLO control (+/- SEM, n=3). B Western blot of whole cell lysates using the same 
conditions (mRNA and protein extracted in parallel). Representative of n=3 
experiments. 
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5.3 LCN2 expression is unaffected by NF-κB inhibition. 
Given that inhibition of GLI did not affect LCN2; it was decided to investigate other 
potential factors were able to affect its expression. Of the numerous potential 
candidates, the transcription factor NF-κB has been previously shown in the 
literature to be a key regulator of LCN2 expression. There are known to be NF-κB 
binding sites at the LCN2 promoter(Karlsen et al., 2010, Li et al., 2009) and a 
number of studies have linked the two genes. Notably, Li et al (2009). used the NF-
κB inhibitor BAY-11-7082 to suppress LCN2 expression in  murine breast cancer 
cells (Li et al., 2009). A similar approach was also used by Leng et. al., (2009) also in 
breast.  However, significant changes were only observed above 50μM/L  Also, 
Mahadevan et al. (2011) successfully employed BAY-11-7082 to reduce LCN2 
expression in the prostate cell line TC1 which had been subject to endoplasmic 
reticulum stress.  BAY-11-7082 is not a direct NF-κB inhibitor per se, rather it inhibits 
the Iκκ complex which in turn binds to NF-κB, and sequesters it in the cytoplasm 
(Lee et al., 2012). Phosphorylated IKK is chaperoned to proteasomal degradation 
sites, freeing the NF-κB complex. BAY-11-7082 acts to permanently inhibit the 
phosphorylation of  Iκκ, and thereby NF-κB (Lee et al., 2012). 
In order to investigate the role of NF-κB in the regulation of LCN2, a strategy similar 
to that used by Li. Et al (2009) was used. PC3 cells were treated for 6 hours with the 
drug, then were supplemented with fresh media for a further 24 hours. A range of 
concentrations from 0-30nMol were used.  It was discovered that BAY-11-7082 was 
highly toxic to cells. Indeed, all concentrations above 5µmol/ml killed virtually all cells 
within 24 hours. Cells were therefore harvested only at concentrations of 1µM, and 
2µM.  A 5µM/mL concentration was also used although it should be noted that 
approximately 50% of cells died before harvesting. 
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Inhibition of NF-κB was confirmed by a reduction in IL-1B expression (Jiang et al., 
2004). This was strongest at 5µM (-8.5 fold). A -4.1 fold was seen at 2µM and 1.95 
fold for 1µM. When LCN2 was analysed via qPCR however, no significant changes 
were observed under any condition (Figure 5.3). In addition, experiments were 
attempted whereby PC3 cells were treated for 24hours with BAY-11-7082 with no 
media change, however this proved to be too toxic, and cells either died or looked 
unhealthy. Contrary to previous studies therefore (Mahadevan et al., 2011, in murine 
prostate and Li et al., 2009 in 231BR murine breast cell lines), NF-κB inhibition did 
not show any affect in LCN2 expression at concentrations used. It is possible 
however that the toxic effects of BAY-11-7082 are stronger than the effects on LCN2 
expression, and that cells died before any change to LCN2 could be observed. 
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Figure 5.3 LCN2 expression is not affected by BAY 11-7082 qPCR analysis of 
LCN2 and known target gene IL1B in response to BAY11-7082Cells were treated for 
6 hours, followed by 24hrs in fresh media. All data is relative to PC3 cells treated 
with DMSO only.  Data is mean of n=3 experiments +/- SEM ***p<0.001. Statistical 
analysis was carried out using Student’s t-test 
 
 
 
 
 
 
 
*** 
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5.4 Effect of a range of Pharmacological Inhibitors on LCN2 expression. 
Since NF-κB inhibition had no effect on LCN2 expression, a range of 
pharmacological inhibitors were tested to observe they effect LCN2 expression.  For 
this, inhibitors targeting previously proposed LCN2 regulatory pathways were used 
namely the PI3 Kinase (Lee et. al. 2011), the MEK/ERK pathway (Yang et. al. 2009) 
AKT pathway and the EGFR signalling pathway (Mir et. al. 2012) The inhibitors used 
were U0126 (MEK/ERK), Wortmannin (PI3K), API2 (AKT) and AG1478 (EGFR). 
PC3 cells were treated with each of the drugs for 48 hrs before harvesting. 
qPCR analysis for LCN2 in treated cells revealed that the drugs Wortmanin, U0126 
and API2 had no significant effect on LCN2 expression, although the EGFR inhibitor 
AG1478 did reveal a 4 fold decrease in expression of LCN2 (Figure 5.4A). [It should 
be noted that for all previous experiments the housekeeping gene GAPDH was used 
as a loading control. However, both Wortmanin and AG1478 gave rise to a >2 fold 
decrease in GAPDH expression relative to DMSO treatment alone, therefore in 
terms of LCN2 values, AG1478 treatment showed an 7 fold decrease in expression 
and wortmanin a 2 fold decrease. Despite this, when LCN2 protein was analysed via 
Western blot there was only minor reduction in expression suggesting that the LCN2 
protein is fairly stable within PC3 cells. 
The reduction of LCN2 in response to AG1478 was similar to the results found by Mir 
et al. (2011) who also noted a loss of expression in treated A549 adenocarcinoma 
cells. In this paper however, the authors only noted notable loss of expression at 
30µM. Moreover, they also presented protein based data, not mRNA analysis. To 
further analyse the efficacy of AG1478 in reducing LCN2 expression, and in an 
attempt to confirm Mir et. al.’s 2012 results. PC3 cells were treated with the drug at 
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concentrations of 1µM, 5µM, 10µM, 30µM and 100µM. The 100µM concentration 
proved to be highly toxic to the cells and therefore discarded. qPCR analysis showed 
that 1µM and 5µM did not result in any notable effect on LCN2 expression, whereas 
10µM and 30µM both resulted in a 4.2 fold and 4.0 fold reduction. This shows that 
the effect of AG1478 on LCN2 is not linear, or as potent in PC3 cells as A549 
(Human alveolar adenocarcinoma) cells, although it should be noted that at 30µM, 
there was notable cell death, and many of the cells looked unhealthy before 
harvesting (visual observation only). 
For positive controls, as p-ERK (the traditional U0126 target ) and p-AKT (wortmanin 
and API2 targets (Carnero et al., 2008)) were relatively low in PC3cellls, the 
keratinocyte cell line NEB1 which have higher levels of these proteins was employed 
to determine the efficacy drugs. P-EGFR was used to determine AG1478 activity, 
also in NEB1 cells (Figure 5.4B)  
When taken together, it appears that in PC3 cells at least regulation of LCN2 is 
unaffected by a range of pharmacological inhibitors with the exception of the EGFR 
inhibitor AG1478.  These drugs included those targeting pathways already shown to 
interact with LCN2 expression. This suggests that regulation of LCN2 is likely to be 
fairly robust, and possibly not controlled by a single pathway alone. 
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Figure 5.4: LCN2 expression in response to a range of pharmacological 
inhibitors. A PC3 cells were exposed to a range of pharmacological inhibitors- 
U1026 (Targeting MEK/ERK); Wortmanin (MAPK pathway) API2 (Targeting AKT) 
and AG1478 (Targeting EGFR) at a range of concentrations. Data are mean of n=3 
experiments +/- SEM. Statistical analysis was carried out using Student’s t-test 
***p<0.001. B Western blots for positive controls. NEB1 cells were treated with 
U0126, Wortmanin API2 and AG1478 (All at 30μM/ml for 48hrs). Representative of 
n=3 experiments.  
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  5.5 shRNA based suppression of LCN2 in PC3 cells 
Since pharmacological inhibitors were not successful in suppressing LCN2, in order 
to fully suppress expression, alternative methods were required. For this, it was 
decided to utilise shRNA technology. While a number of commercial vectors exist, 
none of these at the time had been proven in any previous publication.  Therefore, 
vectors were obtained from Zhimin Tong’s laboratory (M.D Anderson, Texas) as 
used in their 2009 study (Tong et al., 2009) which were originally developed by Lee 
et. al., (2007). The shRNA was contained within a pLL-317 plasmid vector. This 
plasmid also contains a blasticidin resistance gene. Alternatively, vectors containing 
no shRNA insert were used. This was transfected into FT293 to generate viral 
particles (see Materials and methods section 2.6). Viral particles were transfected 
into PC3 cells and selected for 2 weeks with blasticidin.  This resulted in the creation 
of 2 cell lines namely PC3-shLCN2 and PC3-shControl (hereafter shCon). 
5.6 Confirmation of LCN2 suppression in PC3-shLCN2 cells 
Following 2 weeks of selection, cells were grown until 80% confluent, then split, and 
grown in a T25 flask before being split again, this time with samples taken for mRNA 
and protein extraction. qPCR analysis of PC3-shLCN2 cells showed a >1000 fold 
reduction in LCN2 expression (Figure 5.5A).  There was no significant difference in 
expression between PC3-shCon and PC3-Parental cells. Furthermore, protein 
expression of LCN2 from protein lysates was also reduced significantly when 
analysed via Western blot (Figure 5.5B). Again, there was no notable difference 
between PC3-shCon and PC3-Parental cells. 
Subsequently, media conditioned on PC3-shLCN2 cells was analysed for secreted 
protein expression. Both PC3-shCon and PC3-shLCN2 samples contained 1.8-
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2.0ng/ml. PC3-shLCN2 cells on the other hand recorded <0.01ng/ml (Figure 5.6C). 
All of the above experiments were repeated at numerous passages with similar 
results and suppression was found to persist even after 15 passages. 
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Figure 5.5: Suppression of LCN2 in PC3 cells. A- qPCR analysis of LCN2 mRNA 
expression in PC3-shLCN2 and PC3-shLCN2 cells relative to parental. Data is mean 
of n=4 experiments +/- SEM ***p<0.001. PC3. B- Western blot analysis of whole cell 
lysates (MAB1757 antibody) representative of 4 blots (mRNA and protein extracted 
in parallel). C- ELISA analysis of secreted LCN2 in ng/ml +/- SEM Statistical analysis 
was carried out using Student’s t-test ***p<0.001 (n=3). 
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5.7 PC3-shLCN2 cells exhibit a distinct morphology  
Parental PC3 cells are an average of ~15-20μm in size (Li et al., 2008) While there is 
a fair degree of variability between cells, the majority maintain a polarised structure, 
with a roughly ovoid shape, and are visually similar to fibroblastic cells. The majority 
of PC3 cells contain cellular protrusions, lamellipodia and filopodia which are used 
for migration and cell movement. PC3 cells do form colonies, but cells are not tightly 
packed, and cells may migrate from the original colony (Figure 5.6 A and B (Sobel 
and Sadar, 2005). 
PC3-shLCN2 underwent selection for 2 weeks, followed by a further 4 days until 
cells reached 80% confluence.  At this point, no visual changes were evident, 
although at this stage, there were not enough cells to extract mRNA or protein. 
However, following 2 further passages significant changes were observed to PC3-
shLCN2 cells. Most notable was that cells were much larger in surface area relative 
to controls. Cells appeared to have a loss of cell polarity and overall shape. There 
was considerable loss of a defined cell edge, and colonies were less compact. There 
was considerable variation in morphology between cells.  As can be seen in Figure 
5.6C-D some cells were more spheroid than others, and lost fillapodia. Others on the 
other hand did not completely lose this function.  Interestingly, there was a subset of 
cells which had an even more radical morphology. These cells were extremely large 
and flat and have no protrusions and had numerous vacuoles Figure 5.6, 
arrows).Under a phase light microscope, it was notable that these large cells 
appeared to lose some phase contrast, and had a dramatic loss of a defined cell 
edge. Visually, approximately 10% of the PC3-shLCN2 population were of this cell 
type, but were more evident a few days post seeding. Also, visually, there appeared 
to be a higher number of apoptosing or dead cells in the media. 
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Figure 5.6 PC3-shLCN2 cells exhibit a marked change in morphology: Left 
panel- PC3-shCon cells in larger (A) or smaller colonies (B). Right panel. PC3-
shLCN2 cells in a larger colony (C), enlarged cells are labelled with red arrows. 
Note- this is how the majority of colonies appear (D) Colony of PC3-shLCN2 cells 
with particularly pronounced morphological changes with the loss of defined cell 
edge  (arrows). Note- pictures have been sharpened and contrast enhanced for 
printing purposes only. X20 magnification. 
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5.8 PC3-shLCN2 cells are not senescent  
The drastic morphological changes observed in PC3-shLCN2 cells suggested that a 
number of cellular processes were involved with LCN2 suppression. One of these 
processes was senescence.  The large, flattened cells seen in PC3-shLCN2 cells 
were very reminiscent of the typical ‘fried egg’ like morphology of a central nucleus 
surrounded by a flattened cytoplasm classically associated with a senescent 
phenotype (Goldstein, 1990, Shin et al., 2011). It was therefore hypothesised that 
PC3-shLCN2 cells were entering a senescent state. 
To test this theory, PC3-shLCN2 and controls were tested for markers of 
senescence. Senescent cells are known to produce β-Galactosidase which is able to 
cleave X-Gal, leaving a blue precipitate. PC3-shLCN2 cells and controls were tested 
for β-Galactosidase activity through a commercial kit (Goldstein, 1990). H2O2 treated 
PC3 cells were used as a positive control. Results showed that contrary to 
expectations, PC3-shLCN2 cells did not show any β-Galactosidase activity (Figure 
5.7A). PC3-shCon cells did also not show any activity.  
To investigate senescence further, PC3-shLCN2 cells were tested for the expression 
of known senescence induced genes DEC, DEC2 and SHP1 (Xu et al., 2012b) by 
qPCR (Figure 5.7B). However, no change to expression was observed in any of 
these markers. Overall therefore, it may be seen that PC3-shLCN2 are likely not to 
be in a senescent state and that morphological changes observed are not part of this 
mechanism, 
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Figure 5.7 PC3-shLCN2 cells are not senescent. A Left- PC3-shLCN2 cells were 
treated with β-Galactosidase. Right-  Positive control, PC3-shCon cells were treated 
with H2O2 for 48hrs before β-Galactosidase testing. Black spots indicate positive 
staining. Images have been modified for extra contrast for printing purposes only 
(Representative of n=4 experiments) x20 magnification. B qPCR analysis of 
senescence related genes DEC1, DEC2 and SHP1. Values are relative to PC3-
shConl +/- SEM 
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5.9 PC3-shLCN2 cells exhibit a multi-nucleated phenotype and shifts on cell 
cycle. 
Since PC3-shLCN2 cells were found not to be senescent, the cause of the 
phenotypic changes was unclear. Therefore, FACS analysis using propidium iodide 
(PI) was performed on cells to determine any changes to cell cycle. Figure 5.8A 
shows the FACS cell cycle profile for PC3-shCon cells. Unlike a normal cell line, PC3 
cells shows an highly proliferative phenotype, with a large proportion of cells in S and 
G2 phase, indicative of fast proliferation. 31% of cells were in S phase, and a further 
19% of cells were found to be in G2 phase (Figure 5.8B) 
PC3-shLCN2 cells showed a markedly different FACS cell cycle profile which was 
highly skewed.  Firstly, (as seen in Figure 5.8C-D) there were a high percentage of 
apoptotic or dead cells (labelled P3) comprising 11.8% of the population analysed, 
and which therefore backed up the visual observations. 57% cells of cells were in the 
G1 (P6) phase. 22% of cells were found to be in S phase (P5), which is relatively 
high for a cell line. However, 16.3% of cells were in G2 (P5), which is far lower than 
found in PC3-shCon cells indicating a loss of aggression in these cells. Most 
interestingly however was the observation that 3% (+/-2) of cells were in a >G2 state, 
suggesting that are these cells are in a state of polyploidy or have multiple nuclei. 
Indeed, the data showed cells with up to 16N. This unexpected result suggests that 
the suppression of LCN2 leads major disruption of the cell cycle or cell division 
process which may also be leading to cell death. To help confirm the results 
observed via FACS, cells were stained with the nuclear dye DAPI. As can be seen in 
Figure 5.9, the majority of PC3-shCon cells contain only a single or dividing nucleus. 
Although a small minority of cells do contain more than one nucleus, these cells are 
rare and many were undergoing apoptosis. 
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Figure 5.8 FACS cell cycle analysis using propidium iodide. Left panel, whole 
population graph. A- FACS profilePC3-shCon cells. B Breakdown of cell cycle 
populations: P3-G0 phase, P4- G1 phase P5-S Phase, P6-G2/M phase. C- PC3-
shLCN2 cells FACS analysis. D P3- G0 phase, P4- G1 phase P5-S Phase, P6-G2/M 
phase. P7-9 >G2 phase. Representative of n=3 experiments taken at different 
passages. 
A 
B 
C 
D 
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By contrast, PC3-shLCN2 cells had a very different nuclear morphology which 
supports the FACS data. Approximately 85-90% of cells had single nuclei. These 
corresponded to cells which were smaller and rounder. However, in the cells which 
were highly enlarged and flattened, ~10-15% contained multiple nuclei. There was 
significant variation between cells. Some cells contained 3-4 nuclei, whereas others 
contained many more, indeed, some cells had upwards of 40 nuclei. Notably, many 
of these nuclei were small or incomplete and fragmented which may be indicative of 
mitotic checkpoint dysregulation (Figure 5.9). Also, within these cells, there appeared 
to a loss of nuclear structure, with nuclei appearing near the cell surface and 
dispersed apparently randomly.  In the vast majority of cases, the multi-nucleated 
phenotype corresponded to flattened and unorganised cell morphology. Indeed, the 
more abnormal the morphology tended to correspond to a higher level of 
dysregulation in the nucleus. The presence of a multi-nucleated phenotype suggests 
that PC3-shLCN2 cells had lost a critical component of their cell-cycle mechanism or 
nuclear organisation.   There are a number of reasons why this phenotype may be 
occurring, and it was unclear whether this was due to a loss of LCN2, or an off-target 
effect remained unclear.  Indeed, it raises a number of questions, for instance: are 
the multi-nucleated cells viable? Are they able to divide? Also, why does this 
particular phenotype occur only in 10-15% of cells? 
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Figure 5.9 DAPI image analysis of PC3-shCon andPC3-shLCN2 cells. PC3-
shCon and PC3-shLCN2 cells were fixed in paraformaldehyde and stained with 
DAPI. x40 magnification of cells . Scale bars- 100μm  
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5.10 Generation of a PC3-shLCN2 clonal cell line. 
While PC3-shLCN2 cells virtually a complete loss of LCN2 expression as assessed 
by qPCR and Western blotting, in order to fully eliminate any chance of residual 
PC3-parental cells interfering with subsequent results, single cell colonies were 
derived from PC3-shLCN2. This process would also help determine whether all  
PC3-shLCN2 cells  all had the capability to divide, particularly with regards to the 
multi-nucleated sub-population. 
PC3-shLCN2 cells were diluted manually to a concentration of ~1cell/100 μl and 
plated on a 96 well plate. Following 24 hours, 57/96 wells contained 1 cell, 16 
contained 2 or more cells and 23 contained no cells and were therefore discounted.  
9/55 single cell colonies were determined to have the more enlarged and flattened 
morphology associated with the multi-nucleated phenotype.  Following 7 days of 
culture, only 49 wells still contained  cells.  Of these, 35 had only a single cell, or had 
divided once only. Of the flattened and enlarged cells, none of the 9 formed colonies 
(1 cell had died). The remaining 14 wells contained colonies of at least 20 cells, but 
of varying cell number. 6 of these colonies were selected for further culturing 
representing a range of different colony sizes. These colonies were labelled A7, B4, 
B7 E5, F1 and F3 according to their position on the plate Figure 5.10A). 
All 6 colonies were cultured in T25 flasks until 80% confluent. However, while none 
of the colonies derived from larger/flat cells. In all 6 cases, larger and flattened cells 
were present (Fig 5.11A). Moreover, in every sub-colony, the percentage of these 
enlarged cells was 10-20% (Fig 5.10B). LCN2 suppression was confirmed for each 
clone by qPCR which showed virtual total knockdown as per the heterogeneous 
population.  
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The results from single cell colony formation reveal that it is likely that the enlarged 
and multi-nucleated cells were not capable of forming colonies.  However, there were 
only 9 of these cells in the sample; therefore this result is not conclusive. Additionally, 
not all PC3-shLCN2 cells were capable of colony formation, indeed only 25% of cells 
divided more than once, indicating that PC3-shLCN2 cells do not have stem-like 
characteristics. Most notably, in each clonal line, the ratio of multi-nucleated cells 
remained constant suggesting that this characteristic is not spontaneous, but rather 
is part of the overall PC3-shLCN2 phenotype is inherent to the cell line and not an 
artefact of the transfection.  
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Figure 5.10 Generation of PC3-shLCN2 clones. A Single cells were seeded and 
grown for 10 days in a 96 well plate- layout shown. No large cells formed colonies. B 
Bright field images of sub-colonies B4 and F7 after 20 days of culture. x20 
magnification.  
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5.11 Aberrant PC3-shLCN2 cells are migratory and motile 
PC3-shLCN2 wells were found not to be senescent, however whether cells, 
especially the highly enlarged cells were capable of movement was unknown.  To 
address these issues, 10000 PC3-shCon and PC3-shLCN2 cells were seeded in 6 
well plates (3 wells for each cell line) and cultured for 48 hours to enable cells to 
settle. Plates were imaged using time-lapse photography, with images taken every 
15 minutes for 12 hours. Unfortunately, due to issues with CO2  leakage, cells started 
to die after 9 hours. Nevertheless,. Images were then collated into videos. Figure 
5.11 displays sample images from PC3-shCon cells over 12 hours. Considerable 
variation existed within the population with some cells maintaining their morphology 
throughout, whereas others showed changes over time. As would be expected, PC3-
shCon cells migrate through the use of lamellipodia.  
By contrast, PC3-shLCN2 cells revealed a remarkably different behaviour. The 
population of relatively smaller cells migrated in a similar manner to PC3-shCon 
cells. Notably, cells showed evidence of lamellipodia when migrating, but with 
apparently less directionality than PC3-shCon. Also, morphology was relatively 
stable over the time period.  
The most obvious feature of the PC3-shLCN2 population was the highly enlarged 
and flattened cells.  As seen in figure 5.11, these cells did not remain in this state 
continuously. Rather, these cells contracted and expanded rapidly. The cells were 
also migratory, however rather than following thin or protruding lamellipodia, the cells 
followed a broader edge, or appeared to move at random. This data suggests that 
these aberrant cells are not senescent, and are indeed highly active. It also shows 
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that there are significant regulatory pathways being activated or deactivated rapidly. 
However, this data may also indicate that the cells are under stress and have lost 
some form of internal regulation. 
 
 
 
 
197 
 
 
Figure 5.11 Time lapse imagery of PC3-shLCN2 cells. PC3-shLCN2 cells were 
cultured at low density before being analysed via a time lapse microscope. Images 
were every 14-15 minutes. Cells of interest are labelled with arrows. Each group of 
images is from a different well. x20 magnification 
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5.12 PC3-shLCN2 cells display reduced proliferation in 2D and 3D cultures. 
Since PC3-shLCN2 cells showed such a notable shift in cell cycle. This was likely to 
be affecting cell proliferation rates. Alamar Blue was employed to analyse 
proliferation rates. Results confirmed that over 7 days, PC3-shLCN2 cells 
proliferated on average 0.61x the rate of PC3-shCon (Figure 5.14). No statistically 
significant difference was observed between PC3-shCon and PC3-Parental cells. 
(Figure 5.12) 
All of the above experiments involving PC3-shLCN2 were performed on a 2D plastic 
substrate. However, this method of culture does not accurately mimic the conditions 
within a tissue whereby cells grow in three dimensions and are able to grow into a 
soft matrix rather than impervious plastic. To overcome this issue, PC3-shCon, PC3-
shLCN2 and PC3-Parental cells were grown in a soft agar suspension consisting of 
3 layers: 1% agar 0.6% Agar and cells and media. Cells were cultured for 14 days 
with media changed every 3 days.  
PC3-shCon and PC3-Parental cells both formed 3D colonies in culture (Figure 5.13). 
These colonies ranged in size from a 10’s of cells to colonies 1000-2000μM in 
diameter. These colonies in most cases were either compact spherical or ovoid in 
shape. From ~1000 cells seeded, colony density was 6 colonies/cm2 whereby a 
colony was defined as >50 cells. By contrast, PC3-shLCN2 cells did not form any 
colonies whatsoever in soft agar (Figure 5.13), and no cells in the matrix were able 
to divide more than twice to form colonies >50 cells (i.e. 0 colonies/cm2), although 
notably some single divisions were common.   Indeed, it appeared that the majority 
of cells had died indicating that PC3-shLCN2 cells are incapable of growth within a 
3D substrate.  
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5.12 PC3-shLCN2 proliferation in 2D culture Alamar Blue proliferation assay- cells 
were cultured for 7 days until PC3-shLCN2 cells obtained 100% confluence. Values 
are mean of n=3 experiments +/- SEM for each data point. Statistical analysis was 
carried out using Student’s t-test.. ***p<0.001 
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5.13 PC3-sLCN2 colony formation in 3D culture. Soft agar colony formation 
assay. x10 magnification. Cells were cultured 14 days in a 0.6% Soft agar/ media 
mixture layered on a 1% soft agar solution and supplemented with media and 
stained with crystal violet. (n=3). Images are representative of n=3 experiments. All  
conditions performed in triplicate. 
 
 
 
 
 
1000μm 1000μm 
201 
 
5.13 Hormone receptor regulation PC3-shLCN2 cells. 
PC3 cells are an androgen independent PCa cell line which do not express the AR 
protein, and mRNA expression of AR is very low (Alimirah et al., 2006). However, 
PC3 cells are not totally hormone independent and have been shown previously to 
still express both ERα and ERβ.  Indeed, at a protein level, ERβ is expressed at a 
relatively higher level than ERα (Mak et al., 2010). ERβ expression has also been 
shown to inhibit EMT in PC3 cells (Mak et al., 2010).  Given that LNCaP-LCN2 cells 
showed significant changes to both ER and AR expression, it was hypothesised that 
suppression of LCN2 in PC3 cells would also be affecting their expression as well. 
 Previously, I found that LNCaP-LCN2 cells had increased levels of AR protein (but 
not mRNA) expression (See section 4.16.1). I subsequently investigated AR 
expression in PC3-shLCN2 cells to determine any changes to expression. AR mRNA 
is expressed very weakly in PC3 cells, and mRNA expression also did not change 
PC3-shLCN2 cells (Figure 5.14A). However PC3 cells do not express AR protein; 
this was unchanged in PC3-shLCN2 cells (Figure 5.14B). As such, these results 
indicate that LCN2 has little effect on AR in PC3 cells, or that due to low initial 
expression in control cells, any changes were undetectable. The role of AR signalling 
in PC3-shLCN2 therefore was not explored further. 
Previously, I found that LNCaP-LCN2 cells had reduced ERα expression, but 
increased ERβ expression (See section 4.16.2). Therefore, I aimed to see if and 
changes to ERα/β expression occurred when LCN2 was suppressed in PC3-shLCN2 
cells. qPCR analysis of both the ESR1 and ESR2 genes (which encode ERα and 
ERβ respectively) did not show any change in expression relative to PC3-shCon 
cells (Figure 5.14A).  
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With regards to ER protein expression. ERβ was also found to be expressed at a 
higher level than ERα in PC3-shCon cells. Thus agreeing with previous studies in 
PC3 cells (Mak et al., 2010). In PC3-shLCN2 cells however, ERα expression was 
markedly increased (Figure 5.14B). This was mirrored by a loss of ERβ expression. 
This therefore, was the opposite effect seen in LNCaP-LCN2 cells (See section 
4.16.2). 
To test the functional relevance of the change in ER expression, Downstream  ERα 
targets were analysed. The classical ER target HER2 (Li et al., 2009) however was 
unchanged in PC3-shLCN2 cells relative to controls and remained only weakly 
expressed suggesting that classical ER signalling had not been activated. 
Alternatively, this may be due to fairly weak mRNA signals in both PC3-shLCN2 and 
control cells. However, a further ER target, EGFR did display a decrease in 
expression mRNA level (reduced 2.3 fold) (Figure 5.14A).  At the protein level, PC3-
shLCN2 cells also showed a reduction both phospho-EGFR and to total EGFR 
(Figure 5.14B. Loss of EGFR expression therefore was in direct contrast to LNCaP-
LCN2 cells which showed increased EGFR mRNA expression (See figure 4.16A) 
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Figure 5.14 PC3-shLCN2 cells display altered ER protein expression. A- qPCR 
analysis of ERα, ERβ, and the target genes HER2 and EGFR IN PC3-shLCN2 cells 
relative to PC3-shCon. Values are mean of n=3 experiments taken at different 
passages.+/- SEM ***p<0.01 B- Western blot analysis of ERα, ERβ, AR EGFR and 
p-EGFR. Representative of n=3 blots. Protein and mRNA extracted in parallel. 
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5.14 PC3-shLCN2 cells are responsive to Estradiol. 
To assess the functional relevance of the shift in ERα to ERβ ratio, PC3-shCon and 
PC3-shLCN2 cells were supplemented with both the ER agonist Estradiol (E2) and 
the ER antagonist ICI-182-780. Since normal culture media with FBS contains a 
range of endogenous steroids, both PC3-shCon and PC3-shLCN2 cells were first 
cultured in charcoal stripped (CS) serum for 7 days to assess the effect on 
proliferation via Alamar blue assays.  CSS had a small anti-proliferative effect on 
both sets of cells.  Following 7 days of culture in CS serum, PC3-shCon cells 
proliferated at 0.86x rate of those grown in normal serum. PC3-shLCN2 cells 
proliferated at 0.80x of rate of those grown in normal serum (Figure 5.15). Therefore, 
the ratio between proliferation between PC3-shLCN2and PC3-shCon and remained 
relatively stable at 68%. This data also shows that PC3-shLCN2 cells have not 
become hormone dependent, and are able to proliferate, at least for 7 days, without 
the presence of steroids.  
75,000 cells/ well PC3-shCon and PC3-shLCN2 cells were seeded in CS serum 
containing media, and treated with either E2 (5nM/ml) or ICI-182-780 (10μM/ml). In 
addition, cells were also treated with a combination of both E2 and ICI-182-780. 
Cells were cultured for 5 days, at which point PC3-shCon cells were >90% confluent. 
PC3-shCon cells were slightly, but still significantly responsive to E2, and proliferated 
14% more than rate of untreated cells (p<0.01). In contrast, PC3-shCon cells were 
unresponsive to ICI-182-780 and showed no statistically significant change to 
proliferation.  Unexpectedly however, cells treated with both E2 and ICI-182-780 
showed a notable reduction in proliferation after 5 days (85% of untreated cells, 
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p<0.01) which may be indicative of a synergistic, albeit counter-intuitive effect 
between the two compounds.   
PC3-shLCN2 cells on the other hand were strongly responsive to E2, with a 45% 
increase in proliferation relative to untreated cells (p<0.001. Indeed after 5 days of 
culture, proliferation increased to a similar level of that found in untreated PC3-
shCon cells, suggesting that ERα is active in these cells and able to drive growth. 
However, ICI-182-780 had no statistically significant effect on proliferation. As with 
PC3-shLCN2 cells, a combination of both ICI-182-780 and E2 had a highly 
significant inhibitory effect, reducing proliferation by 47.8% relative to untreated cells 
(p<0.01). There are a number of reasons why this may be the case. Firstly, ICI-182-
780 has been shown to promote ERα degradation by localising the protein to the 
nuclear matrix (Long et. al, 2006). ICI-182-780 is also known to prevent dimerization 
of ERα, and undimerized protein has been shown to have anti-proliferative effects 
which may be exaggerated by additional E2. 
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5.15 PC3-shLCN2 cells in response to ER agonists and antagonists. Alamar 
blue assay. Cells were treated with either the ER agonist E2, or antagonist ICI-
182,780 with readings taken at 0, 1, 2 and 5 days at which point PC3-shCon cells 
attained near confluence. Graph represents readings after 5 days only. Values are 
mean of n=3 +/- SEM. ***p<0.001 
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5.15 E-cadherin Expression  in PC3-shLCN2 cells 
As well as steroid receptor expression, the effects of LCN2 were also investigated 
with regards to EMT. LCN2 has been previously been shown to down-regulate E-
cadherin (Yang et. al, 2009; Leng et. al. 2009), and this was also associated with an 
increased vimentin expression. However, in LNCaP-LCN2 cells, I observed the 
opposite effect of E-cadherin expression being increased. Also, PC3-shLCN2 cells 
exhibited visible changes to cell membranes, (such as loss of phase contrast and 
defined edges) and size which may be indicative to changes to structural proteins 
such as E-cadherin. Therefore, I aimed to investigate the effects of LCN2 
suppression on E-cadherin, as well as a range of classical EMT markers in PC3-
shLCN2 cells. 
PC3 cells display signs of a partial EMT signature, with high expression of vimentin 
and CD44 (Tai et. al,. 2009). However, PC3 cells still express low levels of E-
cadherin. In my experiments, E-cadherin protein was detected at identical low levels 
in PC3-Parental cells and PC3-shCon cells. However in PC3-shLCN2 cells, E-
cadherin protein expression was completely lost. vimentin and CD44 however did 
not show any change to protein expression in PC3-shLCN2 cells (Figure 5.16A).  
With regard to mRNA expression, E-cadherin (gene name CDH1) was strongly 
repressed in PC3-shLCN2 cells. Initial results revealed a 10.1 fold reduction (Figure 
5.16B) subsequent qPCR analysis consistently showed between an 8-12 fold 
reductions in CHD1. When other EMT markers were tested however, no change to 
mRNA expression was observed for vimentin (VIM), CD44 or ΔNP63. Combined with 
protein expression, the therefore suggests that the loss of LCN2 (as with ectopic 
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expression) is not influencing EMT as a whole, but rather appears to acting 
specifically on E-cadherin.  
E-cadherin (CHD1) mRNA expression is known to be regulated by a range of 
transcription factors. Of these, TWIST1, SNAI1 (a.k.a Snail), SNAI2 (a.k.a Slug) and 
ZEB1 have been implicated with controlling E-cadherin’s role in EMT. While there is 
some debate to the precise roles of these transcription factors, TWIST1, Snail and 
Slug have been shown to positively regulate E-cadherin, whilst ZEB1 has been 
shown to repress its transcription.  qPCR analysis was therefore carried out on these 
genes to observe if any changes in expression were observed in PC3-shLCN2 cells. 
Results revealed that there were indeed changes to transcription factor expression 
(Figure 5.16B). TWIST1 displayed a modest but consistent increase in expression of 
1.33 fold in PC3-shLCN2 relative to PC3-shCon (p=0.021). SNAI2 (Slug) did not 
show any significant change. SNAI1(Snail) however did show a 4.2 fold decrease in 
expression (p<0.01). Conversely, ZEB1 showed a 4.31 fold increase in PC3-
shLCN2. While no protein analysis on these genes was performed. It appears 
therefore that observed changes to expression are in accordance with previous 
literature and give an insight into the mechanisms by which E-cadherin is being 
repressed in PC3-shLCN2 cells.  
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Figure 5.16 EMT marker expression inPC3-shLCN2 cells: A- Western Blot 
analysis of E-cadherin and vimentin. Representative of 3 blots B-qPCR analysis of 
EMT linked genes. Values are relative to expression in PC3-shLCN2 cells +/- SEM 
Statistical analysis was carried out using Student’s t-test. **p<0.01 ***p<0.001. 
Average of n=3. 
*** 
*** 
** 
A 
B 
(110kDA) 
 
(55kDA) 
 
(50kDA) 
 
210 
 
5.16 Discussion 
In this chapter I have demonstrated that suppression of LCN2 in PC3 cells results in 
changes in cell morphology coupled with changes to both ER and E-cadherin 
expression. 
LCN2 was investigated in PC3 cells as it was hypothesised that LCN2 may be a 
target gene of the hedgehog pathway or GLI1 based on previous data from 
microarray analysis of LNCaP-GLI1 cells. However, no change to LCN2 expression 
was observed upon suppression of GLI1. It may be the case that GLI may activate 
LCN2 in a non-reversible method, as was seen for ΔNP63 and CD44 (See section 
3.4). However, since GLI is such a widely expressed gene this is unlikely given that 
having a non-reversible switch would have major implications for all cells. More likely 
is that GLI interacts with other pathways which are not turned off when GLI is 
inhibited. For instance, GLI may be activating the NF-κB pathway (Riobo et al., 2006) 
which is known to bind to the LCN2 promoter (Karlsen et al., 2010). .As GLI interacts 
with a wide range of pathways, it is difficult to identify exactly which factors these 
may be, and may involve more than one pathway.  Alternatively, LCN2 expression 
may by symptomatic of an unrelated pathway which does not interact with GLI 
directly. GLI1 is known to confer morphological changes and changes to cell cycle, 
and LCN2 expression may be a result of these. 
NF-κB has been shown to be one of the key regulators of LCN2 expression and has 
been shown as a promoter of LCN2 mRNA expression (Li et al., 2009, Tung et al., 
2013). The NF-κB inhibitor BAY-11-7082 had a strong toxic effect on PC3 cells, 
however, unexpectedly; it did not affect LCN2 expression at all.  It may be that NF-κB 
acts only as an initiator of transcription, or that other factors are involved as well. 
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Alternatively, it may be that in PC3 cells, the toxic effects of the drug simply occur 
before any inhibition of LCN2 can occur or be detected. NF-κB is known to interact 
with a range of apoptotic factors including BCL2 and BCLxL (Chen et al., 2000, 
Viatour et al., 2003). Therefore apoptosis may be occurring before any interaction 
with LCN2 can take effect. 
Aside from NF-κB, I observed that EGFR inhibition led to partial suppression of 
LCN2, correlating with other studies which have shown similar results (Mir et al., 
2012, Viau et al., 2010). PC3-shLCN2 cells showed decreased expression of both 
total and phosphor-EGFR. This may therefore be indicative of a feedback 
mechanism between the EGFR and LCN2 whereby the expression of one activates 
the other. Indeed, a study by Lim at al. showed that LCN2 expression was positively 
correlated to EGFR expression in ovarian cells (Lim et al., 2007). Both positive and 
negative feedback loops exist for EGFR (Avraham and Yarden, 2011), and involve 
numerous interconnected mechanisms including estrogen receptor (Filardo, 2002). 
Therefore, in PC3-shLCN2 cells the data suggests that suppression of LCN2 leads 
to increased ERα, which in turn inhibits EGFR. 
Following suppression of LCN2 I observed marked morphological changes in PC3-
shLCN2 cells. These included a loss of cellular protrusions and increased cell size. A 
notable effect was the presence of a sub-population of multi-nucleated cells 
comprising ~12% of total cells. Moreover, this population was maintained in clonally 
derived cell lines. However, the multi-nucleated cells themselves were incapable of 
cell division themselves. This may be indicative of LCN2 disrupting cell division and 
nuclear assembly and this was backed up by subsequent microarray analysis. 
During the course of the project, it emerged that Tung et al (2013) also used 
suppression. LCN2 in PC3 using shRNA. In this study, the authors also noted a large 
212 
 
reduction in proliferation of PC3-LCN2 knockdown cells of 480% after 3 days, 
although those statistics are somewhat misleading as they are a measurement 
relative to cell number at day 0. The group also noted an increase in LCN2 
knockdown cells in G0/G1 phase, which is also consistent results obtained in this 
study. The Tung et al. study did not however mention any phenotypic change or 
changes to nuclear organisation. Notably, the study also showed PC3 LCN2 
knockdown cells having increased p53 and p21 levels coupled with a loss of cyclin 
D1.It appears therefore that the highly enlarged cells may be as a result of key cell 
cycle checkpoint proteins being dis-regulated, which over time may build up, 
resulting in catastrophic loss of cellular and nuclear organisation.  This may also be 
why these effects were not noted until a few weeks post viral transfection. 
In these results I have demonstrated that PC3-shLCN2 cells showed increased ERα 
expression, coupled with a loss of both ERβ and E-cadherin. This directly mirrored 
data from LNCaP-LCN2 (See chapter 4) and confirmed a negative correlation 
between LCN2 and ERα. With regards EMT expression however, a positive 
correlation was observed between E-cadherin and LCN2 (also directly mirroring 
LNCaP-LCN2 data). This correlation was the opposite of what was previously 
described in breast cancer cells (Yang et al, 2009) with ERα traditionally being 
described as suppressing  E-cadherin expression (Oesterreich et al, 2003). As well 
as E-cadherin, opposing expression was also seen for the E-cadherin transcriptional 
repressor ZEB1. As to why there are differences between my study and the Yang et 
al. 2009 study; it may be that breast cells also express an unknown co-activator or 
co-repressor which does not occur in PC3-shLCN2 cells. The methylation activity of 
repressors such SNAIL is also variable between cell type. Also, estrogen receptor 
itself has been shown to directly interact with E-cadherin expression and can act as 
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either a activator or repressor depending on whether it is bound to a ligand or not 
(Cardamone et al., 2009). The data suggests therefore, that unlike in breast cancer 
cells, in prostate PC3-shLCN2 cells, ER is inhibiting E-cadherin and that differences 
to breast cancer cells are due to another factor which is different in the parental 
populations between PC3 and breast cancer cells. 
A number of studies have indicated that LCN2 expression contributes to an EMT 
phenotype (Liao et al., 2013, Yang et al., 2009). Conversely, a recent study by Wang 
et al. showed LCN2 inhibition of an EMT phenotype in hepatocarcinoma cells (Wang 
et al., 2013a). In my study, I observed that LCN2 expression was positively 
correlated to E-cadherin expression, and this may be mediated through ZEB1 
repressor activity. However, contrary to previous studies mentioned, the effects of 
LCN2 appeared to affect only E-cadherin and did not affect other EMT markers such 
as vimentin. This therefore suggests that LCN2 is interacting with more specific 
signalling pathways. Indeed, the expression of E-cadherin and vimentin are often 
independent of other each other and to other EMT markers, and E-cadherin 
expression does not necessarily lead to loss of vimentin and vice versa (Micalizzi et 
al., 2010, Kalluri and Weinberg, 2009). 
In conclusion, a few key points emerge from the data presented in this study: 
1. LCN2 suppression in PC3 cells has a marked effect on cell morphology, 
proliferation and nuclear stability 
2. Further confirmation of a negative correlation between LCN2 and ERα, but a 
positive correlation to E-cadherin expression 
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Chapter 6 
Global analysis of gene expression 
 in PC3-shLCN2 cells. 
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Results 
6.1  Microarray Analysis of PC3-shLCN2 cells. 
LCN2 has been implicated in a wide range of signalling pathways as previously 
mentioned, including NF-κB (Mahadevan et al., 2011), steroid receptor signalling 
(Guo et al., 2012), IL1β (Cowland et al., 2006)and angiogenesis (Yang et al., 
2013)pathways among others. Studies on these pathways have tended to be 
focussed on just one of pathway or mechanism. To date however, no comprehensive 
study has been performed which has looked at global expression patterns in 
response to either suppressed or ectopic LCN2, and no microarrays have been 
performed. As LCN2 is still a relatively under-studied protein, there are still many 
gaps in our understanding of the downstream effects of LCN2. As such many 
potential LCN2 targets and pathways may have been overlooked or simply not 
considered in the first instance. As LCN2 is now being proposed as a therapeutic 
agent and biomarker (Xu et al., 2012a) it is therefore necessary to obtain a fuller 
picture of what the effects of LCN2 suppression are. 
The gap in knowledge of LCN2 function, combined with the numerous phenotypic 
changes observed in PC3-shLCN2 cells therefore provides a good opportunity to 
elucidate exactly what influence LCN2 has in cells. mRNA microarray analysis was 
carried out comparing PC3-shCon cells with PC3-shLCN2. Arrays were carried out in 
triplicate using AFFYMETRIX arrays. This system contains on average 6-10 mRNA 
binding sites for approximately 19500 genes. The array also includes data for a 
sample of 180 microRNAs. The raw data was then analysed by the Robust Multi-
array Average (RMA) technique which adjusts for background noise. Statistically 
corrected values were then anti-logged to provide fold change values. 
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The results of the microarray revealed numerous changes in expression. Using an 
arbitrary cut off point of 1.5 fold, 842 genes were up-regulated in PC3-shLCN2 
relative to PC3-shControl. Conversely, 808 genes were down regulated < -1.5 fold in 
PC3-shLCN2, in total 8.04% of all genes were differentially regulated at least 1.5 
fold. Using more stringent criteria of 2 fold change, 255 genes were up-regulated, 
whereas 191 were down-regulated, representing 2.28% of all genes. While tending 
towards slightly higher numbers of up-regulated genes, overall the numbers of genes 
either up or down was approximately equal.  Tables 6.1A-B list the top 20 up and 
down genes respectively in PC3-shLCN2 cells relative to PC3-shCon cells.  From 
this list, a number of interesting genes emerge including (up-regulated)VEGFR and 
SPARC and IL1B  as well as (down-regulated) CHD1/E-cadherin, ACTG2 and KLK6. 
Also notable was in increase in expression of HSD17B12 which is involved with the 
steroid synthesis pathway.  
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A: PC3-shLCN2Up-regulated genes 
Symbol Description Accession No. 
Fold Change v 
PC3-shControl 
KDR 
Kinase insert domain receptor (a type III receptor tyrosine 
kinase) 
NM_002253 10.056107 
SPARC Secreted protein, acidic, cysteine-rich (osteonectin) NM_003118 9.426137111 
TFPI Tissue factor pathway inhibitor NM_006287 9.126109727 
CADM2 Cell adhesion molecule 2 NM_001167674 8.594021184 
AGR2 Anterior gradient homolog 2 (Xenopus laevis) NM_006408 8.0556444 
HSD17B2 hydroxysteroid (17-beta) dehydrogenase 2 NM_002153 6.558351987 
TBXAS1 thromboxane A synthase 1 (platelet) NM_001130966 6.119158774 
SPRY1 
sprouty homolog 1, antagonist of FGF signaling 
(Drosophila) 
NM_005841 5.869889452 
B3GALT1 
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 1 
NM_020981 5.630774336 
GABBR2 gamma-aminobutyric acid (GABA) B receptor, 2 NM_005458 5.0396842 
SPTLC3 serine palmitoyltransferase, long chain base subunit 3 NM_018327 4.637455164 
HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) NM_000860 4.428035126 
HIST2H2BF histone cluster 2, H2bf NM_001024599 4.267328972 
SLC2A12 
solute carrier family 2 (facilitated glucose transporter), 
member 12 
NM_145176 4.218314518 
FAM131B family with sequence similarity 131, member B NM_001031690 4.218314518 
IL1B interleukin 1, beta NM_000576 4.189176491 
TMPRSS2 transmembrane protease, serine 2 NM_001135099 3.908639874 
 
B: PC3-shLCN2 down-regulated genes 
Symbol Description Accession No. 
Fold Change v 
PC3-shControl 
ACTG2 actin, gamma 2, smooth muscle, enteric NM_001615  -36.42019311 
ESRP1 epithelial splicing regulatory protein 1 NM_017697  -29.10778861 
PRND prion protein 2 (dublet) NM_012409  -18.98340216 
KLK6 kallikrein-related peptidase 6 NM_002774  -14.6213032 
ST14 suppression of tumorigenicity 14 (colon carcinoma) NM_021978  -13.86459273 
LAD1 ladinin 1 NM_005558  -13.8325957 
IL13RA2 interleukin 13 receptor, alpha 2 NM_000640  -13.547925 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) NM_004360  -11.36610991 
CALB1 calbindin 1, 28kDa NM_004929  -10.17295333 
LCN2 lipocalin 2 NM_005564  -10.03289928 
CST1 cystatin SN NM_001898  -9.849155307 
CDH3 cadherin 3, type 1, P-cadherin (placental) NM_001793  -9.713559075 
NNMT nicotinamide N-methyltransferase NM_006169  -9.232150014 
KLK5 kallikrein-related peptidase 5 NM_012427  -8.243936163 
LPAR4 lysophosphatidic acid receptor 4 NM_005296  -5.856342784 
TNS4 tensin 4 NM_032865  -5.683054957 
MAL mal, T-cell differentiation protein NM_002371  -5.656854249 
ANKRD1 ankyrin repeat domain 1 (cardiac muscle) NM_014391  -5.553253802 
GRHL2 grainyhead-like 2 (Drosophila) NM_024915  -5.476800516 
VCAN versican NM_004385  -5.438969491 
Table 6.1: List of top 20 up and down regulated genes in PC3-shLCN2 cells. All 
values on these lists were all found to be statistically significant. A- Top up-regulated 
genes in PC3-shLCN2 vs PC3-shCon. B- Top 20 down regulated genes. Values are 
the inverse log2values of fluorescence intensity ratios. Due to multiples probes per 
gene, all genes presented had p values of at least p<1x10-5 
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6.2 Functional grouping of gene expression in PC3-shLCN2 by PANTHER 
In order to determine precisely what pathways and biological functions are 
associated with LCN2 suppression, raw microarray data may be analysed by a range 
of different software. PANTHER gene classification software 
(http://www.pantherdb.org) sorts gene lists into their roles in biological processes. 
The software is also able to place genes into known signalling pathways based on 
previous literature. For analysis, all genes with at least a 1.5 fold increase or 
decrease in PC3-shLCN2 were used as input values. It should be noted that many 
genes do not appear in any category due to insufficient information, whereas others 
appear multiple categories. 
Genes were categorised into gene ontology (GO) broad biological processes. Of the 
842 up-regulated genes, 722 are maintained on the PANTHER database. This 
generated 1741 hits, due to significant overlap in function, specifically with grouping 
‘cellular processes’ which comprised entirely of other groups.  Excluding this group, 
the GO grouping with the highest number of hits was ‘metabolic processes’ with 369 
hits. Within this group, 347 are classified as ‘primary metabolic pathways’. This is a 
somewhat broad term containing a range of different cellular mechanisms. Notably, 
within this list, the grouping nucleic based metabolic processes and protein 
metabolic processes had the highest number of hits (142 and 136 hits respectively), 
whereas the carbohydrate had far fewer hits (50) indicating that there appear to be 
significant changes to both DNA/RNA and protein regulation based processes rather 
than affecting energy generation (Figure 6.1A) 
Excluding ‘cellular processes’ other groupings with large number of genes were ‘cell 
communication’ (217 hits); ‘developmental processes’ and ‘immune response’ (both 
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with 134 hits).  122 hits were also recorded for ‘Transport’, within which 70 were 
involved with protein transport. 
With regards to down-regulated genes, 773 genes were listed in the PANTHER 
database. Genes were categorised into GO groupings as above. Notably, the 
percentage of genes in each category was extremely similar to that found with up-
regulated genes, with the categories metabolic processes, developmental 
processes, and immune response all having the largest number of hits (347,161,109 
and 104 hits respectively). Ratios within the groups were also highly similar. A slight 
exception was in metabolic processes, where there were a larger percentage of 
genes involved with nucleotide metabolism, and fewer genes associated with both 
carbohydrate and lipid metabolism (Figure 6.1B).This shows therefore that there is 
not a single GO classification which was differentially regulated in either up or down-
regulated gene. It also reveals that that LCN2 suppression is having a major effect 
on a wide range of cellular processes. These processes also correlate to phenotypic 
changes seen, such as changes to cellular proliferation   In particular, the GO 
grouping of metabolic processes contains many genes associated with cell division 
and growth. 
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Figure 6.1:  PANTHER GO processes.  Genes which had a minimum 1.5 fold difference 
in expression between PC3-shCon and PC3-shLCN2 were grouped by PANTHER according 
to biological process. Sub-categories of ‘metabolic processes’ are detailed in the middle and 
right pie charts. A- Up-regulated genes B-Down regulated genes. 
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While GO groupings show the overall function of genes, PANTHER software also enables 
genes to be categorised according to known signalling pathways.  Out of 722 up-regulated 
genes on the PANTHER database, 344 were included in pathway analysis (Figure 6.2A).  
Hits were recorded for over 100 signalling pathways. Of these, the grouping with the highest 
number of hits was ‘inflammation mediated by chemokine and cytokine signalling pathway’  
with 18 hits. This pathway contains genes regulated by interleukins and some NF-κB 
targets.The category with the second highest number of hits (16) was ‘Gonadotropin 
releasing hormonal receptor pathway’. This pathway covers the ER, AR and progesterone 
receptor pathways.  The WNT pathway also scored 16 hits. Other pathways with high 
numbers of hits were ‘hererotrimeric G-protein signalling pathway’ (13 hits) ‘Integrin 
signalling’ (12) and angiogenesis (10 hits). 
Of the 730 down-regulated genes in the database, only 217 were included in pathway 
analysis (Figure 6.2B). The pathway with the highest number of hits in this case was the 
WNT pathway (14), followed by integrin signalling (12). Gonadotropin releasing signalling, 
inflammation and angiogenesis all had 9 hits. Unlike the up-regulated genes, cadherin 
signalling and the p53 pathway were both strongly represented with 10 hits each. Also, 
hererotrimeric G-protein signalling had only 2 genes represented. 
When combined, the WNT signalling pathway shows the strongest overall 
representation with a total of 48 hits, followed by inflammation, gonadotropin 
releasing, integrin and angiogenesis pathways. From this data, it may therefore 
concluded that while LCN2 suppression is affecting a wide range of pathways, WNT 
signalling significantly over-represented. 
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Figure 6.2 (Legend on next page) 
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Figure 6.2 continued: PANTHER pathway analysis: Genes which had at least 1.5 
fold change in PC3-shLCN2 were categorised into to pathways according to pre-
defined algorithms. For brevity, only top ranked pathways are listed.  A- Up-regulated 
genes. B- Down regulated genes. 
 
 
 
 
B 
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6.3 Functional and pathway analysis by METACORE. 
PANTHER analysis is useful in generating crude pathway analysis and associations. 
However this is done simply by inputting gene symbols into the database thereby 
providing a yes or no answer to whether a particular gene is in a pre-determined 
grouping or not. PANTHER software therefore does take into account the rank of the 
gene, the fold change and fluorescence intensity. It also excludes all genes which 
are not inputted (i.e. those with less than 1.5 fold change in this instance). 
METACORE analysis on the other hand includes all these factors. METACORE 
analysis was carried out by Tracy Chaplin at the QMUL Genome centre using 
dedicated software Ontological and pathway analysis of DEGs (FC>2, p<0.05) was 
completed using Metacore and its GeneGo database. Differentially expressed genes 
were compared to known cellular pathways and process networks and P values and 
FDR were calculated for each pathway. Only pathways with a P value and FDR 
below threshold (0.05) were considered. 
Networks were established for the DEGs using the ‘analyse network’ tool. Briefly this 
involved using the DEGs (fold change>2 and p<0.05) as a seed list, then expanding 
the network using direct interactions annotated within the GeneGo database and 
classified according to Z-score and canonical pathway involvement.  
Table 6.2A-C demonstrates the biological pathways that were impacted the most 
significantly. Table 6.2A demonstrates the pathways affected by the up regulated 
DEGs in PC3-shLCN2 cells. Table 6.23B by the down-regulated DEGs and Table 
6.2C by total DEGs. Amongst the highest ranked pathways up-regulated in PC3-
shLCN2 cells, the top ranked pathway was TGF, WNT and cytoskeletal remodelling 
(Table 6.2A). This correlated well to PANTHER data. Other top ranked pathways 
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were and Chromosome condensation in prometaphase and Regulation of actin 
cytoskeleton by Rho GTPases. With regards to the highest scoring down-regulated 
pathways (Table 6.2B), the most represented pathways were ATP/ITP metabolism, 
Spindle assembly and chromosome separation, Nucleotide excision repair and 
Spindle assembly and chromosome separation. This therefore appears to fit in well 
with the morphological changes observed including a low rate of proliferation, 
aberrant cell division and a multi-nucleated phenotype. Overall (Table 6.2C), the 
pathway with the highest level of dis-regulation was the clathrin-coated vesicle cycle. 
This pathway is associated with vesicle assembly and the shuttling of proteins 
between the golgi and the cell surface membrane. This therefore may help explain 
why PC3-shLCN2 cells have such an abundance of vesicle-like structures present 
within the cell. 
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               Up-regulated DEGs, pathway analysis 
# Pathway Maps p-value 
1 TGF, WNT and cytoskeletal remodeling 1.88E-06 
2 Chromosome condensation in prometaphase 2.30E-06 
3 Tricarbonic acid cycle 3.39E-06 
4 Regulation of actin cytoskeleton by Rho GTPases 4.60E-06 
5 Ligand-Dependent Transcription of Retinoid-Target genes 6.22E-06 
6 LRRK2 in neurons in Parkinson's disease 6.22E-06 
7 Ras family GTPases in kinase cascades (scheme) 1.14E-05 
8 Regulation of CFTR activity (norm and CF) 1.14E-05 
9 Antigen presentation by MHC class I 1.94E-05 
10 Function of MEF2 in T lymphocytes 2.20E-05 
 
                Down-regulated DEGs, pathway analysis 
# Pathway Maps p-value 
1 ATP/ITP metabolism 7.26E-12 
2 Spindle assembly and chromosome separation 9.49E-12 
3 Nucleotide excision repair 4.44E-11 
4 Clathrin-coated vesicle cycle 1.10E-10 
5 Transition and termination of DNA replication 1.71E-10 
6 Regulation of translation initiation 1.65E-09 
7 Mismatch repair 9.47E-09 
8 Ligand-Dependent Transcription of Retinoid-Target genes 2.57E-08 
9 CTP/UTP metabolism 2.61E-07 
10 GTP-XTP metabolism 3.14E-07 
 
                  Total DEGs-pathway analysis 
# Pathway Maps p-value 
1 Clathrin-coated vesicle cycle 4.55E-13 
2 Transition and termination of DNA replication 1.38E-11 
3 ATP/ITP metabolism 2.02E-11 
4 Nucleotide excision repair 1.74E-10 
5 Spindle assembly and chromosome separation 3.68E-10 
6 Mismatch repair 2.47E-09 
7 Regulation of translation initiation 1.91E-08 
8 Ligand-Dependent Transcription of Retinoid-Target genes 4.05E-08 
9 GTP-XTP metabolism 1.56E-07 
10 LRRK2 in neurons in Parkinson's disease 3.55E-07 
Table 6.3  List of up and down regulated pathways in PC3-shLCN2 cells via 
METACORE analysis. A- list of top 10 up-regulated pathways in PC3-shLCN2 cells.B-
Down regulated pathways C-Overall pathway analysis. 
A 
B 
C 
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6.4 Analysis of gene expression by GENE-E software 
 
While there were many genes which showed a high level of fold increase, the fold 
increase alone does show how important such a change would be. If a gene was 
only very weakly expressed, or mRNA expression is close to zero in PC3-shCon 
cells, a 2 or 3 fold increase may have little real impact, as the gene is still only 
expressed at a very low level. By contrast, if a gene is already highly expressed, 
even a small fold change may result in a much larger amount of extra mRNA being 
transcribed by the cell. As it would logistically difficult to pursue all up or down-
regulated genes, it is necessary therefore to exclude those genes which had very 
low levels of total mRNA in either sample. Using GENE-E software, a graph was 
generated which plots total levels of gene expression in PC3-shCon vs PC3-shLCN2 
cells based on the average intensity of gene tags in the array. Figure 6.3A shows the 
expression of all 19500 genes in both cell lines. Each gene is represented by a 
single dot. The lower the value, the lower the gene expression.  The lowest possible 
value is 2.4 which corresponds to the background intensity or noise. The highest 
values were approximately 14.2, at which point signal saturation occurs.  By using a 
comparison with genes already tested (EGFR, GAPDH-both highly expressed, PSA-
AR (not expressed in PC3 etc.), it was observed that genes with intensity scores of 
<5 were undetectable by qPCR, or had detectable expression only after 40 cycles 
and can therefore be excluded from any genes to be pursued Gene expression 
between genes overall was found to be linear, although fewer genes had either very 
low or very high expression.   Hence, when deciding what genes to explore further. 
Ideal candidates would preferably be have at least a 2-fold change in expression and 
have high total intensity readings (Fig 6.3A Circled in red for up-regulated genes, 
blue for down-regulated genes). 
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Figure 6.3: Total gene expression values in PC3-shLCN2  A: Scatter plot of all 
17000 genes from the microarray analysis showing the fluorescence intensity in 
PC3-shCon vs PC3-shLCN2. Genes of interest are labelled in circles. B: Scatter plot 
containing only genes with a >2 fold increase in PC3-shLCN2. C- <-2 fold decrease 
in PC3-shLCN2. Colours are for identification only. 
- B 
C 
A 
230 
 
 
Figure 6.3B displays only the genes which were up-regulated by at least 2 fold in 
PC3-shLCN2. Genes which have a higher fold in increase in PC3-shLCN2 are higher 
on the X-axis. Utilising this data, it is possible to select targets for further research 
and which may be excluded. For instance, the gene CLEC2B showed a high fold 
increase in expression. However since both values are below 5, the actual effect on 
the cell is likely to be negligible. By contrast the genes IL1B, TBAXS1 and HPGD 
have high expression profiles in PC3-shLCN2 and are hence of more interest as they 
are likely to have a far greater influence on the cell overall and to signalling 
mechanisms.  From this set of genes, SPARC, IL1B, KDR and AGR2 were selected 
for further investigation based on both the high fold change, but also the volume of 
literature and importance of these genes, as genes such as HPDG and SPTLC3 
have only scant information regarding their role etc.  
SPARC encodes for the protein osteonectin. SPARC is associated with extracellular 
matrix remodelling and calcium binding (Reviewed by Arnold & Brecken 2009). 
SPARC has been linked to the progression of a range of cancers. Specifically, in 
prostate, high levels of SPARC are associated with increased metastatic potential 
(Derosa et al., 2012). However, SPARC also has some anti-tumorigenic properties 
which may be dependent on its methylation status (e.g in ovarian cancer) (Arnold 
and Brekken, 2009).  
IL1B (Encoding for IL-1β protein) is a key mediator of inflammation and immune 
response. It is also initiates the IL1B pathway which is associated with MAPK 
signalling activation, as well as NF-κB signalling mechanisms. In terms of cancer, 
IL1B is often associated with tumour progression and in particular inflammation in 
tumour sites.  IL1B is particularly intriguing as it has previously been shown to induce 
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LCN2 expression in murine adipocytes (Sommer et al., 2009).In human tissue too, 
IL-1β has been shown to specifically up-regulate LCN2 expression via the NF-κB 
pathway (Cowland et al., 2006). 
KDR, encoding for the protein VEGFR is the receptor for the chemokine VEGF, 
which is a critical mediator of angiogenesis (Holmes et al., 2007).  Notably, KDR 
itself has not been previously associated with LCN2 expression, however its ligand 
VEGF has been shown to be induced upon ectopic LCN2 expression in breast 
cancer (Yang et al., 2009). 
AGR2 (Anterior Gradient homologue 2 ) (Reviewed by (Brychtova et al., 2011)) is 
associated with development and differentiation. AGR2 has also been linked to 
cancer, although whether it acts as a tumour promoter or suppressor is still uncertain 
and may be tissue specific or dependent on other factors. Most notably however, is 
that AGR2 has been shown to be transcriptionally activated by estrogen via direct 
binding of ER to the AGR2 promoter and shows a positive correlation to ER+ BCa 
tumours. 
Figure 6.3C displays all genes which had a >2 fold reduction in expression in PC3-
shLCN2 relative to PC3-shCon. In contrast to up-regulated genes, there were a 
larger number of genes which show a very significant decrease in expression, 
indeed a number of genes were further from the line of best fit than LCN2 itself.  
From these, genes were selected for further characterisations based on overall fold 
change, expression in original PC3-shCON cells, and potential importance of these 
genes based on literature searches. Genes selected were: CDH1, CDH3, ST14, 
ESRP1, ACTG2 and KLK6. 
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CDH1 and CDH3 encode for E-cadherin and P-Cadherin respectively. P-Cadherin is 
not as studied as E-cadherin, but also plays a role in BCa progression. In contrast  to 
E-cadherin however, it is often cited as a marker of tumour progression (Albergaria 
et al., 2011). 
ST14 (Suppressor of tumorigenicity 14) encodes for the protein matriptase which 
functions as a serine protease. Contrary to its name, ST14 has been shown to be 
up-regulated in a number of cancers where it associated with metastasis, particularly 
BCa progression (Uhland, 2006). 
ACTG2 (Actin Gamma 2) is a cytoskeletal protein which is a member of the actin 
family. While this particular gene is very poorly studied, ACTG2 is a known mediator 
of internal cell motility (Yonemoto et al., 2006). The ACTG2 showed the highest fold 
decrease in expression in PC3-shLCN2 cells and is therefore a good candidate for 
more detailed analysis given then structural changes seen in cells. 
ESRP1 (Epithelial splicing regulatory protein 1)  has recently been shown to regulate 
the splicing of different variants of EMT related genes, in particular CD44 and Snail 
(Yae et al., 2012).  
 KLK6 is also a serine protease which is up-regulated in a number of cancers, in 
particular ovarian and BCa (Ghosh et al., 2004). KLK is also of interest in PCa due to 
its structural similarity with KLK3/PSA  (Bayani and Diamandis, 2012). 
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6.5 Validation of selected microarray based genes via qPCR 
Using the genes selected above, validation of results was carried out using qPCR 
analysis which is more sensitive and accurate. Microarray data is also constrained 
by the minimum and maximum fluorescence of tags which is not the case in qPCR.  
With regards to genes which were up-regulated in PC3-shLCN2 cells. The genes 
KDR, SPARC, ARG2 and IL1B were validated (Figure 6.4A).  Microarray analysis 
provided KDR with a 10.05 fold increase in PC3-shLCN2 cells relative to PC3-shCon 
cells. When analysed by qPCR however, this was raised to a 119 fold increase. 
SPARC had a 9.42 fold increase via microarray, qPCR validation increased this 
greatly to 133 fold.  AGR had a 8.06 fold increase via qPCR, whereas a 19 fold 
increase was recorded via qPCR. IL1B (4.19 fold increase from microarray) showed 
an 11.8 fold increase by qPCR analysis. 
For validation of down-regulated genes, CDH1, CDH3, KLK6, ESRP1 and ACTG2 
were selected (Figure 6.4B). When analysed by qPCR. Both CDH1 and CDH3 
showed similar decreases in expression to microarray data (11.3 vs 14 fold for 
CDH1, 9.7 vs 10.8 fold for CDH3). KLK, ESRP1 and ACTG2 on the other hand, 
when analysed by qPCR all showed >150 fold decrease in expression. Indeed, in 
these three genes, expression was effectively nil, and undetectable by qPCR at 40 
cycles.  In these cases therefore, the data suggests that transcription of these genes 
has been turned off almost completely.  It may also be hypothesised that other genes 
from the microarray have also been turned off, but were not analysed. 
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Figure 6.4: Validation of Microarray genes. Fold expression relative to PC3-
shLCN2 as detected by either microarray or by qPCR analysis A- Up regulated 
genes B- Down regulated genes. Values are fold change relative to PC3-shCon 
A 
B 
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cells. qPCR data: n=3  +/- SEM. All qPCR values had p values of p<0.01 relative to 
PC3-shCon cells Statistical analysis was carried out using Student’s t-test.  
6.6 Rescue of gene expression in PC3-shLCN2 cells by conditioned media. 
LCN2 is a secreted protein, however its roles in terms of paracrine or autocrine 
signalling are currently poorly understood, and there is little data regarding how 
LCN2 precisely functions with regards to pathways. While microarray analysis 
provides important information, it does not reflect which genes are directly influenced 
by LCN2 itself, or which are indirectly linked.  To help elucidate this further, two 
approaches were taken. Firstly- rescue of gene expression by supplementary LCN2 
protein. Secondly by employing temporary suppression of LCN2 by siRNA. 
The stability of LCN2 protein has not previously been described, nor is it known 
whether LCN2 is targeted for degradation either inside or outside of the cell. 
However, LCN2 protein was previously shown to be secreted by PC3-shCon cells at 
high levels, where it was present in cell supernatants as analysed by ELISA. To 
analyse whether this secreted LCN2 was able ellicit an effect on PC3-shLCN2 cells, 
PC3-shCon cells were seeded and cultured for 48 hours. Conditioned media (CM) 
was then filtered and added on PC3-shLCN2 cells for a further 24 hours before 
harvest (Figure 6.5A). 
qPCR analysis carried out on the LCN2 gene  revealed that conditioned media had 
no influence on expression and that the gene remained  repressed under the 
influence of shLCN2.  Analysis was then carried out on genes identified from the 
microarray, namely SPARC, KDR, AGR, IL1B (all up-regulated in PC3-shLCN2) as 
well as, ST14, CDH1 ESRP1, KLK6 and ACTG2 (down-regulated).   
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Highly significant reductions in the expression of all up-regulated genes was 
observed, although in no case did expression levels return fully to those found in 
PC3-shCon cells.  SPARC expression was reduced from a 185 fold increase relative 
to PC3-shCon to a 21.4 fold increase in cells cultured in CM (i.e there was a 21.1 
decrease relative to non CM media). KDR also showed a reduction in expression 
from 107 fold to 24. AGR2 was reduced from a 19 fold increase relative to PC3-
shCon to only a 4.0 fold increase. IL1B on the other hand showed no significant 
change in expression (Figure 6.5B). 
Notably, there were also changes observed in these genes between PC3-shCon 
cells grown in CM for the full 72 hours compared to those which had media changed 
after 48 hours. While SPARC had no statistically significant change, KDR expression 
was increased 6.3 fold in PC3-shCon cells cultured for 72 hours in CM relative to 
those that underwent media change. Similarly, a 3.2 fold increase was seen in AGR2 
CM grown PC3-shCon cells relative to PC3-shCon cells grown in fresh media, thus 
showing that the expression of these genes is rapidly sensitive to changes to media 
and environment, and as such may also be a factor when considering the results 
above.  
A different pattern emerged when down-regulated genes were analysed under CM 
conditions.  ST14 showed increased expression (3.2 fold) in PC3-shLCN2 cells 
cultured in CM compared to those grown in non CM. The genes KLK6, ESRP1 and 
ACTG2 did not show any response to CM media, and remained effectively non-
transcribed.  By contrast, CDH1 expression was suppressed even further under CM 
conditions than non-CM. Under non CM conditions, CDH1expression was found to 
be 7.5 fold lower than in PC3-shCon. Under CM conditions however, this was 
decreased further still to 31.15 fold (I.e there was an 8 fold decrease from CM+ 
237 
 
compared to CM- conditions). Overall, CM appeared to affect up-regulated genes 
more significantly that down-regulated genes. It may be the case that the silencing of 
these genes is irreversible by CM alone. 
 
 
 
 
 
 
 
Figure 6.5: PC3-shLCN2 gene expression in response to conditioned media: A- 
Diagram of experimental procedure. PC3-shCON cells were cultured for 48hrs, 
supernatant was then removed and filtered, then added to PC3-shLCN2 cells for a 
*** 
*** 
*** 
*** 
A 
B 
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further 24hrs. B qPCR analysis of LCN2 target genes. Gene expression is relative to 
levels in PC3-shCon cells with fresh media +/- SEM, n=3 Statistical analysis was 
carried out using Student’s t-test.  ***p<0.001 
Protein Expression 
 
In addition to gene expression, the effect of CM on protein expression in PC3-
shLCN2 cells was also observed. Using identical conditions to above, protein 
samples were harvested simultaneously with mRNA samples.  ERα was previously 
shown to be strongly up-regulated in PC3-shLCN2 cells. This was confirmed in PC3-
shLCN2 cells grown under normal conditions.  However, when PC3-shLCN2 cells 
were cultured under CM conditions, ERα protein expression was markedly reduced 
(Figure 6.6). ERβ was also found to be reduced in PC3-shLCN2 cells. However, 
there was little change to expression in PC3-shLCN2 cells grown under CM. 
Expression of E-cadherin was absent in PC3-shLCN2 cells under non CM 
conditions, and there was no change observed under CM conditions, thus correlating 
with qPCR data. 
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Figure 6.6: PC3-shLCN2 cells protein response to conditioned media: Culture 
conditions same as above- Western blot analysis. PC3-shCON cells were cultured 
for 48hrs, supernatant was then removed and filtered, then added to PC3-shLCN2 
cells for a further 24hrs. Data is representative of 3 experiments. Protein was 
extracted in parallel to mRNA (Figure 6.5). 
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6.7 Rescue of gene expression by recombinant LCN2 protein 
While conditioned media significantly changed the expression of both genes and 
proteins in PC3-shLCN2 cells, these effects cannot be attributed to LCN2 alone. 
Indeed, while only LCN2 has been suppressed in PC3-shLCN2 cells, there are likely 
to be many other secreted factors, including other proteins, steroids etc., which may 
be influencing expression of the genes previously analysed. Therefore, to more 
precisely identify which genes are influenced by LCN2, and exclude other factors 
cells were supplemented with commercially available recombinant LCN2 protein 
produced from E.Coli bacteria. Recombinant LCN2 has previously been shown by 
Yang et al. (2009) to reduce E-cadherin protein expression in modified MCF7 cells, 
however in the Yang et al. study’effects were only observed at concentrations of 
100μg/ml, which are clearly far in excess of what would naturally be found 
physiologically. Indeed, recombinant protein in the 2009 Yang et al. study was 
obtained from the same source as X-ray crystallography studies. Hence, to obtain a 
more accurate qualification of LCN2’s effects, PC3-shLCN2 cells were supplemented 
by the same level as detected in PC3-shCon cells via ELISA of 2ng/ml (See Section 
4.10). 
 PC3-shLCN2, as well as PC3-shCon cells were incubated for 24hrs and with 
recombinant LCN2 before mRNA and protein harvesting to mimic CM culture 
conditions. No changes to cell morphology were observed in any case. Cells 
remained healthy, and there was no visually obvious change in cell death as 
analysed by the number of floating or dead cells in the media.  
qPCR analysis of genes selected from the microarray showed a similar trend to that 
found with conditioned media, but with less effect. Of the up-regulated genes, 
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SPARC, KDR, AGR2 and IL1B were analysed. SPARC, KDR and AGR2 all showed a 
reduction in expression in PC3-shLCN2 cells treated with recombinant LCN2 protein 
of 2.17, 2.46 and 2.21 fold respectively (corresponding to a 72, 74 and 21 fold 
increase relative to PC3-shCon cells). IL1B on the other hand did not show any 
response in expression (Figure 6.7). With regards to genes down-regulated in PC3-
shLCN2 cells, no change in expression was observed for CDH1, ESRP1 or to 
ACTG2. However, an increase in expression was noted for ST14 (as was also seen 
with conditioned media). In addition, the LCN2 gene itself was also unaffected in 
PC3-shCon cells, potentially ruling out any feedback mechanisms. It appears 
therefore that LCN2 is indeed able to partially reverse the changes in gene 
expression in some but not all genes. The response also correlates well with CM 
media suggesting that LCN2 is involved, but that other factors are also likely to be 
acting on PC3-shLCN2 cells as well. As with CM conditions, the genes which were 
up-regulated in PC3-shLCN2 cells appeared to be more responsive than those 
down-regulated. 
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Figure 6.7 PC3-shLCN2 cells in response to recombinant lipocalin 2 protein.  
PC3-shLCN2 cells were cultured for 48hrs with 2ng/ml recombinant LCN2 (qPCR 
analysis).Values are relative to untreated PC3-shCon cells Untreated PC3-shLCN2 
values are the same as in figure 6.6. Average of n=3 experiments values +/- SEM. 
Statistical analysis was carried out using Student’s t-test.  **p<0.01 ***p<0.001 
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Protein Expression 
 
In addition to gene expression, the effects of recombinant LCN2 were simultaneously 
assessed on protein expression. As before, ERα was found to be strongly up-
regulated in PC3-shLCN2 cells. However, after only 24 hours exposure to 2ng/ml 
recombinant LCN2, expression was highly reduced (Figure 6.8). Expression for ERβ 
however was relatively unchanged. In both these cases, mRNA expression was 
found to be unchanged, and was identical between PC3-shLCN2 and PC3-shCon, 
thus further reinforcing a post-transcriptional regulation of this ERα by LCN2. EGFR, 
previously found to be down-regulated in PC3-shLCN2 cells also showed moderate 
signs of an increase in expression.  E-cadherin also did not show any response to 
recombinant LCN2 and remained unexpressed. In every case, recombinant LCN2 
had no effect on the expression of any protein tested in PC3-shCon cells. 
To determine exactly what concentrations were necessary for the changes to protein 
expression to be observed, PC3-shLCN2 and PC3-shCon cells were subjected to 
treatment of recombinant LCN2 at a range of dosages (0, 1.5 , 5 and 15ng/ml) for 48 
hours.  
Expression of ERα in PC3-shLCN2 cells was reduced by of LCN2 protein, and 
showed reductions at both 1.5ng/ml and showed most response at 5ng/ml. 
Interestingly, reduction was not as high with 15ng/ml LCN2 protein. No change was 
observed to E-cadherin expression under any dosage. 
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Figure 6.8: PC3-shLCN2 protein expression in response to recombinant 
lipocalin 2 protein. Western blot analysis of ERα, ERβ, E-cadherin and p-EGFR in 
PC3-shCon and PC3-shLCN2 cells in response to 48hrs treatment with recombinant 
LCN2 protein. Representative of n=3 blots.  
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Effect of Recombinant LCN2 on cell proliferation 
 
Concurrent with analysis of mRNA and protein expression, recombinant LCN2 
protein was employed to observe if there were any effects of LCN2 on cell 
proliferation using Alamar Blue assays.  Both PC3-shCon and PC3-shLCN2 cells 
were supplemented with 2ng/ml of recombinant LCN2 for 7 days until confluence 
was reached. Results showed that while after 6 days there was a slight increase in 
proliferation in treated PC3-shLCN2, there was no statistically significant change in 
proliferation to either cell type (Figure 6.9) 
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Figure 6.9: Recombinant LCN2 does not affect PC3-shLCN2 proliferation 
Alamar blue assay. Cells were cultured with or without 2ng/ml recombinant LCN2 
protein for 7 days until PC3-shCon cells were confluent. Fluorescence intensity 
measured @590 nm +/- SEM, n=3 
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6.8 Targeted siRNA suppression of LCN2 
shRNA is able to provide long term suppression of a target gene, however shRNA 
may not give a true representation of which pathways are directly associated with 
LCN2 and which are indirect effects of suppression as other signalling pathways are 
likely to activated over time. Two siRNA sequences targeting the LCN2 gene were 
transfected into PC3 cells (Labelled 5G and 5U based on their sequences.) at 100 
nmol/ml concentration for 72hrs (according to the manufacturer’s optimal 
specifications). Transfection was validated by siGLO fluorescence in control cells.  
Analysis by qPCR showed that transfection was highly effective. The 5U sequence 
reduced LCN2 expression by 178 fold, whereas the 5G sequence reduced LCN2 
expression by 235 fold.  As the 5G sequence was determined by qPCR to be the 
more effective of the two siRNA sequences, it was selected for further analysis on 
gene expression. PC3-Parental cells were transfected with 100nMol/ml siLCN2 and 
harvested after 2, 4 and 6 days. No morphological changes were evident at any time 
period.  qPCR analysis showed that suppression of LCN2 siRNA was effective at all 
three time points displaying a 68, 158 and 191 fold decrease in expression 
respectively (Figure 6.10A). However, analysis by Western blot showed that there 
whilst there was a slight reduction over time, intracellular protein expression of LCN2 
remained strong (Figure 6.10B).  Based on these results, data therefore appears to 
show that LCN2 is relatively stable within the cell, and may have a low rate of 
turnover. It also suggests that the effects of the siRNA are likely to be minimal due to 
LCN2 protein still being present over the time scale observed. This may also help 
explain why morphological changes in PC3-shLCN2 cells were observed only after 2 
weeks of growth and selection, and why relatively little changes were seen in LCN2 
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Figure 6.10: siRNA targeted suppression of LCN2 A- qPCR analysis of LCN2 
following siRNA targeted suppression. Parental PC3 cells were transfected with 
siLCN2 for 2, 4 or 6 days. Values are relative to expression at day 0 +/- SEM, n=3 
Statistical analysis was carried out using Student’s t-test..  B- Western blot analysis 
of LCN2 protein after 2, 4 and 6 days post transfection. Protein was taken in parallel 
to mRNA samples. Data is representative of 3 experiments. 
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qPCR analysis of target genes siRNA transfection. 
 
Whilst total suppression of LCN2 protein was not achieved by siRNA, nevertheless, 
the effects of partial suppression was analysed. Effects were assessed both on 
genes identified by microarray. 
It was previously found that KDR, AGR2 and SPARC were up-regulated in PC3-
shLCN2 cells (See section 6.4). I therefore investigated whether these genes were 
up-regulated by siLCN2. PC3-parental cells were treated with siLCN2 for 2, 4 and 6 
days and mRNA expression analysed by PCR. 
Results showed that even after 6 days of expression of KDR was unchanged at any 
time point (Figure. AGR2 expression showed no change in expression after 2 or 4 
days, but did show a 2.1 fold increase after 6 days (Figure 6.11). SPARC expression 
was unchanged after 2 days, but showed a 2.4 fold increase after 4 days and 
similarly a 2.5 fold increase after 6 days. Indeed, overall down-regulated genes 
showed a greater overall response than for the up-regulated genes such as KDR. 
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Figure 6.11: Expression of target genes after siLCN2 transfection: qPCR 
analysis of LCN2  target genes following 2, 4 and 6 days siRNA transfection. Values 
are relative to expression in PC3-siGLO controls +/- SEM Statistical analysis was 
carried out using Student’s t-test.  *p<0.05, **p<0.01, ***p<0.001, n=3. 
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Previously (See section 5.13), it was observed that ERα protein expression was 
increased in PC3-shLCN2 cells, coupled with a loss of both ERβ and E-cadherin. 
Therefore, to determine whether these effects were observable in short term 
suppression of LCN2, siLCN2 was used in PC3-parental cells (as in figure 6.13) 
hence assessed the effect of siLCN2 on the protein expression of ERα, ERβ and E-
cadherin following 2, 4 and 6 days of targeted suppression. 
Following siLCN2 transfection, expression of ERα showed a slight increase after 24 
and 48 hours however following 6 days of treatment, there was a marked increase in 
ERα expression. However there was no apparent change to either ERβ or E-
cadherin expression (Fig 6.12). This data therefore indicates that even though LCN2 
protein was still present, a small reduction in LCN2 is able to elicit an effect on ERα 
expression and hence ERα is likely to be a bona-fide LCN2 target protein. 
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Figure 6.12 Expression of LCN2 target proteins after siLCN2 transfection: 
Western blot analysis of ERα, ERβ and E-cadherin in response to siLN2 after 0,2,4 
and 6 days. Data is representative of n=3 experiments. 
 
 
 
 
 
 
 
 
 
(45kDa)
) 
 
 (45kDA) 
(65kDa)
) 
 
 (45kDA) 
(110kDa)
) 
 
 (45kDA) 
(50kDa)
) 
 
 (45kDA) 
253 
 
6.9 Discussion 
While some of the mechanisms of LCN2 regulation have been studied, there is 
relatively less data regarding its downstream effects . 
Microarray analysis of PC3-shLCN2 cells provided a more global analysis of the 
pathways and genes associated with LCN2. As well as pathways which have already 
been linked to LCN2 such as Wnt (Ziegler et al., 2007), other pathways such as 
integrin signalling and gonadotropin-linked signalling have not yet been described 
and demonstrate that LCN2 has a much wider range of effects than seen previously. 
Microarray analysis also strengthens LCN2’s links to angiogenesis and the p53 
pathway in greater detail (Mahadevan et al., 2013). As the effects of LCN2 
suppression were fairly wide-ranging, it is therefore difficult to determine precisely 
which pathways are directly linked to LCN2 and which are downstream effects. 
Indeed, while some common factors such as NF-κB were implicated in LCN2 
signalling, there was no single pathway which stood out as being prominent. Even 
with regards to Wnt signalling (which had many hits via microarray), defining whether 
canonical or non-canonical signalling was activated more was unclear. There is 
significant interplay and interaction between different pathways (Nelson and Nusse, 
2004, Gordon and Nusse, 2006). 
One of unknown factors with regards to LCN2 is whether the protein has differing 
intracellular function compared to extracellular function. Here, I have noted that in 
PC3 LCN2 has high intracellular expression, and that within the cell, LCN2 
potentially exists as a dimer. Moreover, by employing both conditioned media and 
recombinant LCN2 protein I demonstrated that some genes or proteins are activated 
by secreted LCN2, whereas others such as E-cadherin are not. Recombinant LCN2 
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protein was used by Yang et al (2009) to induce a reduction of E-cadherin, but only 
saw a minor reduction after 100μg/ml of treatment, which is over 1000 times 
physiological levels. Other studies, using recombinant LCN2 have shown it leading 
to translocation of the pro-apoptotic protein BAX, and have been shown to partially 
restore growth in LCN2 knockdown thyroid FRO cells (Ianetti et al, 2008). 
 
While the crystal structure of LCN2 is now well known (Goetz et al., 2000), there is 
virtually no data regarding its post-translational stability. It is not known whether 
LCN2 is targeted for proteasome degradation and its rate of turnover is also 
unknown. In this study I noted that pharmacological inhibitors, had relatively less 
effect than was expected, especially the NF-κB inhibitor BAY-11-7082. Also, siRNA 
targeted suppression of LCN2 was able to completely inhibit mRNA expression, but 
had far less effect on protein expression even after 6 days post transfection. 
Previous studies using siRNA targeting human LCN2 are notably absent. Tong et al. 
(2008) used siRNA targeting LCN2 in pancreatic cell lines. However, they noted only 
partial protein suppression in the DLD1 cell line and only minor change in the 
HCT116 cells. Ianetti et al. (2008) also used siRNA to demonstrate a knockdown of 
LCN2 protein. However in the Ianetti et al. study, the siRNA construct was 
constitutively transfected in a plasmid vector. This data therefore seems to suggest 
that LCN2 protein is actually relatively stable and has a low turnover rate If LCN2 is 
indeed stable, this may have implications if it is to be used as a drug target. 
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In conclusion, a number of key points may be derived from the data in this chapter. 
1. LCN2 influences the expression of a wide range of genes and signalling 
pathways including many genes such as SPARC which have not previously 
been associated with LCN2. 
2. That LCN2 acts in a paracrine manner, but that recombinant LCN2 protein 
was not able to affect expression of genes such as E-cadherin suggesting a 
further intracellular role for LCN2. 
3. Extracellular LCN2 is able to influence ERα expression. 
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Chapter 7: Defining Network  
Pathways associated with LCN2  
suppression 
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7.1 Defining network pathways associated with LCN2 suppression 
In summary of previous results (See section 6.1), I observed suppression of LCN2 in 
PC3 cells led to significant changes to the expression of numerous genes. 
Microarray analysis of PC3-shLCN2 cells also suggested that rather than affecting a 
single signalling pathway, LCN2 is able to interact with a wide range of networks 
(See section 6.2). siRNA suppression of LCN2 further confirmed that although some 
genes are likely to be indirectly affected, expression of genes such as KLK6, and 
proteins such as ERα show a more rapid response to LCN2 levels. 
Combining the data from microarray analysis, drug treatment, shRNA and siRNA it 
appears that LCN2 is able to regulate a number of separate pathways See sections 
5.2, 6.2, 6.8), in particular, LCN2 appears to most significantly influence steroid 
receptor pathways, EGFR signalling, and WNT signalling. However, how exactly 
LCN2 is eliciting these effects is unknown given that it has no known phosphorylation 
activity, and is not known to bind to any other proteins aside from MMP9 
(Chakraborty et al., 2013).  Indeed, while functional groupings were listed (section 
6.2), exactly how LCN2 is interacting with these networks and pathways remains 
unknown.  Hence a range of potential pathways were investigated to observe if they 
were affected by LCN2 suppression, namely ERK signalling, AKT signalling and 
mTOR signalling. 
ERK is a member, and one of the classical effectors of the MAPK pathway, and has 
been shown to act directly downstream of a wide range pathways, in particular 
EGFR and ERα (Filardo et al. 2000). ERK is also of interest as G-coupled receptor 
(critical mediators of the receptor-tyrosine-kinase to RAS bridge signalling) was 
highlighted as being up-regulated by PANTHER analysis (Section 6.2).  As ERK is a 
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kinase, total levels of the protein are generally consistent, however p-ERK levels are 
subject to rapid change. Links between LCN2 and ERK have been previously been 
linked to LCN2 by Tong et al, 2009 and by Yang et al., 2013 who suggest ERK acts 
as a mediator of LCN2 activity. However, previously, the MEK (upstream of ERK) 
inhibitor U0126 was found to have no influence on LCN2 (Section 5.4). To 
investigate further, levels of ERK were therefore investigated in PC3-shLCN2 cells. It 
was found that in PC3-shCon cells, p-ERK was found only at very low levels. LNCaP 
cells by contrast have high expression and used for positive control purposes. There 
was also no change to p-ERK expression in PC3-shLCN2 cells (Figure 7.1). It was 
therefore concluded that p-ERK signalling is not a suitable candidate, in PC3 cells at 
least for acting as a mediator of LCN2 expression. 
 
 
  
 
 
 
 
 
Figure 7.1 ERK expression in PC3-shLCN2 cells. Western blot of phospho-ERK 
and total ERK in PC3-shCon and PC3-shLCN2 cells. LNCaP-pBP used as a positive 
control. 
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7.2 LCN2 and mTOR signalling 
mTOR is a protein kinase which is associated with a range of cell functions including 
cell growth, autophagy and angiogenesis (Sarbassov et al., 2005, Laplante and 
Sabatini, 2012). mTOR is associated with either of two complexes known as mTOR1 
and mTOR2. The mTOR1 complex consists primarily of Raptor, DEPTOR mLST8, in 
addition to mTOR itself. mTOR2 comprises primarily of mTOR, as well as Rictor and 
mLST8 (Laplante and Sabatini, 2009). mTOR1 is particularly associated with 
autophagy inhibition through its activation of ATG13 (Lapnte and Sabatini, 2009). 
mTOR1 also plays a significant role in transcription and mitochondrial based 
metabolism (Groenewoud and Zwartkruis, 2013). mTOR2 on the other hand is 
strongly associated with cytoskeletal remodelling (O'Reilly et al., 2006). Both mTOR1 
and mTOR2 complexes are regulated in part by ATK phosphorylation. The two 
complexes are interdependent, with mTOR1 able to activate mTOR2 and vice-versa 
(Sarbassov et al., 2005).  The primary downstream targets of the mTOR1 complex 
are p-70S6Kinase (a.k.a p-S6K) and p-4EBP1, which are both phosphorylated and 
which lead to changes to post-transcriptional regulation of genes (Tabatabaian et al., 
2010, Laplante and Sabatini, 2009). 
mTOR signalling emerges as a potential candidate in LCN2 signalling for a number 
of reasons. Firstly, while mTOR signalling itself did not emerge as a significant 
pathway from microarray analysis via PANTHER, the biological functions designated 
by METACORE analysis point towards some of the processes traditionally linked to 
mTOR including pentose phosphate pathways angiogenesis and cytoskeletal 
remodelling (Sarbassov et al., 2004). The extreme phenotypic changes observed in 
PC3-shLCN2 cells may also be indicative of autophagy dis-regulation whereby 
dysfunctional cellular components are degraded.  
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Previous results demonstrated that ERα and ERβ levels appear to be regulated in 
PC3-shLCN2 cells by post-transcriptional or post translational mechanisms. mTOR 
signalling is a key component of post-translational regulation within the cell. Indeed, 
mTOR signalling has been proposed as an estrogen receptor regulator (O'Reilly et 
al., 2006) it was therefore hypothesised that LCN2 suppression was affecting mTOR 
signalling either directly or indirectly.  
The mTOR pathway acts primarily through phosphorylation, and has effects more 
often associated with post-transcriptional regulation rather than direct mRNA 
changes (Hay & Sonenburg, 2004).The effects of mTOR therefore are unlikely to be 
readily obvious from Microarray analysis as most of mTOR’s effects are only seen 
post-transnationally. Indeed there was no significant difference in the mRNA 
transcription levels of mTOR, P70S6K (encoded by the RPS6KB1gene) or 4EBP1. 
To assay for mTOR activity, Western blot analysis was performed on PC3-shCon 
and PC3-shLCN2 cells. These populations were also treated with 100 nmol/ml of 
Rapamycin (the traditional inhibitor of mTOR) for 48hrs. 
Regarding p-mTOR expression, under normal conditions, expression was found to 
be moderately lower in PC3-shLCN2 compared to PC3-shCon cells (Figure 7.2A). 
However, when cells were treated with rapamycin, PC3-shCon cells were found to 
unresponsive, and expression of p-mTOR did not change (Figure 7.2A). By contrast, 
PC3-shLCN2 cells were responsive to rapamycin treatment, and p-mTOR 
expression was reduced.  Levels of total-mTOR were unchanged between both cell 
types, and between treated and untreated cells. Expression of the classical mTOR 
target p-S6K was assessed by two antibodies targeting the pSer371 and pThr37/46 
phosphorylation sites however no expression for either cell type was observed for 
pThr37/46. Using the pSer371-pS6K antibody, expression was found to be 
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significantly reduced, but still present in PC3-shLCN2 cells compared to PC3-shCon 
cells. In both cell types, treatment with rapamycin totally abolished expression. With 
regards to p4E-BP1, expression was also found to be similar in PC3-shLCN2 cells 
compared to PC3-shLCN2 cells. Rapamycin treatment was effective in reducing 
p4E-BP1 levels in both cell types, but did not totally abolish expression. In addition, 
levels of p-AKT were assessed in PC3-shLCN2 cells, however levels were found to 
be similar to PC3-shCon cells and in both cell types p-AKT signals were strong 
(Figure 7.2B). These results therefore appear to show a notable down-regulation of 
the mTOR pathway which also fits with the phenotypic changes observed, especially 
cytoskeletal changes, and post-transcriptional changes observed to genes such as 
ERα/β. 
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Figure 7.2 mTOR signalling in PC3-shLCN2 cells: A-Western blot analysis of p-
mTOR and substrates p-S6K and p-4EB-BP1. PC3-shCon and PC3-shLCN2 cells 
were treated with 10μmol rapamycin. Note shown is p-S6K (Thr378) which showed 
no expression in either cell type.  B- Western blot of p-AKT. All data is representative 
of n=3. 
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7.3 Effects of recombinant LCN2 and siLCN2 on mTOR signalling in PC3-
shLCN2 cells  
To further investigate the effects of LCN2 on mTOR signalling, recombinant LCN2 
protein was employed to examine if it would affect mTOR and its downstream 
proteins.  Using the same conditions as before (See section 6.7), PC3-shCon and 
PC3-LCN2 cells were supplemented with 0.5, 1.5, 5 and 15ng of LCN2 protein for 
24hrs. p-mTOR expression showed little change following LCN2 treatment. p- 
S6K(SER371) expression on the other hand did show a positive response to 
recombinant LCN2. As before, p-S6K expression was higher in PC3-shCon cells, 
however expression which increased with dosage, with the highest expression at 
15ng/ml of treatment. PC3-shLCN2 cells also showed increased expression in 
response to treatment. With regards to p-4E-BP, the effect of recombinant LCN2 was 
less obvious; however minor increases in expression were seen in both PC3-shCON 
and PC3-shLCN2 cells at 15ng/ml of treatment (Figure 7.3) 
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Figure 7.3 mTOR substrates in response to recombinant LCN2 protein. Using 
identical conditions to figure 6.8, PC3-shCon and PC3-shLCN2 cells were treated 
with recombinant LCN2 for 48hrs.Data is representative of n=3 experiments. 
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7.4 Effects of siRNA suppression of LCN2 on mTOR signalling 
In order to observe whether temporary suppression of LCN2 affected mTOR 
associated protein expression, siRNA targeting LCN2 was employed. 
Using the same conditions as section 6.8 above, the effects of temporary siRNA 
mediated LCN2 knockdown was investigated on mTOR linked proteins. Suppression 
of LCN2 mRNA expression is was already confirmed for previous experiments (See 
Section 6.8, figure 6.10A) although expression of LCN2 protein remained strong 
despite the loss of mRNA (See figure 6.10B above).  Under these conditions, no 
observable change was noted to either p-S6K or p-4E-BP1 expression in PC3-
Parental cells (Figure 7.4), thus indicating that a more substantial or long term loss of 
LCN2 may be required to illicit an effect. 
When combining all the data therefore, there is evidence for LCN2 affecting mTOR 
signalling, although effects appear to be dependent on protein levels. Quite how 
LCN2 is able to influence mTOR phosphorylation remains unknown as p-AKT, which 
is the primary kinase upstream of mTOR remained unchanged in PC3-shLCN2 cells. 
However, a large caveat is that AKT is phosphorylated at multiple sites and it may 
simply be that the antibody used does not detect the correct phosphorylation site. 
Indeed, the mTOR complex is known to be phosphorylated via the T246 site, 
whereas the antibody used detected only the S473 site. mTOR signalling is activated 
by a wide range of kinases. mTOR has been linked to AMPK which is associated 
with energy production and stress, and is strongly associated with the TSC1/2 
complex.  Hence, it is possible that LCN2 is able to influence one or more of these 
signalling mechanisms 
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Figure 7.4 Expression of mTOR substrate proteins after siLCN2 transfection: 
siRNA suppression of LCN2 mRNA was previously confirmed (Figure 6.10). Western 
blot analysis of p-S6k and p4EB-BP1 -in in response to siLCN2 after 0,2,4 and 6 
days. Blot is representative of n=3 experiments. 
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7.5 LCN2 signalling and iron homeostasis. 
The effects of LCN2 suppression on such a wide range of genes, proteins and 
pathways is somewhat surprising given the small size of the protein itself, and its 
lack of any phosphorylation site, or indeed of any other conserved enzymatic domain 
aside from the lipocalin domain itself (Flower, 2000). LCN2 was first described as an 
iron chelator (Kjeldsen et al., 1994). This function has been linked to immunity 
against bacteria, but is believed to play a role in the overall homeostasis of the Fe3+ 
ion within the cell (Torti and Torti, 2011). However, the effects of LCN2 shuttling in 
and out of the cell are poorly understood. It was therefore hypothesised that the 
effects and signalling seen previously may be a result of LCN2 altering intracellular 
iron levels. Within this hypothesis however, there are two possible outcomes of 
LCN2 suppression: Firstly, LCN2 suppression may lead to the inability of cells to 
import Fe3+ from their surroundings, leading to iron starvation, conversely, LCN2 
suppression may result in cells being unable to export iron, thus leading to iron 
overload. 
LCN2 does not bind to Fe3+ directly, but rather to iron bound to siderophores (Flo et 
al., 2004). Deferoxamine (a.k.a Desferrioxamine; DFOX) is a commercially available 
siderophore derived from Streptomyces pilosus bacteria. DFOX functions by binding 
to free iron within the media, thus preventing its use by cells.  Hence, DFOX acts as 
a model for iron depletion. As DFOX is a long chain siderophores, it is unable to be 
bound by LCN2 (Gomez-Casado et al., 2013). 
PC3-shCon and PC3-shLCN2 cells were treated with 10μg/ml of DFOX (as 
previously described by Ndong et. al., 2009 for 48 hrs. Following treatment, distinct 
morphological changes were observed in both cell types. PC3-shCon cells treated 
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with DFOX were noticeably flattened and larger than untreated cells (Fig 7.5). Under 
bright field lighting, cells also appeared to lose phase contrast, with a notable loss of 
cytoskeletal structure. Indeed, treated PC3-shCon cells displayed a phenotype that 
was strikingly similar of that found in PC3-shLCN2 cells. Cells also looked unhealthy, 
and higher numbers of dead cells were observed. When PC3-shLCN2 cells were 
treated with DFOX, cells presented an even more extreme phenotype. In these cells, 
there was a dramatic loss of phase contrast, cells also became highly flattened. A 
distinct loss of cell edge definition and in particular of cell-cell edges was observed. 
Cells appeared to have a dramatic loss of cell shape integrity, and also contained 
numerous vacuoles. The evidence therefore appears to suggest that preventing PC3 
cells from obtaining iron is able to induce a PC3-shLCN2 like phenotype, and can 
lead to cytoskeletal disruption and loss of cell polarity. 
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Figure 7.5: Deferoxamine treatment of PC3 cells. PC3-shCon and PC3-shLCN2 
cells were treated with 10μM Deferoxamine (DFOX) for 48 hours. Following 
treatment, PC3-shCon cells showed phenotypic change similar to PC3-shLCN2. 
DFOX treated PC3-shLCN2 cells showed a further loss of phase contrast and 
defined cell edges. Images are representative of n=3 experiments. x20 
magnification. 
 
PC3-shCon DFOX - PC3-shCon DFOX + 
PC3-shLCN2 DFOX - PC3-shLCN2 DFOX + 
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7.6 qPCR analysis of DFOX treated PC3 cells shows effects opposite to those 
found in PC3-shLCN2 cells. 
qPCR analysis was carried out on DFOX treated cells to determine effects on mRNA 
expression (Figure 7.6). Firstly, LCN2 expression itself in PC3-shCon cells was 
found to be decreased slightly, but significantly, by 1.7 fold . Significant changes 
were observed a range of other tested genes previously identified from Microarray 
data. It was found that in DFOX treated cells, in many cases, expression was the 
opposite of what was previously found in PC3-shLCN2 cells. With regards to genes 
which were previously found to be upregulated in PC3-shLCN2 cells. A 3.2 fold 
reduction in SPARC expression was also recorded in treated PC3-shCon cells it was 
found that PC3-shLCN2 cells treated with DFOX showed a 12 fold reduction in 
SPARC expression relative to untreated cells (Figure 7.6). A 2.5 relative fold 
reduction was also observed in KDR expression in both PC3-shCon and PC3-
shLCN2. Expression of AGR2 was also reduced in both treated PC3-shCon and 
PC3-shLCN2 cells. 
Changes to mRNA expression were also observed to genes previously found to be 
down-regulated in PC3-shLCN2 cells. ACTG2 expression in DFOX treated PC3-
shCon cells was found to be increased 1.9 fold relative to untreated cells. Also, 
ACTG2 expression in PC3-shLCN2 cells (which was ~62 fold lower than PC3-shCon 
cells) was increased by 2 fold when treated with DFOX (Figure 7.6). A similar pattern 
emerged with CDH1; expression was increased in treated PC3-shCon cells (2.8 
fold), whereas expression increased 4.5 fold in PC3-shLCN2 cells (2.2 fold). 
However, this pattern was not universal. KRT7 expression was reduced in both PC3-
shCon and PC3-shLCN2 cells; although there was a greater effect seen in PC3-
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shLCN2 (2.4 and 6.6 fold reductions respectively). Expression of KLK6 was 
unchanged.  
 
 
 Figure 7.6 PC3 gene expression in response to Deferoxamine. PC3-shCon cells 
were treated with 10μM Deferoxamine (DFOX) for 48 hours. qPCR analysis of a 
selection of genes previously identified from microarray analysis as being strongly up 
or down regulated in PC3-shLCN2 cells (See section 6.2). Values are relative to 
untreated PC3-shCon cells +/-SEM Statistical analysis was carried out using 
Student’s t-test.  *p<0.05 ***p<0.001, n=3. 
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7.7 Effects of DFOX treatment on protein Expression 
In addition to mRNA expression, the expression of key proteins was assessed, in 
particular those associated with steroid metabolism, or to mTOR signalling. 
As with mRNA expression, LCN2 protein was found to be unchanged upon DFOX 
treatment. With regards to ER expression, Expression of ERα was increased slightly 
in treated PC3-shCon cells, and also a possible increase in treated in PC3-shLCN2 
cells (Figure 7.7A). There was slight reduction in E-cadherin expression in treated 
PC3-shCon. However, no change was observed in PC3-shLCN2 cells and E-
cadherin remained unexpressed. 
Protein expression analysis was also carried out on the mTOR pathway. The primary 
reason for investigating this is due to the interaction of HIF1α and mTOR (Hudson et 
al., 2002). HIF1α is susceptible to changes in iron levels (Maxwell and Salnikow, 
2004), and thus may provide a link to LCN2.  HIF1α was very weakly expressed in 
both PC3-shCon and PC3-shLCN2 cells. When treated with DFOX however, 
expression was up slightly in DFOX treated PC3-shCon and in PC3-shLCN2 cells, 
although the level of increase was higher in PC3-shCon than the other(Figure 7.7B) . 
It should be noted that in all cases, strong bands were seen at ~48 kDa and ~ 52 
kDa which may be representative of HIF1α breakdown in normoxic conditions. As 
such, despite the changes observed, HIF1α is unlikely to be a mediator for LCN2 
under these conditions.  
With regards to other members of the mTOR signalling pathway, p-mTOR itself was 
found to be unchanged under DFOX conditions. On the other hand, p-S6k 
expression was found to be reduced in treated PC3-shCon cells, however, in PC3-
shLCN2 cells, this reduction appeared to be greater (Figure 7.7B).  
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Overall therefore, when combining the data from phenotypic change, qPCR and 
protein expression, the data suggests that iron chelation is able to induce a PC3-
shLCN2 like phenotype, but that this does not correlate to similar gene expression 
patterns. What the data does show however, is that genes which were associated 
with LCN2 either from the microarray or otherwise do show a response to DFOX. 
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Figure 7.7 PC3 protein expression in response to Deferoxamine: A Western blot 
analysis of ERα, E-cadherin in PC3-shCOn and PC3-shLCN2 cells in response to 
deferoxamine treatment. B mTOR linked proteins HIF1α and p-S6K in response to 
Deferoxamine (Note, loading controls were the same for both A and B). Data is 
representative of n=3 experiments) 
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7.8 Discussion 
Despite research into the effects of LCN2, and its suitability as a biomarker, relatively 
little is known about its methods of action and exactly how it gives rise to 
downstream effects. Given that LCN2 lacks any kinase domains, and has no 
transcriptional activity, the wide ranging effects of LCN2 suppression are likely to be 
due either to an unknown binding protein, or more likely due the effect LCN2 has on 
intracellular iron levels . 
A number of signalling pathways have previously been proposed for LCN2, including 
ERK (Mir et al., 2012). However, I found that in PC3 cells at least, ERK is unlikely to 
be a target of LCN2, although this may be due ERK being only weakly expressed in 
PC3 cells. Weak ERK expression in PC3 cells may also explain why the ERK 
inhibitor U0126 had no effect on LCN2 cells ( See section 5.2). 
In this chapter, I demonstrated that PC3-shLCN2 cells have reduced expression of 
the mTOR pathway including p-s6K. Moreover, expression of p-s6k was partially 
restored upon addition of recombinant LCN2 protein. To date, no studies have 
reported any link between the mTOR pathway and LCN2. The data in this chapter 
however does suggest that LCN2 is able to directly interact with this signalling 
mechanism. The mTOR pathway is associated with a number of cellular functions, 
but particularly autophagy and post-transcriptional regulation. PC3-shLCN2 cells 
were enlarged and contain a sub-population of cells with a high degree of nuclear 
aberration. This phenotype may be suggestive of reduced autophagy in the cell 
which allows the build-up of dysfunctional cellular components (Pattingre et al., 
2008).  Also, it was previously noted that ERα:β ratios in PC3-shLCN2 cells was 
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changed (See section 5.13) and that this change was post-transcriptional which may 
be explained in part by changes to mTOR activity. 
In the results shown here, I demonstrated that treatment of PC3 cells with the iron 
chelator deferoxamine led a phenotype similar to that of LCN2 knockdown cells, 
coupled with a slight increase in ERα expression. This would seem to suggest that 
LCN2 is acting to increase the labile iron pool.  However, although the morphology of 
DFOX treated cells was similar to PC3-shLCN2 cells, this did not correlate with gene 
expression patterns seen in PC3-shLCN2 cells. The role of LCN2 in regulating the 
intracellular labile iron pool is still unclear. Current hypotheses state that LCN2 binds 
to siderophores, trafficking iron into the cell where is released. Iron is critical for cell 
growth, however if there is too much intracellular iron, Fe3+ in the cell leads to 
reduced pH which can lead to activation of mechanisms such as cell cycle arrest 
(Torti and Torti, 2011). 
As LCN2 has no phosphorylation activity, it is probable that LCN2 functions through 
regulating iron levels, and this may be affecting mTOR expression as well as other 
phenotypic changes observed.  Reduced iron levels in cells has been shown down-
regulate the TSC1/2-mTOR pathway (Ndong et al., 2009). Moreover, uptake of 
nutrients such as iron have also been shown modulate cell size via the AKT/mTOR 
pathway (Edinger and Thompson, 2002). 
High Fe3+ levels are also known to activate HIF-1α (Maxwell and Salnikow, 2004). 
HIF-1α is a known activator of the mTOR pathway (Agani and Jiang, 2013),. As such 
it appears that   suppression of LCN2 leads to the reduction of the labile iron pool. 
This in turn may be deactivating pathways such as mTOR, and hence leading to the 
extreme phenotype seen in PC3-shLCN2 cells. 
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In this chapter, I demonstrated that while Deferoxamine treatment of PC3 cells led to 
these cells acquiring a PC3-shLCN2 like phenotype, mRNA expression patterns of 
target genes such as SPARC and E-cadherin were the opposite of those found in 
PC3-shLCN2 cells. However, expression of ERα was elevated in Deferoxamine 
treated PC3 cells. The data suggests therefore that although LCN2 may be acting in 
regulating intracellular iron levels, the precise effects of iron withdrawal are likely to 
somewhat complex, and effects are also likely to be influenced by other factors such 
as DNA methylation status, interaction between different cellular pathways and the 
expression of other iron-related factors such as transferrin (Torti and Torti, 2011). 
One issue with LCN2 is that it has been shown to have either pro- or anti- apoptotic 
effects depending on whether it is bound to iron or not (Devireddy et al., 2005). 
Hence, removal of iron by deferoxamine may not be having the same effect as 
suppressing LCN2 completely.  Whether iron bound LCN2 affects signalling is very 
poorly understood, and it therefore possible that iron-free LCN2 is responsible some 
of the mRNA expression changes observed. A further issue is that LCN2 has been 
shown not to bind directly to iron, but rather only to siderophores. (Although 
deferoxamine is a sub-class of siderophore it has been shown not to bind to LCN2 
by Correnti et al., 2012). While some siderophores are produced endogenously by 
human tissue (Raffatellu et al., 2009), there are likely to be fewer siderophres in 
culture media compared to in vivo and thus may influencing results.   
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In conclusion, the data in the chapter suggests the following: 
1) Suppression of LCN2 expression in PC3 cells leads to down-regulation of the 
mTOR pathway which is partially restorable upon supplementation of 
recombinant LCN2 protein 
2) That treatment of PC3 cells with the iron chelator Deferoxamine results in a 
phenotype similar to that of PC3-shLCN2, including elevated ERα levels, but 
opposing effects to expression of some LCN2 target genes. 
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Chapter 8 
Suppression of LCN2 in the MCF7  
breast cancer cell line. 
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8.1 Generation of an MCF7-shLCN2 cell line 
To identify whether the effects seen in PC3-shLCN2 cells were characteristic of 
LCN2 expression in general, or specific to PC3 cells, LCN2 suppression was also 
performed in a further cell line. Ideally, a further prostate cancer cell line would be 
preferable in this instance, however out of all the commonly used PCa cell lines, only 
PC3 shows LCN2 expression at sufficient levels. GEO profiling, which included rarer 
PCa cell lines such as SV-1 further confirmed PC3 cells as having the strongest 
LCN2 expression amongst PCa cell lines. Breast cancer cell lines share a number of 
properties which provide a useful comparison to PCa. Firstly, BCa cell lines are 
primarily derived from epithelial tissue. Secondly, BCa cell lines are strongly 
associated with hormone receptor signalling, particularly ERα/β (Alderton, 2012).  
In their 2009 study, Yang et al. used the MCF-7 cell line to demonstrate a negative 
correlation between ERα and LCN2 expression. The MCF-7 cell also line provides a 
highly suitable model for LCN2 suppression: MCF-7 cells are epithelial and express 
ERα and E-cadherin (Ye et al., 2010).  
LCN2 levels were assessed in MCF-7 cells by qPCR, and ELISA. When analysed by 
qPCR, MCF-7 showed LCN2 mRNA levels comparable to those found in PC3 cells 
(Figure 8.1A). ELISA showed that MCF-7 secreted 1.8ng/ml LCN2 protein, slightly 
less than in PC3 cells, but significantly higher than other PCa cell lines (Figure 8.1B) 
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Figure 8.1. LCN2 expression in MCF7 cells. A qPCR analysis of LCN2 expression 
in MCF7 cells relative to PC3 cells (+/- SEM) Statistical analysis was carried out 
using Student’s t-test.*p<0.05 B ELISA analysis of secreted LCN2 protein in MCF7 
and PC3 cells. Data is mean of n=3. 
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The MCF-7-shLCN2 cell line was generated using identical methods and vectors as 
previously described for PC3-shLCN2 (See Materials and methods section 2.7). 
Empty vector controls were simultaneously used to create an MCF-7-shCon cell line. 
Cells were selected for 2 weeks under blasticidin treatment. Following a further 10 
days of growth and splitting, mRNA and protein extraction was performed. qPCR 
analysis showed that suppression was successful, showing 22 fold decrease in 
LCN2 expression relative to both MCF-7-parental and MCF-7-shCon (Figure 8.2A). 
No difference in LCN2 expression was recorded between MCF-7-parental and MCF-
7-shCon cells. Protein analysis via Western blot also showed a significant reduction 
in expression, although expression was not as total as seen with PC3-shLCN2 cells 
(Figure 8.2B). Suppression of LCN2 was confirmed using both the MAB1757 
antibody (showing a 48 kDa band) and ELISA analysis confirmed a reduction in 
secreted protein, with MCF-7-shLCN2 cells secreting 0.55ng/ml of LCN2 (Figure 
8.2C). 
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Figure 8.2: Characterisation of the MCF-7-shLCN2 cell line: A- qPCR analysis of 
LCN2 gene expression in MCF7-shCon and MCF7-shLCN2 cells. Values are relative 
to MCF7-shCon +/- SEM n=3 B- Western blot of LCN2 in MCF7-shCon and MCF7-
shLCN2 suppression using both the MAB1757 antibody which detects bands at ~and 
the AF1747 antibody which detected bands at 25 kDa. Represenative of n=3. Protein 
and mRNA were extracted in parallel C- ELISA analysis of secreted LCN2 protein 
following 48 hrs of culture.(+/- SEM, n=3. ***p<0.001) 
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8.2 MCF-7-shLCN2 cells exhibit morphological changes. 
Following 3 weeks of selection, MCF-7-shLCN2 cells were investigated for 
morphological changes. Under normal conditions MCF-7 cells are non-polar and 
roughly rounded but irregular in overall shape. Cell protrusions are present, but not 
prominent. MCF-7 cells form colonies which are moderately tight, but not notably 
dense. When MCF7-shLCN2 cells were observed however, a distinct morphological 
change was observed. Cells became flattened, and significantly larger in terms of 
cell surface area (Figure 8.3). This was combined with a loss of phase contrast 
under. Cells also showed signs of a loss of cell shape. A number of cells also 
contained large vacuoles. Indeed, overall, MCF-7-shLCN2 cells displayed a roughly 
similar phenotype to that found in PC3-shLCN2 cells (See section 5.7). 
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MCF-7-shCon              MCF-7-shLCN2 
 
 
 
Figure 8.3: Morphology of MCF-7-shLCN2 cells. Bright field image analysis of 
MCF-7-shCon cells and MCF-7-shLCN2 cells following 3 weeks of selection. MCF-7-
shLCN2 cells were notably flatter and displayed a loss of phase contrast. Images 
have been sharpened for printing purposes only. X20 magnification. 
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8.3 Gene expression in MCF-7-shLCN2 cells  
To determine whether MCF-7-shLCN2 cells displayed similar characteristics in terms 
of gene or protein expression to PC3-shLCN2 cells, qPCR and Western blot analysis 
was carried out respectively using genes previously identified as possible LCN2 
targets. 
qPCR analysis was carried out on a range of genes identified from the PC3-shLCN2 
microarray to be either highly up regulated or down regulated (See section 6.1), 
namely : SPARC, KDR, AGR2 (all up-regulated in PC3-shLCN2), AGTG2, KLK6, 
KLK5, ESRP1 and ST14 (all down regulated in PC3-shLCN2). 
With regards to SPARC, no statistically significant difference in expression was 
observed. Both KDR and AGR2 on the other hand showed slight but consistent 
decreases in mRNA expression of 1.58 and 1.48 fold respectively (Figure 8.4A). 
While the SPARC and KDR  showed little change, genes that were previously found 
to be down-regulated in PC3-shLCN2 cells (See section 6.1) showed a generally 
greater level of response.  ACTG2 was found to have a 13 fold increase in MCF-7-
shLCN2 cells relative to MCF-7-shCon cells.  A 7.3 fold increase was also observed 
for KLK5 in MCF-7-shLCN2 relative to MCF7-shLCN2. Increased expression was 
also observed for ESRP1 (2.1 fold), and for KLK6 (2.6 fold) (Figure 8.4B).  
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Figure 8.4: Analysis of LCN2 target genes in MCF-7-shLCN2 cells. qPCR 
analysis A- Analysis of SPARC, AGR2 and KDR, all of which were previously up-
regulated in PC3-shLCN2 cells (Section 6.2). B-  Analysis of ACTG2, KLK6, ESRP1 
and KLK5 which were  all down-regulated in PC3-shLCN2. All values +/- SEM. 
*p<0.05 ***p<0.001, Statistical analysis was carried out using Student’s t-test.  n=3) 
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8.4 ERα and E-cadherin expression in MCF7-shLCN2 cells. 
In addition to qPCR analysis, the effects of LCN2 suppression on protein expression 
were also investigated with regards to steroid receptor EMT marker expression.  In a 
previous study, Yang et. al. (2009) described a negative correlation between LCN2 
expression and ERα levels, thus agreeing with data derived from PC3-shLCN2 cells 
(See figure 5.15). However, the group also described a negative correlation between 
LCN2 and E-cadherin in contrast to PC3-shLCN2 cells (See Figure 5.18). However, 
the Yang et al. study used only siRNA targeting LCN2 and did not utilise longer term 
suppression. 
To identify if MCF7-shLCN2 cells agreed with the Yang et al. 2009 study, ERα, ERβ 
and E-cadherin protein expression was investigated. ERα protein expression was 
found to be increased in MCF-7-shLCN2 cells relative to MCF-7-shCon cells (Figure 
8.5A), thus agreeing with both PC3-shLCN2 cells (See Figure 5.16) and with the 
Yang et. al. study. ERβ expression was relatively unchanged in MCF-7-shLCN2 
cells. E-cadherin expression was also found to be increased in MCF-7-shLCN2 cells 
(Figure 8.5A), thus agreeing with the Yang et. al. study, but is the converse of  PC3-
shLCN2 cells (See Fig 5.18). In addition, qPCR analysis was carried out for both 
ESR1 (ERα) and ESR2 (ERβ) (Figure 8.5B). No significant change in expression 
was observed for either gene in MCF-7-shLCN2 cells, therefore implying that as with 
both LNCaP-LCN2 cells and PC3-shLCN2 cells, regulation of estrogen receptor by 
LCN2 is post-transcriptional. 
To assess the activity of ERα activity, expression of downstream markers was 
assessed. HER2, the traditional marker of ER expression was found to be reduced 
5.2 fold relative to controls. This was mirrored by EGFR which had a 5.8 fold 
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increase. Overall therefore, the data shows that LCN2 had an direct effect on ER 
expression. Unlike previous genes discussed however, the negative correlation 
between ERα and LCN2 appears to be same as that found in PC3-shLCN2 cells.. 
The influence on HER2 was not seen in PC3-shLCN2 cells however, although it 
should be noted that HER2 mRNA expression in PC3 cells is very low and as such 
was not pursued. 
In PC3-shLCN2 cells, I previously found that these cells had reduced levels of E-
cadherin, which was associated with an increase in expression of the E-cadherin 
repressor ZEB1 (See section 5.15), but that vimentin expression was unchanged. To 
assess whether any EMT related genes were being differentially regulated in MCF-7-
shLCN2 cells, qPCR analysis was performed on E-cadherin, vimentin, SNAI1, SNAI2 
ZEB1 and TWIST.  
E-cadherin mRNA expression was increased 2.2 fold in MCF7-shLCN2 cells relative 
to MCF7-shCon (Figure 8.5B). This was coupled with deceases in expression for 
both ZEB1 and TWIST1 (-2.1 fold and -8.3 fold respectively), both of which are 
regarded as E-cadherin suppressors (Montserrat et al., 2011). No changes were 
observed for vimentin or SNAI2 expression. This therefore shows that LCN2 
suppression is affecting E-cadherin expression, and this may be regulated through 
TWIST1 and ZEB1, but that its effects are opposite to that found in PC3-shLCN2 
cells (See Section 5.15).  The lack of change to vimentin expression also further 
confirms that LCN2 is affecting E-cadherin specifically rather than all EMT related 
genes (Fig 8.5B). 
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Figure 8.5: Expression of ER and EMT related genes: A- Western blot analysis of 
ERα, ERβ and E-cadherin in MCF-shLCN2 cells relative to controls. Representative 
of n=3 blots B-qPCR analysis of ERα, ERβ and downstream targets HER2 and 
EGFR. Also, analysis of gene expression for CDH1 and its negative regulators 
TWIST1 and ZEB1. All values are relative to expression in MCF7-shCon cells +/- 
SEM Statistical analysis was carried out using Student’s t-test.  **p<0.01 ***p<0.001 
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8.5 mTOR signalling in MCF7-shLCN2 cells .Previously, I identified mTOR as a 
possible effector of LCN2 signalling in PC3-shLCN2 cells, and where p-s6K 
expression was found to be reduced in PC3-shLCN2 cells (See section 7.2). 
Therefore I investigated whether mTOR signalling was differentially regulated in 
MCF7-shLCN2 cells. pMTOR expression itself was unchanged in MCF-7-shLCN2 
relative to MCF7-shCon (Figure 8.6), however an increase to expression was 
observed for p-S6k. p-4E-BP1 also showed a moderate increase although 
expression was weak in both MCF-7-shLCN2 and MCF-shCon cells. As such, the 
effects observed in MCF7-shLCN2 cells were opposite of those found in PC3-
shLCN2 cells. 
 
 
 
 
 
 
 
 
 
Figure 8.6: mTOR signalling in MCF-7-shLCN2 cells. Western blot analysis of p-
mTOR and its downstream targets p-S6K and p-4EB-BP1. (α-Tub is identical to that 
in figure 8.5A). Data is representative of n=3 experiments. 
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8.6 DFOX treatment  of MCF-7-shLCN2 cells  
Previously, I found that chelation of iron by Deferoxamine in PC3 cells elicited a 
PC3-shLCN2 like morphology (See section 7.3). I therefore aimed to investigate 
whether a similar effect occurred in MCF7 cells. MCF-7-shCon and MCF-7-shLCN2 
cells were treated with 10μg/ml for 48hrs. Treated MCF-7-shCon cells displayed a 
distinct change in morphology (Figure 8.7), and became flattened and enlarged and 
in looked visually similar to MCF-7-shLCN2 cells.  Notably, there was less apparent 
effect on MCF-7-shLCN2 cells (Fig 8.7) 
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Figure 8.7 Deferoxamine treatment of MCF-7 cells. MCF-7-shCon and MCF-7-
shLCN2 cells were treated with 10μM Deferoxamine (DFX) for 48 hours .Following 
treatment, PC3-shCon cells showed phenotypic change similar to PC3-shLCN2. 
DFX treated PC3-shLCN2 cells showed a further loss of phase contrast and defined 
cell edges. X20 magnification, n=3. 
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Gene expression of DFOX treated MCF7 cells. 
 
Following 48hrs of DFOX treatment, mRNA was extracted from cells and assessed 
to determine whether there were any effects to gene expression. No significant 
changes were observed for KDR AGR, CDH1 or KLK6. However, a reduction of 3.8 
fold was observed for SPARC in DFOX treated cells (Figure 8.8), a value close to 
that found in DFOX treated PC3 cells (See figure 7.6). Notably, a decrease of 5.2 
fold was recorded for HER2 which was similar to HER2 levels found in MCF7-
shLCN2 cells (See Figure 8.5). Therefore, while the changes to gene expression in 
DFOX treated cells were not as widespread as for PC3-shLCN2 cells (See Fig 7.6), 
there was a trend that suggests that DFOX treatment of MCF7 cells gives rise to a 
similar phenotype to MCF7-shLCN2 cells, which indicates that in MCF7 cells at least 
LCN2 is acting as an iron chelator suppression of LCN2 in MCF7 cells leads to a 
loss of intracellular iron. 
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8.8: Gene expression in MCF-7-shCon cells in response to Deferoxamine: 
MCF-7-shCOn cells were treated with 10μM Deferoxamine (DFX) for 48 hours. 
qPCR analysis of LCN target genes with the addition of HER2. Values are relative to 
untreated MCF7-shCon cells +/- SEM Statistical analysis was carried out using 
Student’s t-test.   *p<0.05, ***p<0.001. 
 
 
 
 
 
 
*** 
*** 
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8.7 Discussion 
In a previous publication by Yang et al., 2009, LCN2 was shown to have a negative 
correlation to both ERα and E-cadherin. This contradicted other studies which have 
shown that ERα expression represses E-cadherin (Oesterreich et al., 2003). As 
such, I aimed to investigate whether LCN2 has similar effects in PCa cells compared 
to the Yang et al. 2009 study in BCa cells. Results presented in this chapter 
therefore suggest that MCF7 and PC3 cells respond very differently with regards to 
gene expression when LCN2 is suppressed. However, I also showed that 
suppression of LCN2 in both cell lines led to an enlarged cell area and that this may 
be due to the loss of intracellular iron.  
In this chapter, it was found that suppression of LCN2 in MCF7 cells resulted in 
increased expression of genes such as ACTG2 and KLK5, which were previously 
found to be down-regulated  in PC3-shLCN2 cells (See section 6.2). This therefore 
suggests that these genes are LCN2 targets, but whether these target genes are 
activated or de-activated differs depending on other factors. That the same gene can 
have both activating and repressive activity is well known. p53 for instance is 
particularly well studied in this regards and can both up and down regulate genes 
depending on their methylation states (Liu and Chen, 2006). Therefore, pre-existing 
states such as gene methylation may determine whether LCN2 target genes are 
respond to the lack or presence of LCN2. 
Also, I observed opposite effects of LCN2 suppression on the mTOR pathway. 
Moreover, In PC3 cells, I have shown that treatment with deferoxamine led to a gene 
expression signature (such as for ACTG2 expression) that was opposite to that 
found in PC3-shLCN2 cells. However, in MCF7 cells treated with Deferoxamine, the 
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gene signature was similar to MCF7-shLCN2 cells. When combined therefore, 
results suggest that there is a fundamental difference between MCF7 and PC3 cells 
in their response to LCN2. This may be due to the presence of unknown factors 
which is acts as a repressor in one cell type but as a promoter in the other. However 
it is also likely that the cell types react differently in response to changes to their 
intracellular iron levels. LCN2 has been shown to have differing effects in different 
tissue types, and its effects appear to vary greatly between cell lines, although 
similar genes such as E-cadherin are commonly associated with LCN2 (Iannetti et 
al., 2008, Tong et al., 2011).  As such, the data in this chapter further demonstrates 
that LCN2’s effects are likely to be dependent on what genes are already active in 
the cell type. The data also shows that findings in one cell or tissue type should not 
necessarily be extrapolated to all cells.  
In conclusion, the data in this chapter suggests that: 
1) Suppression of LCN2 in MCF7 cells leads to a phenotype similar to that of 
PC3-shLCN2 cells. 
2) That while MCF7-shLCN2 cells exhibit a negative correlation to ERα, they 
also display a negative correlation to E-cadherin 
3) Unlike PC3-shLCN2 cells, mTOR pathway activity is increased in MCF7-
shLCN2 cells 
4) Iron chelation in MCF7 cells gives rise to a phenotype similar to MCF7-
shLCN2 cells  
298 
 
 
Chapter 9: Discussion 
 
 
 
 
 
 
  
299 
 
9.1 Overview 
Prostate cancer is the second leading cause of cancer related deaths in males. The 
need for understanding how prostate cancer develops, how to detect it and how to 
treat it is therefore of the utmost importance. Prostate cancer differs to some other 
forms of the disease in that progression is strongly associated with steroid receptor 
regulation.  
The aim of this study was follow on from work done by Dr. Sandeep Nadendla who 
demonstrated that ectopic GLI1 led to an androgen independent and EMT like state 
in LNCaP cells (Nadendla et al 2010).  In chapter 3 presented here I subsequently 
demonstrated that this effect was non reversible and that LNCaP-GLI1 cells 
maintained an androgen independent phenotype despite GLI1 suppression. 
Following on from this it was hypothesised that LCN2, which was greatly increased 
in expression in LNCaP-GLI1 cells was contributing to the androgen independent 
and EMT phenotype. Through a combination of ectopic expression and targeted 
suppression, I have demonstrated that contrary to the original hypothesis, LCN2 
expression led to increased AR expression and E-cadherin, and was coupled with a 
negative correlation to ERα.  
One of the unresolved questions surrounding LCN2 is whether it is pro- or anti- 
tumourigenic. In the data presented here, I have demonstrated that rather being 
simply one or the other, LCN2 demonstrates a range of characteristics. A loss of 3D 
colony formation in PC3-shLCN2 cells, combined with reduced 2D proliferation are 
indicative of a pro-tumorigenic activity. On the other hand, an inverse correlation to 
ERα and E-cadherin (PCa cell lines only) demonstrates an anti-tumorigenic effect.  
Moreover, ectopic expression of LCN2 did not increase proliferation in  LNCaP-LCN2 
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cells. Also, microarray analysis of PC3-shLCN2 cells revealed both pro- and anti- 
tumorigenic functions being regulated. Therefore, a simple good or bad label for 
LCN2 is unsuitable, but may depend on the cancer type. For instance, steroid 
receptor activity is important in breast and prostate, but is less so in other cancers. 
Understanding how LCN2 functions both in normal tissue and cancer is increasing in 
importance. LCN2 is already used as biomarker for acute kidney injury (Bennett et 
al., 2008), and has been proposed as a marker for disease progression in breast and 
pancreatic cancers among others. Gene therapy involving up-regulation of LCN2 has 
now been used to reduce pancreatic cancer growth (Xu et al., 2013), and is also 
being trialled for other cancer types. The overall mechanisms of LCN2 function 
however are still relatively unknown, and there is a lack of consensus particularly 
with regards to cancer.  Many studies on LCN2 have shown opposing effects 
dependent on tissue type which has further complicated the field. Also, most studies 
focus on a particular aspect or pathway in cancer and do not provide a more global 
overview of function. If LCN2 is indeed to be used as either a biomarker or as drug, it 
is hence important to better understand how LCN2 works across a wide range of 
cancer types.  
While LCN2 has been investigated in breast and pancreatic cancer, the role of LCN2 
in prostate cancer has only started to emerge in 2013 (Tung et al., 2013). Given that 
breast and prostate cancer share steroid receptor signalling as key driving 
mechanism, the investigation of LCN2 in AR and ER regulation was a logical step.   
In addition, microarray analysis of PC3-shLCN2 cells revealed many LCN2 linked 
genes such as SPARC and KLK6 which have not yet been described. 
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In my study, a key observation was that ectopic expression of LCN2 in LNCaP cells 
did show changes to steroid receptor regulation, but overall did not show the large 
changes to proliferation or growth which were seen when LCN2 was suppressed in 
PC3 and MCF7 cells. One reason for this difference may be due to rate of LCN2 
secretion from the cell. In both PC3 and MCF7 cells, high levels of both intracellular 
and secreted LCN2 were observed. In LNCaP-LCN2 cells however LCN2 was 
rapidly secreted, which may be in part due to higher LCN2-R expression. This data 
also suggests that intracellular LCN2 is important for the protein’s function, in 
particular how intracellular LCN2 is influencing iron regulation. High levels of 
secreted LCN2 were also observed in LNCaP-GLI1 cells. This therefore seems to 
indicate that there is a characteristic difference in the LNCaP cell line which is not 
present in PC3 or MCF7 cells. A lack of LCN2 receptor protein in LNCaP cells may 
also be reducing the effect of LCN2 itself. This may be due to the levels of LCN2 
receptor proteins which are able to secrete LCN2. Analysis of intracellular LCN2 
protein also showed that both PC3 and MCF7 cells had homodimeric LCN2, 
whereas LNCaP-LCN2 and LNCaP-GLI1 cells secreted the monomeric forms. This 
indicates that another factor may be necessary to control LCN2 dimerization or 
breakdown, although what this factor may be is unknown.  
Another potential issue which may be a difference between cell types is post-
translational modification. LCN2 has been shown to be glycosylated at numerous 
sites, although the effects of this glycosylation on function are unknown and in 
particular whether this affects the 3D structure of the protein (Flower et al., 2000). 
Evidence of glycosylation was observed using the Santa-Cruz 5G5 antibody which 
did show evidence of a doublet band in PC3 cells. However this was not detected 
with other antibodies, and it was not possible to detect the glycosylation state of 
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LCN2 in LNCaP-LCN2 cells. While a full length LCN2 was transfected into LNCaP 
cells, it is also possible that the protein was not correctly folded impacting on 
function. 
One key issue with my results was a lack of in-cell imaging by immunofluorescence 
(IF). The MAB1757 LCN2 antibody from R&D technologies is listed as unsuitable for 
IF from the company datasheet. Nevertheless, repeated IF optimisation was 
attempted, but was unable to produce any results and no fluorescence was detected. 
Indeed, to date no publications have successfully utilised IF for human LCN2 
although suitable antibodies have been employed for mouse LCN2 (Langelueddecke 
et al., 2013).  As new antibodies targeting LCN2 become available, this will no doubt 
elucidate many of its functions 
9.1 Post transcriptional effects of LCN2 
In these results, I noted that while some genes such as E-cadherin showed 
expression changes at both the mRNA and protein levels, expression of both AR and 
ER was regulated at a post-transcriptional level.   
Both ER and AR are also regulated post-transcriptionally by a range of micro-RNAs, 
particularly miR-221, which is up regulated by NF-κB signalling.  Data from 
microarray analysis on PC3-shLCN2 cells did not show any difference in miR-221 
expression, or to most other micro-RNAs. However a 3-fold expression was 
observed for miR-21 which has been shown by to be regulated by androgen receptor 
and the development of an androgen independent phenotype (Ribas et al, 2009). 
The role of LCN2 in micro-RNA transcription or function is currently unknown, but 
would be a worthwhile area of investigation with a more detailed study. 
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ER and AR are known to be regulated post-transcriptionally and post transnationally 
through similar mechanisms. Indeed, targeted proteolysis is necessary for both AR 
and ER function. Upon binding to androgens or estrogens, AR and ER dissociate 
from HSPs where it can enter the nucleus. Alternatively free AR/ER is targeted for 
degradation by ubiquitin ligases. This dual action enables cells to finely control the 
actions of steroid signalling. The balance between signalling and degradation 
however is still under debate. Studies (Chu at al, 2007) have demonstrated that 
proteolysis of ER is dependent on the activity of Src. Recent studies have also 
demonstrated that ER initiates a feedback loop on itself by promoting the expression 
of proteins which activate E2F-1 which chaperones ER for degradation (Stender et 
al., 2007).  With regards to the data presented in my study, it is possible that altering 
LCN2 expression is able to influence the levels of proteolysis. Western blots were 
analysed for both AR and ER breakdown products; unfortunately, the antibodies for 
ERα and AR did not detect these protein fragments. ERβ did show evidence of 
breakdown; however results were inconclusive and not pursued further. Whether 
LCN2 is directly affecting AR/ER degradation or via an intermediary is unknown and 
microarray analysis on PC3-shLCN2 cells did not reveal any stand-out candidates 
for regulation. It is also highly likely that LCN2 influences the post-transcriptional 
regulation of other genes, and hence it would be of interest to perform whole 
proteome arrays. This may also provide a better picture of exactly how LCN2 is 
functioning, particularly on other receptors such as progesterone receptor.  
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9.2 LCN2 signalling pathways 
While some of the mechanisms of LCN2 regulation have been studied, there is 
relatively less data regarding its downstream effects. A key aim of this study was to 
identify some of the downstream signalling pathways of LCN2.  Here I have identified 
a number of pathways including estrogen receptor and EGFR signalling which were 
directly affected by LCN2 levels.  Notably both EGFR and ER themselves have been 
shown to up-regulate LCN2 (Tong et al., 2011. Yang et al., 2009) This therefore 
seems to suggest either bi-directional signalling or a feedback system is active 
between these genes. With regards to EGFR in particular, I demonstrated that the 
EGFR inhibitor AG1478 inhibited LCN2 expression, but that in addition, ectopic 
LCN2 in LNCaP cells increased EGFR expression. AG1478 has previously been 
shown to inhibit LCN2 expression, however the reverse of LCN2 affecting EGFR has 
not yet been described in literature. 
9.3 Future work 
LCN2’s role in prostate cancer is still relatively unclear. The results presented in this 
study provide a number of opportunities for future investigation. 
Firstly, if LCN2 does indeed exist as a homodimer within the cell, then this has 
potential implications for its siderophores binding activities and downstream function. 
I also noted that dimerised LCN2 appears to be cleaved before being secreted. 
Further investigation into the processes underlying this change is therefore 
necessary. It is also worthwhile to see whether this process occurs in vivo as 
opposed to cell lines. This process is likely to become clearer as better antibodies 
targeting LCN2 become available In addition, my study did not employ any xenograft 
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studies in mice.  However, recently Tung et al (2013) did perform a limited xenograft 
which did show reduced tumour growth for PC3-shLCN2 cells in a mouse model. 
However, no in-depth studies were performed on the tumours, and hence it would be 
worthwhile to determine factors such as steroid receptor status, metastasis and 
angiogenesis in further studies.  
A further observation which needs to be investigated further is the overall stability of 
the LCN2 protein.  This may be done through siRNA targeted suppression over a 
much longer time period (e.g. 2 weeks). This would also help identify exactly which 
pathways are related to LCN2, and in which order they are activated.  
In my study, microarray analysis identified the Wnt pathway as being potentially 
regulated by LCN2. Although LCN2 has been linked to Wnt signalling before, this 
was as a target gene and not as an effector.  It would therefore be worthwhile to 
investigate fully the role of LCN2 in Wnt signalling, looking at both canonical and 
non-canonical signalling, and whether any post-translation changes are taking place 
(e.g. with β-Catenin).  
LCN2 is already used as a diagnostic marker for acute kidney injury and post-
surgery stress. Testing for LCN2 in blood or urine is steadily becoming cheaper and 
easier. In prostate cancer, although the PSA test is a good indicator of It cancer 
stage, it is only indicative of AR expression and thus ignores other factors such as  
ER expression or the shift to an androgen independent  state. It would hence be of 
great potential interest to examine the levels of LCN2 in prostate cancer patients, 
either in blood or in urine. LCN2 levels could then be scored against overall 
prognosis or tumour stage, and correlated to the levels of AR or ER expression in 
tumours. 
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Summary of Results 
LCN2 forms intracellular dimers LCN2 is often described as a secreted 
monomer 24kDa in size. Results showed that 
intracellular LCN2 appears as a 48kDa dimer 
which is cleaved before secretion 
LCN2 expression negatively correlates to 
ERα expression 
Ectopic expression of LCN2 led to a loss of 
ERα, whereas shLCN2 in PC3 and MCF7 cells 
increased ERα expression. This expression 
was partially restored by recombinant LCN2 
protein 
LCN2 expression positively correlates to AR Ectopic expression of LCN2 led to increased 
AR expression and increased sensitivity to 
bicalutamide 
LCN2- E-cadherin correlation is dependent 
on cell type 
Expression of LCN2 positively correlated to 
E-cadherin in prostate cells. However E-
cadherin was increased in MCF7-shLCN2 
cells 
LCN2 knockdown leads to phenotypic 
change 
LCN2 suppression in both PC3 and MCF7 
cells led to cell enlargement, loss of cell 
protrusions and effects on cell cycle and loss 
of nuclear organisation. This may be partially 
explained by a loss of mTOR signalling. 
Downstream signalling for LCN2 is multi-
faceted. 
Microarray analysis of PC3-shLCN2 cells 
revealed a wide range of gene expression 
changes particularly to Wnt, integrin and 
cadherin signalling. 
MCF7-shLCN2 cells had gene expression 
which was often opposite to that found in 
PC3-shLCN2 cells 
Many genes which were found to be down-
regulated in PC3-shLCN2 cells were up-
regulated in MCF7-shLCN2 cells and vice 
versa. 
LCN2 has both pro-and anti- tumourigenic 
properties. 
In general, LCN2 appears to demonstrate 
pro-tumourigenic properties such as to cell 
cycle and gene expression. However, 
correlation to ERα expression shows anti-
tumourigenic properties as well 
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